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3Abstract
Evidence suggests induction and regulation of prostaglandin (PG) production is a key 
element in the pathophysiology of inflammatory disorders of the airways such as cystic 
fibrosis (CF). This study reports that human tracheal epithelial cell lines of a CF- 
phenotype, XCFTE29o", and a non CF-phenotype, 9HTEo', constitutively express the 
enzymes cyclooxygenase-1, cyclooxygenase-2, cytosolic prostaglandin E synthase and 
15-hydroxyprostaglandin dehydrogenase at similar levels. Induction of these enzymes 
with pro-inflammatory cytokines could not be observed. PGE2 production was 
significantly higher in £CFTE29o' cells than 9HTEo' cells.
Peroxisome proliferator-activated receptor y (PPARy) ligands are reported to down- 
regulate inflammatory mediator production in the airways. Additionally, 15-deoxy- 
A12’14- PGJ2 (15d-PGJ2) has been shown to induce expression of heme-oxygenase -1 
(HO-1) in a number of cell systems. Tracheal epithelial cells were found to express 
PPARy. PPARy ligands did not affect expression of enzymes involved in PGE2  
generation in either ECFTE29o' or 9HTEo" cells. Troglitazone and 15d-PGJ2 were 
observed to inhibit PGE2 generation and transiently increase HO-1 expression by 
9HTEo‘ cells. In ICFTE29o' cells the effects of PPARy ligands on PGE2 production 
were conflicting, increasing basal PGE2 but inhibiting TNFa induction of this PG. 
Additionally, in XCFTE29o' cells, sustained induction of HO-1 expression could be 
observed in response to 15d-PGJ2.
In summary, the findings of this study indicate that elevated levels of PGE2 are a feature 
of the pro-inflammatory phenotype seen in CF. Furthermore, no significant difference 
in the expression or induction of enzymes involved in the biosynthesis of PGE2 could be 
observed between the cell lines indicating that the source of elevated PGE2 by the CF 
phenotype cell line is an elevated availability of substrate. The data included in this 
study also suggest that PPARy ligands may be negative regulators of inflammation in 
non-CF airway epithelial cells, but in the CF airway epithelium may exacerbate existing 
inflammation.
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1. Introduction 
1.1 Airway Inflammation
1.1.1 Inflammation and the Airway Epithelium
The acute-inflammatory response is a key defense mechanism by which an organism 
protects itself from invading pathogens and irritants. Inflammation is a complex 
process initiated by tissue damage and is, by large, protective. The inflammatory 
response consists of two components: an innate response with no immunological basis, 
consisting of vascular and cellular events orchestrated by chemical mediators released 
from cells and plasma; and a complex acquired response involving lymphocytes that 
recognises self from non-self and is specific for the invading pathogen (Reviewed in 
Bevins, 1999). Ordinarily, the outcome of an inflammatory reaction is eradication of 
the pathogen and healing of the host tissue. However, if inappropriately deployed or if 
the causative agent persists the inflammatory response can be deleterious resulting in 
damage to the host. Chronic inflammation is a feature of a number of diseases of the 
airways such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease.
The airway epithelium represents the largest epithelial surface of the body in contact 
with the external environment and functions to minimise microbial adherence and 
provide a hostile milieu for potential pathogens. The airway epithelium is a physical 
barrier that employs a number of host defence mechanisms to prevent infection and 
stimulation of sensory nerves and smooth muscle by inhaled irritants. Airway epithelial 
cells participate in an inflammatory response in a number of ways; They can act as 
target cells, modulating one or several of their functions, such as mucin secretion, 
ciliary beating and ion transport. Additionally, they can act as effector cells, 
synthesising a number of agents such as cytokines, lipid mediators and reactive oxygen 
species affecting both the epithelium and neighbouring tissues and contributing to or 
inhibiting airway inflammation (Reviewed by Adler et al, 1994). Aberrations in any of 
these functions, as seen with environmental exposure or a number of disease states such 
as cystic fibrosis and asthma can result in an impaired pulmonary response and damage 
to the host tissue. A number of organ and cell culture systems have been implemented
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in order to study the response of the airway epithelium to infection. These studies have 
revealed two complementary defense mechanisms involving first the production of anti­
microbial agents and secondly the induction of signalling networks that recruit 
phagocytic cells to the site of infection (Diamond et al, 2000).
Damaged tissues release mediators including vasoactive peptides, eicosanoids, 
chemokines, cytokines and nitric oxide (NO) resulting in activation of surrounding 
cells, induction of vasodilatation and exudation of fluid. The fluid exudate is carried to 
the lymph glands where products of the invading microorganism trigger an immune 
response. Additionally, some of these mediators are chemoattractants for blood derived 
cells such as neutrophils, eosinophils, monocytes and lymphocytes (Zhang et al, 
2000). Vasoactive peptides such as bradykinin (BK) are formed, during the 
inflammatory response, from a2-globulins and high and low molecular weight 
kininogens by the action of kininogenases (Reviewed by Barnes et al, 1998). In the 
airways BK acts at B2 receptors triggering release of PGE2 and NO from the airway 
epithelium (Ricciardolo et al, 1996) and is capable of causing both constriction or 
relaxation of airway smooth muscle. BK is also a potent vasodilator of bronchial 
vessels and induces microvascular leakage. Additionally, BK stimulates mucus 
secretion from human sub-mucosal glands and is a potent mediator of pain, manifested 
in the airways as cough and tightness of the chest (Fuller et al, 1987). A wide range of 
anti-microbial substances including lysozyme, lactoferrin, phospholipase A2 , defensins, 
proteases and complement can be found in the mucus layer covering airway epithelia 
(Bals et al, 1999). However, the epithelial fluid layer is very thin under resting 
conditions, and the commonly used bronchoalveolar lavage (BAL) method combines 
secretions from anatomically distinct locations, making the assessment of the 
contribution of individual proteins or peptides to the innate immune response 
challenging (Reviewed in Ganz, 2002). Nonetheless, these components are postulated 
to act in synergy to kill bacteria and prevent infection. Furthermore, mediators of the 
inflammatory response such as cytokines, chemokines, COX products and NOS 
products can further stimulate airway epithelial cells inducing mucus hypersecretion 
enabling effective eradication of pathogens (Borchers et al, 1999). The role of 
eicosanoids in inflammation, and in particular airway inflammation, will be discussed in 
detail in the next section. Chemokines are important chemotactic cytokines that play a
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fundamental role in the trafficking of leukocytes to sites of inflammation. They are also 
potent cell-activating factors, inducing cytokine and histamine release and free radical 
production, a fact that makes them particularly important in the pathogenesis of allergic 
inflammation. Much of the inflammatory response is orchestrated by cytokines. 
Cytokines are soluble extracellular signalling proteins that form a network of cell-cell 
communication regulating growth, differentiation and survival of cells; the initiation, 
maintenance and resolution of the innate immune response and subsequent activation of 
the adaptive immune system (Strieter et al, 2001). Cytokines affect cellular activity by 
binding to cell-surface receptors, on immune or non-immune target cells, and a signal 
being transduced to the nucleus inducing transcription of genes. Airway epithelial cells 
have been observed to produce, express receptors for, and be responsive to a number of 
proinflammatory cytokines including interleukin-1 (IL-1) and tumour necrosis factor 
(TNF), and interferon gamma (IFNy) (Mitchell et al., 1994; Asano et al, 1996; Watkins 
et al, 1999; Rodgers et al, 2002; Reibman et al, 2003). The IL-1 family consists of 
two agonists IL-1 a  and IL-ip that bind to the IL-1 type one receptor (IL-1R1). Upon 
binding of IL-1 to IL-1R1 a receptor-associated protein, MyD88, recruits an adapter 
protein, which in turns recruits the IL-1 associated kinase (IRAK). Subsequent to 
activation, IRAK activates TNF receptor-associated factor 6 (TRAF6) which complexes 
with nuclear factor- xB-inducing kinase (NIK). NIK activates the IkB kinase complex 
(IKK) which phosphorylates inhibitor of kBcx (IkB cc) resulting in ubiquitination and 
degradation of inhibitor kB  (IkB). The transcription factor, nuclear factor- kB (NF-kB) 
is then free to translocate to the nucleus and transactivate numerous target genes by 
binding to responsive elements in the DNA (Figure 1). NF-kB induces the transcription 
of genes encoding many proteins involved in the inflammatory response, including 
cyclooxygenase, chemokines, cytokines and NO-synthase (Murphy et al, 2000). IL-1 
can also signal through the p38 mitogen-activated protein (MAP) and the c-Jun N- 
terminal kinase (JNK) pathways, their effects synergising with those of N F-kB. TNF 
signals through two distinct receptors TNRF1 and TNRF2. As with IL-1, TNF 
signalling is mediated by NIK and MAP activation of NF-kB  (Figure 1) (Reviewed in 
Strieter et al, 2001). The production of these cytokines by the airway epithelium not 
only induces the production of mediators of the host defense such as COX, NOS and 
cytokines but can indirectly regulate inflammatory cell recruitment. TNF and IL-1 do 
not directly induce migration of neutrophils, but both cytokines are potent inducers for
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the production of C-X-C chemokines, such as IL-8, by the airway epithelium, 
macrophages and other cells of the airways. The C-X-C chemokines are the major 
chemoattractants for inflammatory cells (Kunkel et al, 1991).
Figure 1 IL-1 and TNF signal transduction: Activation and translocation of NF-kB 
resulting in transactivation of a number of genes involved in the inflammatory response. 
TRADD, TNFR1-associated death domain; RIP, Receptor-interacting protein.
TNFR1 IL-1R1
TRADD MyD88 Membrane
RIP
TRAF2
NIK
IKK
IRAK-1
TRAF6
Target gene
IkB
NF-kB
IkB degredation
Nuclear membrane
Response element L COX, NOS, Cytokines, 
Chemokines etc
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IFNy is a proinflammatory cytokine predominantly derived from lymphoid cells 
(Reviewed in Frucht et al, 2001). Bader and Nettesheim report that the tracheal 
epithelium can be stimulated to produce low levels of IFNy 4 hours after exposure to 
TNFa and that, in response to TNFa, the airway epithelium releases a pattern of 
inflammatory mediators that resembles a Thl response (Bader and Nettesheim, 1996). 
IFNy exerts its activity by binding to and activating the IFNy receptor (IFNGR), which 
comprises of two transmembrane domains (Aguet, 1988). Upon binding of IFNy to the 
IFNGR the sub-units of the receptor dimerize bringing associated Janus kinases (Jaks), 
Jakl and Jak2, into close proximity resulting in their tyrosine phosphorylation and 
increasing their catalytic activity. The phosphorylation of the Jaks correlates with 
tyrosine phosphorylation of the IFNGR components and recruitment of the transcription 
factor signal transducer and activator of transcription 1 (STAT1). STAT1 is 
phosphorylated at the conserved carboxy-terminal tyrosine residue (Reviewed in 
Ramana et al, 2002) and subsequently, homo- or heterodimers of STAT translocate to 
the nucleus and interact with a gamma activation site (GAS) modifying transcription 
and expression of target genes (Figure 2) (Schindler and Darnell, 1995). IFNy plays a 
pivotal role in the host inflammatory response potentiating the respiratory burst and 
activity of professional phagocytes and enhancing generation of inflammatory 
mediators such as nitric oxide (NO) (Barnes and Liew, 1995). Additionally, a number 
of studies have reported that cytokines IL-1, TNF and IFNy can act in concert to 
produce an effect. Martin et al report that, while individually IL-1, TNF and IFNy fail 
to have an effect upon thin lung slices, in combination these cytokines induce 
contraction of the airways by inducing up-regulation of COX-2 expression and 
thromboxane release. This study also reports that challenge with cytokines can produce 
either dilatation or constriction of airway smooth muscle depending upon the time point 
after introduction of the cytokine, demonstrating the ability of the airway epithelium to 
participate in an integrated inflammatory response and the importance of the time 
dependent effects of inflammatory mediators released by the airway epithelium (Martin 
etal., 2001).
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Figure 2 IFNy signal transduction: Activation and translocation of STAT1 resulting in 
transactivation of a number of genes involved in the inflammatory response.
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The ability of the airway epithelium not only to respond to inflammatory mediators by 
altering one or several of its functions, but to generate many substances that may diffuse 
away and affect neighbouring cells and tissues, underlines its critical importance as not 
only a primary defense against pathogens and infection, but as an orchestrator of the 
hosts innate defense able to translate gene-environment interactions.
IFNGR
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1.1.2 Cystic Fibrosis
Cystic fibrosis (CF) is the most common lethal autosomal recessive disorder affecting 
Caucasian populations. In Northern Europe the disease frequency is approximately 
1:2500 live births (Boat et al, 1989; Collins, 1992). CF was first identified as a 
distinct disease in 1938 (Anderson, 1938). However, literature recording infant cases of 
meconium ileus and pancreatic and lung disease typical of CF date as far back as 1650 
(Boat et al, 1989). In 1938 few patients lived past the age of five years and most died 
of rapidly progressive pulmonary infections (Colten, 1995). In the following decades 
the use of antibiotic treatments and early detection of the disease led to a steadily 
increasing number of CF patients reaching adulthood. In 1983 Paul Quinton showed 
that chloride uptake by absorptive sweat duct epithelium was abolished in CF, this 
characteristic is now used as a diagnostic tool for the disease. Improved nutrition, the 
ability to detect CF at early and presymptomatic stages along with effective antibiotic 
therapy have improved both the quality and duration of the CF patient’s life. In 2001 
the median life expectancy of patients bom in 1990 was 40 years of age (Jaffe, 2001).
CF affects several organ systems including the pancreas, gastro-intestinal tract and the 
reproductive system. However, chronic infection and deterioration of lung function are 
the major causes of morbidity and death. An imbalance in the ionic and/or osmotic 
balance of the airway surface liquid (ASL) results in clogging of the airways with thick, 
sticky mucus and facilitates subsequent colonisation by bacteria such as Pseudomonas 
aeruginosa, a bacteria associated with progressive pulmonary deterioration and 
untimely death (Bals et al, 1999).
Studies in the 1980s identified defects in the chloride conductance properties of 
epithelial cells from CF patients (Quinton, 1983) and subsequently that this defect was 
localised to the apical membrane (Widdicombe et al, 1985). In 1989 the CF gene was 
identified and cloned (Riordan et al, 1989; Rommens et al, 1989). Analysis of the 
predicted gene product revealed a 1480 amino acid glycosylated transmembrane 
glycoprotein that functions as a cyclicAMP-regulated chloride channel (Bals et al, 
1999). The gene product was called the CF transmembrane conductance regulator 
(CFTR) because of the link between abnormal chloride ion transport and the CF defect. 
The CFTR consists of two homologous halves, each half comprising of six
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transmembrane domains and a nucleotide-binding domain (NBD). The two halves of 
the CFTR are linked via a regulatory (R) domain that contains a number of consensus 
phosphorylation sites (Riordan et al, 1989). The CFTR is predominantly found in 
epithelial cells where it is transcribed at low concentrations, and found at highest levels 
in the pancreas, proximal lung tissue, salivary glands, sweat ducts, intestine and 
reproductive tract (Collins, 1992).
Gating of the CFTR channel is controlled by two separate processes 1) phosphorylation 
and 2) binding and hydrolysis of ATP. Serine residues in the R domain are 
phosphorylated by cAMP-dependent protein kinase (PKA) the greater the 
phosphorylation, the greater the probability the channel will open (Akabas, 2000). 
Following phosphorylation of the R domain ATP binds to and is hydrolysed in the 
NBDs (Winter and Welsh, 1997). Channel opening allows conduction of anions, 
particularly Cl" ions, across the apical membrane of epithelial cells. The channel is 
subsequently deactivated by the action of phosphatases PP2C and PP2A 
(Vankeerbergen et a l , 2001). To date, over 1,000 mutations of the CFTR gene have 
been associated with a CF disease phenotype (Reviewed by Wagner and Headley, 
2003). Mutations of the CFTR can be grouped into five classes (I-IV) on the basis of 
CFTR alterations (Reviewed in Zeitlin, 1999) (Table 1).
The CFTR regulates the activities of amiloride sensitive Na+ channels, outwardly 
rectifying Cl' channels; the CI7 HCO3 exchanger and the potassium channel Kir 1.1 
(ROMK) (Akabas, 2000). Hypotheses on the mechanisms by which mutated CFTR 
affects the function of lung epithelia consider the role of the CFTR in salt absorption to 
be of cardinal importance. The high salt hypothesis (Smith, 1996, Zabner, 1998) 
postulates that reduced transepithelial Cl* conductance results in high salt levels in the 
ASL that interferes with “salt-sensitive” natural antibiotics and lysozyme. The low 
volume hypothesis (Matsui et al, 1998) suggests that both CF and normal airway ASL 
contain comparable levels of salt, however, in CF airways the volume of liquid is 
reduced because of an increased isotonic fluid absorption resulting in thick mucus 
leading to obstruction and infection. Recent in vivo evidence supports the “low volume 
hypothesis” and provides evidence that, in CF, ASL is approximately isotonic and does 
not contain a high level of salt (Jayaraman, 2001).
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Table 1 Classification of mutations that may lead to CF
G roup M utation
Class I
Synthesis of unstable or truncated CFTR 
RNA, resulting in total absence of CFTR 
protein/function.
Severe disease phenotype.
Class II
Protein translation is completed, but an 
abnormal protein that fails to escape the ER is 
produced. Responsible for approximately 
70% of patients.
Severe disease phenotype.
Class III
Disrupt activation and regulation of CFTR at 
the plasma membrane. The channel is 
postulated to be defective with respect to ATP 
binding and hydrolysis, or phosphorylation. 
Severe disease phenotype.
Class IV
Chloride conductance or channel gating are 
affected resulting in a reduced chloride 
current.
Mild disease phenotype.
Class V
Decrease in the level of normal CFTR due to 
alterations in the promoter or alterations in 
splicing.
Reduction in mRNA to <10% results in a 
disease phenotype.
1.1.3 Cystic Fibrosis and Airway inflammation
The generation of an inflammatory response is a crucial mechanism by which the 
individual protects itself from infectious and non- infectious insults. During the last two 
decades a number of studies have identified the host inflammatory response as a 
potential target to delay the deterioration of lung function that occurs in patients with 
CF. An intrinsic component of the CF phenotype is a persistent and exaggerated 
inflammatory response driven by bacterial infection of the airways (Figure 3).
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Figure 3 The basis of respiratory complications in CF (Adapted from Collins, 1992)
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Epithelial cells respond to bacteria and bacterial products by increasing production of 
cytokines such as TNF, 1L1 and IFNy and IL-8. IL-8 is a potent chemokine that attracts 
neutrophils to the inflammatory site. Furthermore, when macrophages present 
encounter bacteria they respond by producing their own IL-8, TNF-a and IL-ip which, 
in turn, further drives the epithelial cells to produce molecules that participate in the 
inflammatory response (Reviewed by Chmiel and Davis, 2003). The airways of CF 
patients are often colonised early in life by a limited spectrum of bacteria and, in 
response, mount a vigorous inflammatory response. Initially this response contains the 
bacteria and the infection is cleared. Intermittent colonisation of the airways of CF 
patients is common in the first few years of life and in a clinical trial Dakin et al. 
demonstrate, that in infants and young children with CF, the presence of pathogen in the 
lower airways correlates with levels of inflammation (Dakin et al., 2002). However, 
eventually the CF lung is unable to clear infection, and bacterial colonisation first by 
Staphylococcus aureus and then Pseudomonas aeruginosa becomes chronic. Konstan 
et al. report that, in older children and adults with CF, even clinically stable patients 
have large numbers of bacteria in their lower airways accompanied by a neutrophil 
influx and uninhibited elastase activity (Konstan et al., 1994).
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Evidence suggests that the inflammatory process goes awry in the lungs of CF patients 
even in infancy and is ultimately ineffective against the bacteria and damaging to the 
host tissue. Clinical studies indicate that the neutrophil and IL- 8  responses measured in 
bronchoalveolar lavage (BAL) fluid of CF infants are excessive when compared to 
normal infants (Muhlebach et al, 1999). While the subjects observed in the 
aforementioned study appear to be responding to bacteria, other studies of inflammatory 
mediators in BAL fluid have revealed that many CF infants have no detectable bacteria, 
but nonetheless have a modest inflammatory response that exceeds that observed in 
uninfected non-CF subjects (Khan et al, 1995). These findings suggest that, in 
response to bacterial stimulation, the CF lung mounts an excessive inflammatory 
response that is not down-regulated once the infection has been eliminated (Reviewed 
by Chmiel and Davis, 2003). The excessive inflammatory response seen in CF has also 
been observed in studies using mice. In 1997 Van Heeckeren et al published findings 
that CF mice with chronic Pseudomonas infection have a higher mortality than their 
non-CF littermates. Furthermore, the BAL of the CF mice contained excess pro- 
inflammatory cytokines, in response to the same bacterial burden, when compared to 
the non-CF mice (Van Heeckeren et al, 1997). This is supported by the findings of 
Thomas et al, who investigating S100-A8, a calcium binding protein identified as a 
potent pro-inflammatory chemotactic factor, observed that CF-mice show a 4-fold 
higher level of S100-A8 mRNA accompanied by an increased influx of neutrophils and 
increased production of TNF-a in response to bacterial lipopolysaccharide (LPS) than 
their non-CF littermates. These results indicate that the pathology of CF may relate to 
an underlying hypersensitivity of the immune system to bacterial challenge (Thomas et 
al, 2000). However, other clinical studies show that at least some CF infants, 
particularly those that have no known history of lung infection, do not exhibit an 
elevated / detectable inflammatory response and that in young children airway 
inflammation improves when the pathogen is eradicated (Armstrong et al, 1997).
A persistent and exaggerated inflammatory response, associated with an abnormal 
increase in pro-inflammatory cytokines, is one of the major factors leading to damage of 
the host tissue in CF (Escotte et al, 2002). Tiddens et al report that in CF patients 
undergoing lung transplantation up to 23% of the airway was not covered by epithelium 
(Tiddens et a l , 2000). When the airway epithelium is breached the airways are
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rendered susceptible to injury by inhaled pathogens and particles (Reviewed in 
Whitsett, 2002). It has been shown that Pseudomonas aeruginosa preferentially 
adheres to regenerating airway epithelium (de Bentzmann et al, 1996). Furthermore, 
Muraoka et al demonstrate that increased activity of the transcription factor NF-kB 
inhibits growth of the airway epithelium (Muraoka et al, 2000), these findings are of 
interest when taken into consideration with the findings of Venkatakrishnan et a l who 
report that activation of NF-kB is exaggerated in CF bronchial epithelial cells 
(Venkatakrishnan et al, 2000). These studies suggest that NF-kB may inhibit 
epithelial repair and provide evidence of a role for NF-kB in the exaggerated 
inflammatory response seen in CF airways.
Injury to the airway epithelium combined with viscous mucus and the failure of airway 
epithelial cells to ingest and inactivate bacteria contribute to the ability of bacteria to 
colonise the airways of CF patients. Chronic infection of the airways with pathogens 
such as Pseudomonas aeruginosa stimulates a vigorous, but ultimately ineffective, 
inflammatory response that damages the host tissue and results in permanent ongoing 
lung destruction (Reviewed in Dinwiddie, 2000).
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1.2 Prostaglandins
1.2.1 History
Interest in the prostagandins dates back to the early 1930s when Kurzok and Lieb 
observed that strips of uterine smooth muscle could be contracted by the exogenous 
application of semen (Kurzok and Lieb, 1930). The substance in semen that induced 
contraction of the uterine smooth muscle was believed to originate in the prostate and 
subsequently given the misnomer ‘prostaglandin’ by von Euler in 1936. More than two 
decades later it became apparent that prostaglandin was in fact a family of 2 0 -carbon 
unsaturated carboxylic acids with a cyclopentenone ring, and their kinship with 
essential fatty acids recognised.
It is now known that prostaglandins are produced by almost every tissue in the human 
body, their production being increased or decreased in response to a diverse range of 
stimuli. The effects of the prostaglandins influence practically every biological function 
and since the discovery that non-steroidal anti-inflammatory drugs (NSAIDs), such as 
aspirin, exert their activity by inhibiting prostaglandin production (Vane, 1971) there 
has been intense interest in their metabolic pathway and its role in both physiology and 
pathophysiology.
1.2.2 The Cyclooxygenases
Cyclooxygenase (COX), also known as prostaglandin H synthase, is widely accepted to 
exist in two isoforms COX-1 and COX-2, the products of two distinct genes localised 
on chromosomes 9 and 1 respectively (Funk, 1991 and Tay, 1994). COX-1 was 
purified from ovine and bovine seminal vesicles (Hemler et al, 1976; Miyamato et al, 
1976; van de Ouderaa et al, 1977) and is generally thought to be a constitutive isoform 
acting to maintain homeostatic processes such as mucus secretion, platelet aggregration 
and parturition (Reviewed by Smith and Langenbach, 2001). COX-2 was discovered 
more recently (Xie et al, 1991; Kujubu et al, 1991; O’Banion et al, 1991) and is 
mainly an inducible enzyme involved in cell proliferation and inflammatory processes,
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but also has a role in physiological processes such as ovulation and implantation and 
neonatal development (Reviewed by Smith and Langenbach, 2001). Sequence analysis 
of the COX-2 5’-flanking region has revealed potential transcription regulatory 
elements including a TATA box, two NF-kB sites, two AP-2 sites and a CRE motif 
(Tanbe and Tohnai, 2002). Additionally, COX-2 mRNA has multiple AUUUA 
instability sequences dictating rapid degradation and short half-life (Ristimaki et al,
1994). Recently evidence has been published supporting the presence of a third distinct 
acetominophen sensitive COX isoform, COX-3, a splice variant of COX-1 that shares 
all of the important catalytic and structural features of COX-1 and COX-2 (Simmons et 
al, 1999; Chandrasekharan et al, 2002).
COX is the rate-limiting enzyme for the conversion of arachidonic acid (AA) to 
prostanoids. AA is a 20-carbon unsaturated fatty acid containing four double bonds and 
is either derived from dietary linoleic acid or ingested as a component of meat, it is then 
esterified as a component of the phospholipids of cell membranes to be released into the 
cytosol by the action of the enzyme phospholipase A2 (PLA2). Liberated AA is 
converted into prostaglandin (PG) G2 and then PGH2 by the COXs. COX enzymes are 
bifunctional, catalysing two sequential reactions in spatially distinct, but 
mechanistically linked active sites (Kiefer et al, 2000). Initially COX catalyses the 
insertion of molecular oxygen into AA to form the unstable intermediate PGG2 , which 
is rapidly converted into PGH2 by the peroxidase activity of COX. PGH2 is 
subsequently converted into biologically active PGs by their relevant synthases (Figure 
5) (Reviewed by Subbaramaiah and Dannenberg, 2002). As previously mentioned the 
PGs participate in a diverse range of physiological and pathophysiological processes. 
It is the role of the PGs in pathophysiological processes, in particular inflammation, that 
makes the COX enzymes important therapeutic targets.
In 1893, Felix Hoffman, at the Bayer company, set into motion the commercial process 
to produce acetylsalicylic acid (aspirin) a palatable form the active component of 
willow bark, salicylic acid, which has been used by man for thousands of years to 
relieve pain and fever. This lead to the development of the class of drugs termed the 
NSAIDs, which are still the most widely used therapeutic agents over a century later 
(Reviewed by Dubois et a l , 1998). In 1971 Vane showed that the anti-inflammatory 
action of NSAIDs, such as aspirin, rests in their ability to inhibit the activity of the COX
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enzyme, resulting a dose-dependent reduction in PG production (Vane, 1971). NSAIDs 
act at the COX active site in several ways; Aspirin irreversibly inactivates both COX-1 
and COX-2 by acetylating an active-site serine, this covalent modification interferes 
with the binding of AA at the COX active site. NSAIDs including ibuprofen reversibly 
inhibit COX activity by competing with AA for the COX active site and thirdly a group 
of NSAIDs that includes indomethacin causes a time-dependent reversible inhibition of 
COX resulting from the formation of a salt bridge between the carboxylate of the drug 
and arginine 120 followed by conformational changes (Reviewed by Hinz and Brune, 
2002).
Despite the popularity of the NSAIDs, their use is associated with unwanted side effects 
the most common of which being damage to the mucosa of the upper gastrointestinal 
tract (Cichoz and Celinski, 2002). In a prospective study, 13 of every 1000 patients 
with rheumatoid arthritis who took NSAIDs for 1 year had serious gastrointestinal 
complication (Singh and Triadafilopoulos, 1999). The discovery that the COX-2 
isoform was expressed in cells exposed to pro-inflammatory stimuli including 
cytokines, mitogens and endotoxin (O’Banion, 1992, Xie, 1992) led to the postulation 
that the inhibition of COX-1 led to the unwanted side effects of NSAIDs, whereas 
inhibition of COX-2 may lead to the desired anti-inflammatory effects, a hypothesis 
supported by the in vitro findings of Warner et al, who comparing >40 NSAIDs and 
COX-2 selective inhibitors demonstrate an alignment between COX-1 inhibition and 
gastrointestinal complications (Warner et al, 1999). As most NSAIDs inhibit both 
COX-1 and COX-2 (Mitchell et al, 1993), this hypothesis served as the basis for the 
development of a number of COX-2 specific inhibitors. In spite of the similarities in 
crystallographic structures, the two COX isoforms have been found to have different 
selectivities for fatty acids and COX inhibitors which, in part, is attributable to COX-2 
having a more accommodating cyclooxygenase site as a result of the presence of a 
valine residue at position 509 instead of the isoleucine present at position 523 in COX-1 
(Lecomte et al, 1994; Luong et al, 1996; Kurumbail et a l 1996). COX-2 specific 
inhibitors exploit this lateral extension of the cyclooxygenase site (Reviewed in 
Fitzgerald, 2003). COX-2 selective inhibitors have proved to be effective analgesics. 
In 2002 four selective inhibitors of COX-2 -  rofecoxib (Vioxx), celecoxib {Celebrex), 
parecoxib {Dynastat injection) and etoricoxib (Arcoxia) were launched in the UK (NHS 
National prescribing centre, 2002). At present only two phase III clinical trials have
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investigated whether COX-2 specific inhibitors alter the incidence of serious
gastrointestinal adverse events when compared to NSAIDs. One trial, the Celecoxib
Long-term Arthritis Safety Study (CLASS), reported no significant difference in
gastrointestinal endpoints between patients receiving celecoxib, diclofenac or ibuprofen
(Juni et al, 2002), whereas a separate trial, the Vioxx Gastrointestinal Outcomes
Research (VIGOR) study, reported that the incidence of adverse events was reduced
from 4% to 2% in patients receiving rofecoxib compared with naproxen (Bombardier et
al, 2000). To date, the VIGOR study is the only gastrointestinal-outcomes study to
reveal a significant difference between a selective COX-2 inhibitor and an NSAID.
However, patients with symptomatic ulcers were excluded from these trials as in
experimental animals COX-2 has been demonstrated to play an important role in gastric
mucosal defense, its inhibitions delaying healing of chronic gastric ulcers (Peskar et al,
2001; Deviere, 2002). Emerging evidence for a role for COX-2 in the release of
protective PGs when production by COX-1 has been lost, raises questions about the
safety of administration of COX-2 inhibitors. Gilroy et al (1999) report that in
carrageein-induced pleurisy in rats, COX-2 protein expression initially peaked at 2
hours associated with maximal PGE2 synthesis. However, at the 48 hour time point
there was observed to be a second increase in COX-2 expression, 350% greater than
that at 2 hours. Interestingly, this coincided with resolution of inflammation and
1minimal PGE2 synthesis. In contrast, levels of PGD2 and its metabolite 15deoxyA 
14PGJ2 (15d-PGJ2) were elevated at 2  hours, decreased as the inflammatory response 
progressed, and increased again at 48 hours. It is becoming increasingly apparent that 
the role of COX-2 in inflammatory processes is complex and not solely associated with 
the onset of an inflammatory reaction. COX-2 is expressed during and produces PGs 
involved in the resolution of inflammation, its inhibition during this period deleterious 
in that the resolution of inflammation is delayed.
The importance of the PG biosynthetic pathway as a therapeutic target in inflammatory 
conditions, and evidence that generation of alternative series of prostaglandins by COX- 
2  may drive the induction or resolution of an inflammatory response, has led to the 
theory that greater specificity of effect may be obtained by the targeting specific 
prostaglandin synthases.
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Figure 4 The prostaglandin biosynthetic pathway.
Arachidonic acid is converted into prostaglandins by the sequential action of enzymes 
phospholipase A2 (PLA2), cyclooxygenases -1 and -2  (COX-1 and COX-2) and 
specific prostaglandin synthases. Green arrows denote enzyme action whereas purple 
arrows indicate product of enzyme activity.
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1.2.3 The Terminal Prostaglandin Synthases
The prostaglandin metabolic pathway consists of the three major steps: the liberation of 
AA from the lipid membrane, the production of PGH2 via the action of the 
cyclooxygenases, and finally the conversion of PGH2 into a number of bioactive PGs by 
their respective synthases. These specific PG synthases have different structures and 
exhibit cell- and tissue-specific localisation (Ueno et al, 2 0 0 1 ).
PGE2 is the most common prostanoid and exhibits potent and diverse bioactivities. 
PGES activity has been detected in both the cytosolic and microsomal fractions of 
various cells and in most, if not all cases, is glutathione dependent (Murakami et al,
1998). Current evidence suggests that mammalian cells contain at least three forms of 
prostaglandin E synthase (PGES), mPGES-1 that acts in concert with COX-2 
(Murakami et, 2000), cPGES that is preferentially coupled to COX-1 (Tanioka et a l , 
2000), and mPGES-2 a recently identified PGES isoform that acts downstream of both 
COX-1 and -2  (Murakami et al, 2003). mPGES-1 belongs to the Membrane- 
Associated Proteins involved in Eicosanoid and Glutathione metabolism (MAPEG) 
superfamily, and was originally identified as Microsomal GST-Like 1 (MGST-L1) 
(Jakobsson, et al, 1999). Murakami et a l (2000) report that, while not constitutively 
expressed, mPGES-1 expression may be induced in the lung, stomach, kidney and brain 
by pro-inflammatory mediators including, LPS, IL-1 and TNF. This study also reports 
that mPGES-1 is functionally coupled to COX-2 and is sensitive to inhibition by 
dexamethasone. These findings are supported by those of Stichtenoth et al, who, in 
rheumatoid synoviocytes, observe a coordinate upregulation of COX-2 and mPGES-1 
protein expression 24 hours after incubation with IL-1 or TNF that may be completely 
blocked by dexamethasone (Stichtenoth et al, 2001). Additionally, Kamei et al report 
that overexpression of mPGES-1 accelerates PGE2 production and cell proliferation in 
human colorectal adenocarcinoma (HCA-7) cells, and that co-transfection of HEK293 
cells with COX-2 and mPGES-1 resulted in transformation manifested by tumour 
formation when sub-cutaneously implanted into nude mice (Kamei et al, 2003). These 
studies collectively underline the potential role of mPGES-1 as a therapeutic target.
In contrast, cPGES is a cytosolic protein constitutively expressed in a wide variety of 
cells and tissues and is associated with heat shock protein 90 (Hsp90) (Tanioka et al,
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2000). Identical to p23, a putative chaperone molecule, cPGES is also thought to be 
involved steroid hormone receptor stabilisation (Sullivan et al, 1997) and signalling 
(Freeman et al, 2000), however the precise cellular functions of p23 remain obscure. 
cPGES is preferentially coupled to COX-1 promoting the immediate conversion of 
COX-1 derived PGH2 into PGE2 required for tissue homeostasis and does not appear to 
be upregulated by pro-inflammatory stimuli (Tanioka et al, 2000). Recently, 
Murakami et al have described a third PGES, mPGES-2. mPGES-2 is a constitutively 
expressed protein and does not appear to be upregulated by pro-inflammatory stimuli. 
In contrast to cPGES and mPGES-1, mPGES-2 is able to convert both COX-1 and 
COX-2 derived PGH2 into PGE2 in both the immediate and delayed response 
(Murakami et al, 2003). The role of this PGES isoform in health and disease is yet to 
be defined, although overexpression of mPGES-2 in human colorectal adenocarcinoma 
cells implies that this enzyme may play a role in tumorigenesis (Kamei et al, 2003).
Prostaglandin D synthase (PGDS) catalyses the isomerisation of PGH2 to PGD2 . There 
are two distinct types of PGDS: lipocalin- type PGDS (L-PGDS) a secretory enzyme 
abundantly present in the central nervous system, male genitals and heart (Urade et al, 
2004), and hematopoietic PGDS (H-PGDS), the only mammalian member of the a  class 
of glutathions S-transferases, a cytosolic enzyme expressed in mast cells, antigen 
presenting cells, and Th2 cells (Kanoka and Urade, 2003). Activity of PGDS enzyme is 
reported to be biphasic, acting in concert with only COX-1 in the immediate phase and 
only COX-2 in the delayed phase (Murakami et al, 1994). Conversion of PGH2 to 
PGI2 is catalysed by PGI synthase (PGIS), this PG synthase belongs to the cytochrome- 
P-450 family and is reportedly localised in the endoplasmic reticulum (ER) and 
perinuclear membranes coupling with COX-2 in response to LPS (Brock et al, 1999).
These studies suggest that the prostaglandin synthases may be put into three categories 
in terms of their localisation and COX preference: 1) perinuclear enzymes preferentially 
linked to COX-2. This group includes mPGES-1, PGIS and the thromboxane A2  
synthase (TXS) and provokes much interest as a therapeutic target for inflammation and 
carcinogenesis, 2) Cytosolic enzymes that prefer COX-1 such as cPGES and 3) 
Translocating enzymes that utilise both COX-1 and COX-2 depending upon stimulus, 
this group includes mPGES-2 and PGDS (Ueno et al, 2001).
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1.2.4 The prostaglandins
The prostaglandins (PGs) are important autacoids that exert diverse physiological and 
pathophysiological effects on almost every tissue and system in the body, these effects 
include modulation of neuronal activity, regulation of ion and water transport, 
gastrointestinal motility and secretion, and relaxation and contraction of smooth muscle 
(Wright et al, 2001). In response to a diverse range of stimuli, tissues form and release 
PGs. As PGs are either chemically or metabolically unstable, for example they are 
inactivated during a single passage through the lung, it is thought that they only act 
locally near to their tissue of origin (Reviewed in Narumiya and Fitzgerald, 2001). 
Derived from AA, the PGs contain a cyclopentane ring and two side chains named a  
and co. According to modifications of the cyclopentane ring, the prostaglandins are 
classified into types A to J. There are four major physiological prostaglanndins PGE2 , 
PGD2 , PGI2 and PGF2a,each exerting its effect by coupling to distinct G-protein 
coupled receptors. Furthermore, PGE2 and PGD2 are dehydrated in biological fluids 
containing serum albumin to yield the cyclopentenone prostaglandins, PGA2 and PGJ2 . 
PGs B and C are not believed to be naturally occurring but rather are produced 
artificially during extraction procedures (Narumiya et a l , 1999).
One of the most studied prostaglandins is PGE2. PGE2 stereospecifically exerts potent 
tissue specific effects regulating key responses in the major human systems and playing 
an integral role in a multitude of infections and diseases (Serhan and Levy, 2003). The 
biological actions of PGE2 are attributed to result from its interaction with specific 
plasma membrane receptors. Four PGE2 receptor subtypes have been classified and 
cloned, designated as EPi, EP2, EP3, and EP4i the EP3 and EP4 isoforms also being 
functionally expressed in the nuclear envelope (Bhuttacharaya et al, 1999). Each EP 
receptor is coupled with a different second messenger signalling pathway (Figure 5) 
(Harris et al, 2002).
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Figure 5 Prostaglandin E2 receptor signalling pathways: EPi is coupled to G-protein 
Gq/p and ligand binding results in an increase in the level of intracellular calcium. EP2 
and EP4 are coupled to Gs proteins and induce the expression of cAMP which leads to 
gene regulation. EP3 is coupled to G* and is predominantly inhibitory to cAMP. 
Abbreviations: AC, adenylate cyclase; DAG, diacylglycerol; IP3, inositol trisphosphate,; 
PIP2, phosphatidylinositol diphosphate; PKA, protein kinase A; PKC, protein kinase C; 
PLC, phospholipase C.
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PGE2S biological actions are tissue- and organ-specific. In the immune system the 
actions of PGE2 are generally thought to be suppressive, inhibiting macrophage 
production of pro-inflammatory cytokines (Nataraj et al., 2001). Enhanced COX-2 
expression has been noted in many cancers including cancers of the breast, colon and 
prostate (Reviewed in Harris et al., 2002). Subsequently, PGE2 synthesis has been 
observed to be elevated in tumour tissues compared to normal tissues and is linked to 
tumour-cell survival. It is thought that PGE2 contributes to tumour-cell survival by 
inhibition of apoptosis and induction of cell proliferation (Sumitani et al., 2001). 
Furthermore, PGE2 acts as in immunomodulator promoting humoral and Th2-type 
immune responses that do not favour tumour destruction, and inhibiting Thl-type 
responses that do favour tumour destruction. The effects o f PGE2 in the airways are
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diverse and often conflicting and will be discussed detail in the next section. The 
myriad of effects of PGE2 in health and disease have been well documented, however, 
the exact mechanisms by which these actions are exerted is poorly understood. Studies 
using EP receptor knockout mice have contributed to the elucidation of the role of 
individual receptors in physiological and pathophysiological processes (Table 2) 
(Reviewed in Narumiya and Fitzgerald, 2001).
Table 2: Major phenotypes of mice deficient in EP receptors
Disrupted
gene
Phenotype of knockout Reference
EP, Decreased aberrant foci formation in response to 
carcinogen azoxymethane
Watanabe et al., 1999
e p 2 Impaired ovulation and fertilisation 
Salt-sensitive hypertension 
Vasopressor or impaired vasodepressor response 
to intravenous PGE2
Loss of bronchodilation in response to PGE2 
Impaired osteoclastogenesis in vitro
Kennedy et al., 1999 
Kennedy et al., 1999 
Audoly etal., 1999
Fleming et al., 1998 
Li et al., 2000
e p 3 Impaired febrile response to pyrogens 
Impaired duodenal bicarbonate secretion and 
mucosal integrity
Enhanced vasodepressor response to intravenous 
infusion of PGE2
Disappearance of indomethacin-sensitive urine 
diluting function
Ushikubi etal., 1998 
Takeuchi etal., 1999
Audoly etal., 1999
Fleming et al., 1998
e p 4 Patent ductus arteriosa
Impaired vasodepressor response to intravenous 
infusion of PGE2
Decreased inflammation and bone resorption
Nguyen et al., 1997 
Audoly ef al., 1999
Miyaura et al., 2000
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PGD2 has been demonstrated to bind to and activate two G-protein coupled receptors, 
CRTH2 (Chemoattractant Receptor-homologous molecule expressed on T-Helper type 
2 cells) (Sawyer et al, 2002) and DP (Boie et al, 1995). Functional studies have 
revealed that PGD2 activation of CRTH2 results in a G-protein Gai/0 dependent, 
pertussis toxin-sensitive, decrease in intracellular cAMP (Sawyer et al, 2002), whereas 
the activation of the DP receptor by PGD2 leads to stimulation of adenylate cyclase 
activity and an increase in intracellular cAMP levels in a G-protein Gas-dependent 
manner (Boie et al, 1995). Through the DP receptor PGD2 has been implicated in 
different physiological processes including sleep induction (Matsumura et a l , 1994) 
mucus production and allergic responses (Matsuoka et al, 2000), and cell survival 
(Gervais et a l , 2001). The physiological role of CRTH2 is less well characterised. 
However, it has been demonstrated that its activation by PGD2 can increase Th2 cell 
motility (Hirai et al, 2001) and modulate eosinophil morphology, motility and 
degranulation (Gervais et al, 2001).
PGI2 is a potent vasodilator, antithrombotic and antiplatelet agent that mediates its 
effects through ligation with the IP receptor and activation of adenylate cyclase via Gs 
(Reviewed in Smyth and Fitzgerald, 2002). Using carragageenan-induced paw swelling 
and acetic acid-induced writhing as models for acute inflammation and pain in IP 
receptor deficient mice, Murata et a l demonstrate that PGI2 acting on the IP receptor is 
a critical mediator of these responses (Murata et al, 1997). PGF2 binds to and 
activated the Gq coupled FP receptor, resulting in activation of PLC. PGF2 and its 
receptor are implicated in many aspects of reproductive functions and play an important 
role in parturition. (Narumiya et al, 1999).
The PGs are important therapeutic targets and elucidation of tissue- and receptor 
subtype-specific effects may lead to new therapies for cancers and inflammatory 
disorders.
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1.2.5 Prostaglandins in airway inflammation and cystic fibrosis
PGs are produced under both physiological and pathophysiological conditions by all 
cell types in the airways and modulate various airway functions including, airway 
vascular tone, cell proliferation, plasma exudation, inflammatory cell recruitment and 
activity, cytokine release, mucus secretion and parasympathetic and sensory nerve 
function (Belvisi et al, 1997). Numerous studies have suggested that airway 
inflammatory cells produce pro-inflammatory eicosanoids including PGD2 and PGF201, 
whereas airway epithelial cells play a role in dampening the inflammatory response by 
producing PGE2 and PGI2 (Pitt et al, 1998 and references therein). However, it is 
apparent that PGs may have either pro- or anti-inflammatory effects dependent upon the 
time point during inflammation, the receptor subtypes activated, and the model being 
observed.
COX-2 expression may be induced, in airway cells, by a number of pro-inflammatory 
cytokines including TNFa, IL-1 and IFNy (Mitchell et al, 1994; Belvisi et al, 1997; 
Pang et al, 1998; Bonnazzi et al, 2000), whereas cytokines IL-4, IL-13 and IL-10 can 
inhibit COX-2 induction (Berg et al, 2001 and references therein). IL-10 is a cytokine 
with potent anti-inflammatory activity blocking synthesis of TNFa, IFNy and IL- 8  by 
human monocytes (de Waal-Malefyt et al, 1991). Interestingly, Bonfield et al 
demonstrate that production of IL-10 by the CF airway epithelium is significantly lower 
than in normal controls (Bonfield et al, 1999). In the airway epithelium COX-2 is 
constitutively expressed and associated with the production of PGE2 (Watkins et al.,
1999). As the airway epithelium is a first line of defense against inhaled pathogens and 
irritants, constitutive expression of COX-2 may be a consequence of continuous 
exposure to low-level environmental stimuli. Elevated levels of pro-inflammatory 
cytokines coupled with decreased levels of anti-inflammatory cytokines in the airways 
favours expression of COX-2 and PGE2 production which in CF are thought to 
contribute to the inflammatory response and ultimately lung deterioration.
PGE2 is the most common PG in the airways and is predominantly a COX-2 product 
that has complex effects on airway tone. PGE2 induces bronchodilation by activating 
EP2 receptors on airway smooth muscle and, conversely, may indirectly induce 
constriction through ligation of EPi and EP3 receptors and activation of neural pathways
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(Tilley et al, 2003). Furthermore, at high concentrations PGE2 may induce constriction 
of smooth muscle through agonism at the thromboxane receptor (Reviewed in Pang et 
al, 1998). Bradykinin (BK) is a potent inflammatory mediator in patients with 
bronchial asthma inducing airway smooth muscle cells to produce cytokines and 
express COX-2. Pang and Knox state that PGE2 mediates BK induction of IL-8 , a 
potent chemoattractant for pro-inflammatory cells (Pang and Knox, 1998; Rodgers et 
al, 2002). Furthermore, PGE2 can synergise with IL- 8  to enhance neutrophil migration 
(Smith et al, 2002). In CF, BK modification of chloride conductance has been 
attributed to activation of adenylate cyclase by AA cyclooxygenase products. This is 
supported by studies performed in immortalised CF and control cell lines that 
demonstrate BK induces higher AA release from cells expressing the AF508 CFTR 
mutation than the control cell line, this may be a result of dysregulation of PLA2 
stimulation (Levistre et al, 1993).
Pseudomonas aeruginosa causes lethal lung infections in individuals with CF. The 
lethality of the infection is directly related with inflammation and lung tissue 
destruction. Smith et al report that homoserine lactone N-(3-oxododecanoyl) produced 
by Pseudomonas aeruginosa activates transcription factor NF-kB resulting in induction 
of COX-2 expression and PGE2 production in human lung fibroblasts and postulate that 
PGE2 contributes to Pseudomonas induced lung pathology (Smith et al, 2002). 
Furthermore, upregulation of COX-2 expression, through activation of NF-kB, in 
response to lipoteichoic acid produced by Staphylococcus aureus has been observed in 
human pulmonary epithelial cells, providing further evidence that COX-2 and PGE2 are 
involved in airway inflammation (Lin et al, 2001). As previously mentioned, in CF an 
imbalance in the ionic and/or osmotic balance of the airway surface liquid (ASL) results 
in clogging of the airways with thick, sticky mucus facilitating subsequent colonisation 
by bacteria such as Pseudomonas aeruginosa (Bals et al, 1999). PGE2 is postulated to 
influence control of electrolyte movement and mucus secretion co-ordinating with 
intracellular cAMP and calcium to stimulate modifications in the carbohydrate structure 
of glycoproteins during secretion of chloride, bicarbonate-chloride exchange, and 
movement of water through exocrine tissues. Disturbed metabolism of PGE2 in CF is 
thought to inhibit these changes and may contribute to the production of secretions that 
are dry and difficult to clear from the airways (Anderson, 1984).
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Freedman et al report the presence of a membrane lipid defect in the lung, pancreas and 
ileum from cftrA mice, characterised by elevated levels of phospholipid- bound AA and 
a decrease in phospholipid-bound docosahexaenoic acid (DHA). Furthermore, the 
levels of TNFa, PGF201 and PGE2 in BAL fluid from cftr1" mice were elevated when 
compared with those in wild-type controls (Freedman et al 1999; Freedman et al, 
2002). These findings are supported by those of Zakrzewski et al and Strandvik et al 
who report that PG levels in sputum, and metabolites of PGs excreted in the urine of CF 
patients are increased when compared to healthy individuals and may contribute to the 
pathophysiology of the disease (Zakrzewski et al, 1987 Strandvik et a l, 1996). 
Increased levels of COX-2 and prostanoids, in particular PGE2 , are also reported in the 
BAL fluid from asthmatic patients and cultured epithelial cells derived from asthmatic 
patients (Taha et al, 2000; Redington et al, 2001).
As previously stated, the PGs are products of COX enzymes, however, it is also 
reported that PGs participate in the regulation of COX-2 expression and subsequently 
modulate further PG production. Faour et a l observed that, in human synovial 
fibroblasts, the magnitude and duration of the induction of COX-2 mRNA, protein, and 
PGE2 production induced by IL-ip was primarily the result of PGE2 stabilisation of 
COX-2 mRNA decay and protein (Faour et al, 2001). Furthermore, Poligone and 
Baldwin demonstrate that PGE2 promotes the inherent transcriptional activity of the 
p65/RelA subunit of N F-kB, and strongly synergises with TNFa to promote NF-kB- 
dependent transcription and gene expression. In contrast, these authors also report that 
the cyclopentenone PGs can suppress NF-kB activation by inhibition of IkB kinase, 
providing a molecular rationale to explain the pro-and anti-inflammatory nature of 
COX-2 (Poligone and Baldwin, 2001). Activation of N FkB is exaggerated in CF 
bronchial epithelial cells (Venkatakrishnan et al, 2000). Exaggerated NF-kB activation 
observed in CF may be, to some extent, a result of elevated PGE2 produced by a 
constitutively expressed and active COX-2 provided with elevated levels of substrate, 
activated NF-kB further inducing transcription of COX-2 and pro-inflammatory genes 
such as IL- 8  and TNFa, perpetuating the production of PGs.
Accumulating evidence suggests the induction and regulation of COX-2 may be key 
elements in the pathophysiological process in a number of inflammatory disorders of
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the airways such as cystic fibrosis (Pang, 2001). In diseases such as CF where a chronic 
inflammatory response leads to the destruction of the host tissue, therapeutic control of 
PG production may be a target to delay deterioration of lung function. However, the 
constitutive expression of COX-2 by airway epithelium and the ability of PGE2 to exert 
both pro- and anti-inflammatory actions suggests a homeostatic role for COX-2 
products in the airways, therefore long term inhibition of this enzyme may induce 
serious side effects. Elucidation of the exact mechanisms behind PG induced airway 
inflammation will hopefully provide better therapeutic approaches to regulating 
inflammatory disorders of the airways such as asthma and CF.
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1.3 Peroxisome proliferator activated receptor gamma and ligands
1.3.1 Peroxisome proliferator -  activated receptors (PPARs)
In the 1990s peroxisome proliferator -  activated receptors (PPARs) were identified as 
nuclear hormone receptor transcription factors involved in a number of diseases with 
complex causes such as diabetes, obesity, atherosclerosis and cancer (Kersten at a'l,
2000). The name PPAR is derived from the identification of one isoform as a target for 
xenobiotic compounds that can induce proliferation of peroxisomes in the liver (Rosen 
and Spiegelman, 2001). Three PPAR isoforms (a, P, and y) have been identified to 
date. Each isoform is encoded by a separate gene, shows distinct tissue localisation, 
and is associated with selective ligands (Kliewer et al, 1994; Vamecq and Latrouffe,
1999). All members of this super family have a similar structural organisation. An N- 
terminal region that allows ligand-independent activation and is negatively regulated by 
phosphorylation, a DNA binding domain comprising of two zinc fingers separated by a 
linker region, and the C-terminal ligand binding domain (Murphy and Holder, 2000 and 
references therein). PPARs regulate gene expression by binding as heterodimers with 
retinoid -X -  receptors (RXRs) that have been activated by the binding of 9-cis retinoic 
acid, to peroxisome proliferator -  response elements (PPREs) in the promoter regions of 
target genes (Figure 6 ) (Reviewed in Desvergne and Wahli, 1999). PPREs contain the 
hexameric DNA consensus sequence AGGTCA arranged as a direct repeat spaced by 
one nucleotide and sequences recognised by the PPAR-RXR heterodimer. It has been 
recognised that different PPAR isoforms recognise distinct PPREs (Murphy and Holder, 
2 0 0 0  and references therein).
Little is known about the clinical significance of PPARp although it is implicated in 
colon cancer and is linked to basic lipid metabolism (Basu-Modak et al, 1999). 
However, more is known about the physiological roles of PPARa and PPARy. PPARa 
is highly expressed in the liver, heart, proximal tubules of the kidney and intestinal 
mucosa which exhibit high catabolic rates of fatty acids (Braissant et al, 1996). PPARy 
exists in two isoforms 1 and 2. PPARy-2 is expressed in high levels in adipose tissue, 
playing a critical role in the differentiation of pre-adipocytes into adipocytes, whereas 
PPARy-1 is widely distributed and has been observed to be expressed in the immune 
system (Mukheijee, 1997), airway epithelium (Michael et al, 1997; Wang et al, 2001),
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endothelial cells (Bishop-Bailey, 1999) and vascular smooth muscle (Bishop-Bailey,
2001). Studies have revealed that both natural and synthetic ligands of PPARy possess 
anti-inflammatory properties (Serhan, 1996) attenuating the production of macrophage- 
derived cytokines such as IL-1 and TNFa (Jiang et al, 1998; Ricote et al, 1998; 
Welch et al, 2003) and regulating the expression of COX-2 and inducible nitric oxide 
(Coleville-Nash et al, 1998). The down-regulation of inflammatory pathways by 
PPARy ligands makes this receptor isoform a potential target for therapies aimed at 
disorders in which the inflammatory response is elevated or dysregulated. However, 
studies demonstrating that PPARy ligands are able to up- regulate COX-2 expression in 
mammary epithelial cells, colonic epithelial cells (Meade et al, 1999), rabbit comeal 
epithelium (Bonazzi et a l , 2000), and primary human monocytes (Pontsler et al, 2002) 
and, opposingly, down-regulate COX-2 expression in airway epithelial cell lines (Wang 
et al, 2001), human astrocytes (Janabi, 2002), mesangial cells (Sawano et a l , 2002), 
and macrophages (Inoue et al, 2000) suggest that the effects of PPARy may be tissue 
specific. Elucidation of the tissue specific effects of PPARy in inflammation is 
necessary in the development new approaches to therapy for chronic inflammatory 
diseases based upon the effects of PPARy ligands.
PPARy is expressed in several human malignancies including, breast (Mueller et al,
2000), colon (Dubois et al, 1999) and lung (Tubouchi et al, 2000). Recent reports 
suggest that both natural and synthetic agonists of PPARy can have anti-proliferative 
effects and induce apoptosis and terminal differentiation of a number of different 
transformed and cancerous cell lines (Reviewed in Na and Surh, 2003). However, a 
number of studies also demonstrate that PPAR ligands suppress apoptosis and stimulate 
G1-arrested cells to re-enter the cell cycle and induce DNA synthesis (Keller et al, 
2000 and references therein). The different effects of PPAR ligands on apoptosis may 
depend on the PPAR subtype activated or the cell line observed.
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Figure 6 : Activation of PPARs, by binding of PPAR ligands, leads to 
heterodimerisation of the PPAR with activated RXR. Subsequently the receptor 
heterodimer can bind to PPREs in the promoter region of target genes, such as COX-2, 
and regulate transcription in a tissue specific manner.
PPAR ligands 9-c/s-retinoic acid
PPAR RXR
Nucleus
PPAR
RXR
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PPRE
1.3.2 PPARy ligands
As PPARy plays a role in many physiological and pathophysiological pathways, there 
has been intense interest in identifying an endogenous, high-affinity ligand for this 
receptor. In 1995 Forman et al. and Kliewer et al. independently reported that 15- 
deoxy-A1214-PGJ2 (15d-PGJ2) activates PPARy (Forman et al., 1995; Kliewer at al,
1995). 15d-PGJ2 was first identified in 1983 as a degradation product o f PGD2, formed 
after incubation for extended periods of time in the presence of albumin (Fitzpatrick and 
Wynalda, 1983). PGD2 undergoes chemical dehydration, losing a molecule of water to 
form PGJ2 , PGJ2 then undergoes further dehydration, losing the 15-hydroxyl group, in
Introduction 48
addition to migration on the 13,14-double bond of PGJ2 to form 15d-PGJ2 (Figure 7) 
(Reviewed by Powell, 2003).
Figure 7 Prostaglandin D2 Metabolism
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A number of studies have reported 15d-PGJ2 inhibits inflammatory cytokine production 
and macrophage activation (Jiang et al, 1998; Ricote et al, 1998; Hinz et al., 2003). 
However, 15d-PGJ2 has been shown to induce responses in cells that do not express 
PPARy (Jiang et al, 1998; Chawla et a l, 2001). Therefore, role of 15d-PGJ2 in 
inflammation is thought to be attributable not only to its binding and activating PPARy, 
but to its modulation of the activity of the transcription factors NF-kB and AP-1 
(Castrillo et al, 2000; Straus et a l, 2000), activation of H-Ras (Oliva et a l, 2003), 
activation of MAP kinase cascades (Lennon et a l, 2002; Jung et al, 2003), reactive 
oxygen species (ROS) generation (Lennon et a l, 2002) and activation of cell membrane 
DP2 receptors (Monneret et al, 2002). Concentrations of 15d-PGJ2 required to activate 
PPARy or ligate proteins in the NF-kB signalling pathway in vitro range from 2.5 -  
lOOpM (Castrillo et al, 2000; Narumiya and Fitzgerald, 2001) whereas, in vivo, 
biologically active concentrations of conventional exogenous PGs are observed to be in 
the picomolar range (Fitzgerald, 1981). Using a highly sensitive liquid chromatography 
/ tandem mass spectrometry for 15d-PGJ2, Bell-Parikh et al. report that in 3T3-L1 
fibroblasts, COX-2 produces low levels of 15d-PGJ2 (~2pM) and that these levels are 
lower than the amounts required for PPARy dependent differentiation. Levels of 15d- 
PGJ2 detected in urine and synovial fluid were also too low to be an endogenous 
activator of PPARy, and its biosynthesis is unaltered in inflammation in vivo (Bell- 
Parikh et al, 2003). As levels of 15d-PGJ2 produced in vivo (pM) are significantly 
lower than required for modulation of responses and activation of PPARy in 
vitro (pM), this study throws into question the relevance of the physiological role of 
15d-PGJ2. However, further investigation into the tissue specific production and effects 
of 15d-PGJ2 is necessary.
Thiazolidinediones (TZDs) are a class of synthetic compounds that potentiate insulin 
action in target tissues, alleviate hyperglycemia and are efficacious in treating type II 
diabetes (Reviewed in Olefsky, 2000). Additional roles for TZDs were suggested 
following the discovery that, at the molecular level, these compounds function as highly 
specific ligands of PPARy (Lehmann et al, 1995). TZDs include troglitazone, 
rosiglitazone and ciglitazone. Troglitazone has been shown to inhibit inflammatory 
cytokine production and macrophage activation (Jiang et al, 1998; Ricote et al, 1998) 
Despite the TZDs having a binding affinity for PPARy in the nanomolar range (Jiang et
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al., 1998), the concentrations of troglitazone used to elicit these responses was in the 
micromolar range. Additionally, evidence that TZDs can inhibit TNFa and IL- 6  
secretion by 60 -  80 % in PPARy deficient macrophages indicates that, as with 15d- 
PGJ2 , the anti-inflammatory effects of TZDs may be PPARy independent (Jiang et al.,
1998).
NSAIDs such as indomethacin are accepted to exert their clinical activity by inhibiting 
COX, thereby blocking the production of PGs. However, evidence that indomethacin 
blocks adipocyte differentiation and induces terminal differentiation of preadipocyte 
cell lines at concentrations 2 - 3  orders of magnitude higher than those required for 
inhibition of COX (Knight et al., 1987), suggests that the effects of NSAIDs such as 
indomethacin may not solely be attributable to COX inhibition. In 1997 Lehmann et al. 
reported that indomethacin was a micromolar ligand for PPARy and provided evidence 
that the adipogenic actions of this NSAID were a result of its binding to and activating 
PPARy (Lehmann et al., 1997). It is becoming clear that the emerging role of NSAIDs, 
such as aspirin and sulindac in the prevention and treatment of human cancer (Duperron 
and Castonguay, 1997) is a consequence not only of COX inhibition, but the ability of 
NSAIDs to affect alternative cellular targets. This is supported by the findings of Wick 
et al., who report that both sulindac sulfide and ciglitazone stimulate a promoter 
construct containing a PPARy response element linked to luciferase and are able to 
inhibit the growth of non-small-cell lung cancer cell growth. This study also 
demonstrates that overexpression of PPARy strongly inhibits the transformed growth 
properties of the cells (Wick et al., 2002).
In addition to agonists, a small number of PPARy antagonists have been described. 
Bisphenol A diglycidyl ether (BADGE), an antagonist that binds with micromolar 
affinity for PPARy, is a synthetic substance used in the production of plastics 
discovered during a screen for endogenous ligands for this receptor (Wright et al.,
2000). Wright et al. report that, in 3T3-L1 and 3T3-F442A cells BADGE does not 
activate the transcriptional activity of PPARy but antagonizes the ability of ligands, 
such as rosiglitazone, to activate the transcriptional and adipogenic activity of the 
receptor (Wright et al., 2000). However, Bishop-Bailey et al. report that, in the 
ECV304 cell line, BADGE acts as an agonist of PPARy at a similar level to 15d-PGJ2
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and ciglitazone inducing transcriptional activity of a PPAR reporter gene and cell death 
(Bishop-Bailey et al, 2000). These studies, once again, underline the importance of 
cell type specificity with respect to the effect of PPARy ligands upon cellular activity.
1.3.3 The role of PPARy in airway inflammation
Wang et al demonstrate that airway epithelial cells express constitutively high levels of 
PPARy and postulate that one of its roles in the airways to be that of a negative 
regulator of inflammation (Wang et al, 2001). This is supported by the findings of 
Patel et al (2003) who report that PPARy ligands inhibit cell growth, induce apoptosis 
and inhibit GM-CSF release in human airway smooth muscle cells. Additionally, this 
study also demonstrates that the PPARy ligands 15d-PGJ2 and ciglitazone are more 
effective at inhibiting cell growth and GM-CSF release than corticosteroids. These data 
suggest that PPARy ligands may be useful as effective anti-inflammatory therapies for 
treatment of diseases such as chronic obstructive pulmonary disease (COPD) and 
asthma where steroids are ineffective or have deleterious side effects. As previously 
mentioned, the inhibitory effects of PPARy ligands on the production of pro- 
inflammatory mediators are not only attributable to activation of PPARy, but to 
modulation of the activity of transcription factors including NF-kB (Castrillo et al, 
2000; Straus et al, 2000). It has been reported that 15d-PGJ2 inhibits NF-KB-dependent 
transcription by two distinct mechanisms. First, 15d-PGJ2 can interrupt NF-kB 
dependent gene expression through the covalent modification of critical cysteine 
residues in IKK, preventing IkB degradation and nuclear entry of NF-kB and secondly, 
15d-PGJ2 can directly inhibit binding of NF-kB to target DNA (Reviewed in Na and 
Surh, 2003). In diseases such as CF where activation of NFkB is exaggerated resulting 
in increased inflammatory mediator production, the use of PPARy ligands may prove 
effective in reducing inflammation and airway damage. Expression of PPARy is 
augmented in the airway epithelium of asthmatics compared with control subjects, and 
is negatively related to decline in lung function. Furthermore, corticosteroids have been 
observed to decrease the level of PPARy expressed (Benayoun et al, 2001). It is 
postulated that increased expression of PPARy in asthmatics may be a result of 
increased levels of IL-4, a cytokine produced by inflammatory cells with the ability to
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up-regulate PPARy (Huang et al.t 1999) and its down-regulation a result of the 
corticosteroid inhibition of IL-4 production (Bentley et al, 1996). Additionally, the 
ability of PPARy ligands to down-regulate the synthesis and release of macrophage- 
derived cytokines, seen to be elevated in the ASL of CF patients, support a major role 
for PPARy in disorders characterised by inflammation (Jiang et al, 1998; Ricote et al, 
1998; Welch et al, 2003). However, not all studies demonstrate an anti-inflammatory 
role for PPARy in the airways. Pang et a l report that in human airway smooth muscle 
(HASM) cells NSAIDs induce COX-2 expression through PPARy activation which may 
intensify the inflammatory response by increasing PG production (Pang et al, 2003).
In addition to its anti-inflammatory effects, 15d-PGJ2 has also been reported to have 
cytoprotective effects. It has been shown that 15d-PGJ2 can induce expression of the 
anti-oxidant enzyme Heme-Oxygenase-1 (HO-1) in activated microglial cells (Koppal 
et al, 2000), murine macrophages (Colville-Nash et al, 1998; Lee et al, 2003), and 
cardiac myocytes (Wayman et a l , 2002). HO-1 is an enzyme that catabolises heme to 
produce carbon monoxide (CO), free iron and biliverdin. Biliverdin is rapidly 
converted into the anti-oxidant bilirubin by the enzyme biliverdin reductase and any 
free iron is sequestered by ferritin (Maines, 1997). Three distinct isoforms of HO have 
been identified, each the product of a separate gene. HO-1 is an inducible isoform, its 
expression upregulated by pro-inflammatory cytokines, oxidative stress, heavy metals 
and UV light, whereas HO-2 and HO-3 are constitutively expressed isoforms. 
However, to date, HO-3 has only been expressed constitutively in rat neurones 
(McCoubrey et al, 1997). Several studies have shown that HO-1 has anti-inflammatory 
properties and the role of HO-1 as an anti-oxidant is well documented. Poss et al 
demonstrate that HO-1 deficient mice develop a chronic inflammatory state that 
increases with age (Poss et al, 1997). Furthermore, overexpression of HO-1 by gene 
transfer into rat lungs provided protection from hyperoxic injury (Otterbein et al,
1999). Elevated levels of CO are found in the exhaled breath of patients with 
inflammatory diseases such as asthma and CF, the source of which may be the airway 
epithelium (Donnelly and Barnes, 2001). In models of pulmonary inflammation, HO-1 
is potently cytoprotective and it is postulated that the anti-inflammatory effects of HO-1 
are in large measure mediated by CO (Reviewed in Otterbein et al, 2003). Lee et a l
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have demonstrated that HO-1 induced by IL-10 mediates the anti-inflammatory effects 
of this cytokine (Lee et al, 2003).
Levonen et al have shown that 15d-PGJ2, at low micromolar concentrations, induces a 
robust increase in cellular reduced glutathione (GSH) (Levonen et al, 2001). GSH is 
an important component of the cells anti-oxidant defenses. The GSH system effectively 
scavenges oxidants thereby protecting cells and tissues from damage. GSH production 
by the respiratory epithelium of CF airways is deficient compared to production by the 
epithelium of non-CF individuals. It is thought that the production of GSH protects the 
epithelial surface from oxidants produced by activated macrophages and neutrophils 
(Roum et al, 1999). Additionally, preliminary findings by Na et al show that doses of 
15d-PGJ2 (<5pM) rescue rat phenochromacytoma cells from oxidative or nitrosative 
stress (Na and Surh, 2003). This is supported by the findings of Colville- Nash et al 
who report that 15d-PGJ2 induced HO-1 expression is accompanied by a reduction in 
inducible nitric oxide synthase (iNOS) expression and subsequent NO production 
(Colville-Nash et al, 1998). In contrast, at higher concentrations (lOpM) 15d-PGJ2 
induces endothelial cell apoptosis (Levonen et al, 2001).
PPARy has been implicated in the pathophysiology of diverse human disorders 
encompassing inflammation, atherosclerosis, diabetes and obesity (Kersten et al, 2000). 
The ability of PPARy ligands to inhibit the activity of transcription factors such as NF- 
kB and down-regulate the production of pro-inflammatory mediators including 
cytokines, COX-2, and iNOS whilst increasing the expression of protective mediators 
such as GSH and HO-1 show the potential of PPARy ligands to target inflammation. 
These findings are thought to be especially relevant to inflammatory disorders of the 
airways, such as CF, where pro-inflammatory pathways are up-regulated and anti­
inflammatory pathways are suppressed leading to tissue damage and deterioration of 
lung function. However, the inhibition of multiple cell signalling pathways and 
contradicting effects of PPARy in different cell types suggest that the exact mechanisms 
of effect and tissue specific effects need to be further elucidated.
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1.4 Aims of the study
Accumulating evidence suggests the induction and regulation of COX-2 may be key 
elements in the pathophysiological process in a number of inflammatory disorders of 
the airways such as cystic fibrosis (Pang, 2001). Zakrzewski et al, (1987) and 
Strandvik et al., (1996) report that PG levels in sputum, and metabolites of PGs 
excreted in the urine of CF patients are increased when compared to healthy individuals 
and may contribute to the pathophysiology of the disease. Elucidation of the PG 
biosynthetic pathway in the human airway epithelium may facilitate better therapeutic 
approaches to regulating inflammatory disorders of the airways such as asthma and CF. 
Recent evidence suggests that ligands of the nuclear hormone receptor PPARy are able 
down-regulate the production of inflammatory mediators, including COX-2, in the 
airways (Wang et al, 2001; Patel et al, 2003). Additionally, 15d-PGJ2 has been shown 
to increase the expression of HO-1 in a number of cell systems. HO-1 expression, in 
patients with CF, is reported to be cytoprotective and augmentation of its expression is 
proposed as a potential therapy against bacterial injury (Zhou et al, 2004). It is 
therefore of interest to assess the anti-inflammatory potential of PPARy ligands in the 
airway epithelium.
The aim of this project was to investigate whether PPARy ligands are able to modulate 
PG production in the human tracheal epithelium using cell lines with a CF phenotype, 
ZCFTE29o", and non-CF phenotype, 9HTEo\
The objectives of this project were therefore as follows:
• To determine the expression of enzymes of the PGE2 biosynthetic pathway, and 
their regulation by pro-inflammatory mediators, in human tracheal epithelial cell 
lines ICFTE29o' and 9HTEo", cells with a CF and non-CF phenotype 
respectively
• To characterise the production of PGs by human airway epithelial cells and the 
regulation of their production by pro-inflammatory cytokines
• To investigate whether the PG biosynthetic pathway can be modulated by 
PPARy and its ligands
• To determine the cytoprotective effects of PGs in human tracheal epithelial cell 
line
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2. Materials
2- Mercaptoethanol Sigma, Poole, UK
Acrylamide Bio-Rad, UK
Ammonium persulphate BDH, Poole, UK
Aprotinin Sigma, Poole, UK
BADGE Tocris, Bristol, UK
Bovine serum albumin (BSA) Sigma, Poole, UK
Bromophenol blue Sigma, Poole, UK
Cell culture plastics Nunc, Leicestershire UK
cPGES Antibody Cayman Chemicals, MI, USA
COX-1 Antibody Santa-Cruz, CA, USA
COX-2 Antibody Santa-Cruz, CA, USA
Dimethyl sulphoxide (DMSO) Sigma, Poole, UK
Enhanced chemiluminescence detection kit 
(ECL)
Amersham International, UK
Ethylenediaminetetraacetic acid (EDTA) Sigma, Poole, UK
Foetal bovine serum (FBS) Gibco BRL, Paisley, UK
Glycerolf Sigma, Poole, UK
Glycine Sigma, Poole, UK
Human recombinant IL-lp Generous gift from Glaxo Wellcome, 
Greenford, UK
Human recombinant IL-13 Generous gift from Dr A. Minty, Sanofi Elf 
Bio Recherches, Laberges, France
Human recombinant IFNy Boehringer Mannheim, Mannheim, 
Germany
Human recombinant TNFa Generous gift from Bayer, Slough, UK
Hydrochloric acid BDH, Poole, UK |
Materials 56
Hygromycin Calbiochem, Darmstadt, Germany
Leupeptin Sigma, Poole, UK
Methanol Fisons, Loughborough, UK
Molecular weight markers Biorad, Hertfordshire, UK
mPGES antibody Cayman Chemicals, MI, USA
N-(2-(Cyclohexyloxyl)-4-nitrophenyl) 
methanesulfonamide (NS-398)
Sigma, Poole, UK
Ponceau S solution Sigma, Poole, UK
Prostaglandin E2 ELISA kit R&D Systems, Abingdon, UK
Prostaglandin D2 MOX EIA Cayman Chemicals, MI, USA
Sodium azide Sigma, Poole, UK
Sodium chloride Sigma, Poole, UK
Sodium dodecyl sulfate (SDS) Sigma, Poole, UK
Sodium fluoride Sigma, Poole, UK
Sodium hydroxide Sigma, Poole, UK
Sodium molybdate Sigma, Poole, UK
Sodium nitrite Sigma, Poole, UK
Sodium orthovanadate Sigma, Poole, UK
TEMED Sigma, Poole, UK
Tissue culture reagents Gibco BRL, Paisley, UK
Trizma base Sigma, Poole, UK
Trypan blue Sigma, Poole, UK
Tween-20 Sigma, Poole, UK
Versene Gibco BRL, Paisley, UK
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Vitrogen Gibco BRL, Paisley, UK
3. Methods
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3.1 Cell culture conditions
3.1.1 ZCFTE29o‘ and 9HTEo' cell lines
A lack of tissue and the need to determine the biochemical and genetic causes of airway 
disease in CF has led to the development of defined cell culture systems. Primary cell 
culture has played an important role in the characterisation of cell specific functions, 
however its use is limited by availability of tissue and the small number of viable cells 
generated by the available tissue. Additionally, variability between different donor 
epithelia complicates the design and interpretation of data obtained from primary cells. 
Development of immortal cultures of airway epithelial cells has provided a useful 
system in which to study the biochemical defects in CF. The XCFTE29o', a human 
tracheal epithelial cell line homozygous for the AF508 CFTR mutation, and the human 
tracheal epithelial cell line 9HTEo' used in this study were generous gifts from D.C. 
Gruenert (University of San Francisco, CA, USA). These cell lines were created by 
transfecting human tracheal epithelial cell lines with a plasmid containing a replication- 
defective simian virus 40 (SV40) genome. The process resulted in transformed human 
tracheal epithelial cell lines, which have passed through crisis and are immortal whilst 
retaining aspects of the original phenotype. These include the presence of microvilli, 
responsiveness to agonists, Cl* ion transport and the ability to form tight junctions. 
Furthermore, electrophysiologically, £CFTE29o’ cells have been demonstrated to show 
no cAMP-dependent Cl transport as observed in primary cell lines expressing the 
AF508 mutation (Gruenert et al, 1988, Kunzelmann et al, 1993).
The maintenance of phenotypic aspects of primary cells such as Cl' ion transport and 
responsiveness to agonists by the £CFTE29o' and 9HTEo* cell lines make them useful 
in the characterisation of airway epithelial biology and airway surface liquid 
composition in both the presence and absence of defective chloride conductance 
respectively. In this study these cell lines are used in order to determining the biologic 
significance of this mutation in the airway epithelium and its effect on prostaglandin 
production and regulation.
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3.1.2 A549 Airway Epithelial Cell Line
The human type II Alveolar carcinoma cell line A549 (Lieber et al, 1976) was 
obtained from the American Type Culture Collection (ATCC).
3.1.3 Culture of ZCFTE29o' and 9HTEo' cell lines
XCFTE29o‘ and 9HTEo' cells were routinely cultured in Vitrogen coated 170cm tissue 
culture flasks in MEM medium supplemented with 10% (v/v) FBS (referred to as
complete medium), penicillin (10 u/ml), streptomycin (10 pg/ml), and fungizone (0.5
pg/ml). Cultures were maintained in a humidified air / 5% CO2 atmosphere. The 
medium was changed every 2 - 3  days.
A549 cells were routinely cultured in 170cm2 tissue culture flasks in Dulbecco’s 
modified Eagle’s medium with sodium pyruvate + L-glucose + pyroxidine (DMEM). 
The medium was supplemented with 10% (v/v) FBS (referred to as complete medium), 
penicillin (10 u/ml), streptomycin (10 pg/ml), and fungizone (0.5 pg/ml). Cultures 
were maintained at 37°C in a humidified air / 5% CO2 atmosphere. The medium was 
changed every 2 - 3  days.
To subculture confluent monolayers, the medium was removed and the cells washed 
three times with PBS (w/o Ca2+ and Mg2+). The cells were then washed with 3 ml 
Trypsin-EDTA mixture of 0.05% (w/v) Trypsin and 0.02% (w/v) EDTA. The cells 
were incubated at room temperature until the cells had detached from the flask. The 
action of the Trypsin-EDTA was inhibited by adding 10ml of complete MEM or 
DMEM medium and the cell suspension was centrifuged at 200g for 10 min. The pellet 
was resuspended in complete medium and cell counting and viability were checked in a 
Neubauer haemacytometer after mixing with Trypan Blue (Sigma). Dead cells stained 
blue, resulting from uptake of Trypan blue. Cell viability was always greater than 95%. 
Cells were counted and then seeded at 1 -  1.5 x 106 /ml of complete MEM medium, 
into 170 cm tissue culture flasks for further culture, into 92mm petri dishes at 1 x 10 / 
3 ml of complete MEM medium, for western analysis and into 24 well plates at 1 x 104  
/ml of complete MEM medium, for ELISA experimental protocols. Flasks and plates 
reached confluency after approximately four days.
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For storage, cells were resuspended at 3 x 106 /ml of freeze medium. The freeze 
medium contained 10% dimethyl sulfoxide (DMSO), 40% FBS and 50% MEM medium 
supplemented with 40% FBS. The cell suspension was transferred into cryotubes 
(Nunc) at 1 ml/tube, gradually cooled in vapour phase of liquid nitrogen overnight and 
then stored in liquid nitrogen tanks. For resuscitation of cells from liquid nitrogen, cells 
were rapidly defrosted at 37°C in a water bath, resuspended in 15ml o f complete 
medium and centrifuged at 200g for 10 min. Pellets were resuspended in 25ml of 
complete MEM medium and transferred into 170 cm2 tissue culture flasks.
3.2 E xp erim en ta l P rotoco l
Airway epithelial cell lines were seeded into and cultured in vessels appropriate to the 
planned experiment:
Six to Twenty-four hours prior to experimentation confluent monolayers were washed 
and cultured in FBS free medium and stimulated with appropriate doses of drugs, 
cytokines, prostaglandin or vehicle control for the times described in the results section. 
Supernatants were collected for ELISAs and stored at -80°C until assayed, for 
prostaglandin ELISAs 10 pM indomethacin was added to supernatants prior to freezing. 
Total RNA and cellular proteins were extracted as described below. Cell counting and 
viability were routinely checked at the beginning and end of the experiment, by MTT 
assay, phase microscopy and by trypan blue exclusion, using representative wells. Cell 
viability was always greater than 95%.
Culture Vessel
Western analysis 92 mm petri dishes
Cell Number Seeded
1 -  2 x 105 per dish 
1 x 105 per well 
1 x 106 per flaskGlutathione assay
ELISAs 24 well plates 
170 cm2 flasks
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3.3 Western Blot Analysis
3.3.1 Overview
Western blot analysis is a technique that enables visualisation of relative amounts of 
specific proteins expressed within cells. Cells are lysed to extract whole proteins that 
can then be quantified. Whole cell extracts can be run in a current through a 
polyacrylamide gel separating proteins according to their molecular weight. Proteins 
can then be transferred to a nitrocellulose membrane that is incubated with a primary 
antibody specific for the protein to be assessed. A second incubation is then undertaken 
with a labelled secondary antibody against the primary antibody. The membrane is then 
washed and the relative amount of labelled protein assessed, typically by a reaction 
catalysed by a horseradish peroxidase tag on the secondary antibody that can then be 
visualised.
3.3.2 Sample Preparation
Monolayers of airway epithelial cells were stimulated and incubated at 37°C as 
described. Stimulations were terminated at the appropriate times with aspiration of the 
supernatant, a rinse with PBS (w/o Ca2+ or Mg2+) and the addition of ice cold lysis 
buffer. Cells were solubilised using a cell scraper and the resulting lysates transferred 
to 1.5 ml eppendorf tubes. The samples were then centrifuged at 12000g for 5 min and 
the protein containing supernatant transferred to a fresh eppendorf, an aliquot of the 
each lysate was then removed for subsequent protein assay. A relevant amount of 5 X 
SDS sample buffer was then added to the lysate and the resulting solution boiled for 10 
min. The samples were then frozen at -80°C.
3.3.3 Protein assay
Total protein per lysate was determined using the Bio-Rad DC Protein Assay. This 
assay is based on the Bradford dye-binding procedure. Known concentrations of bovine 
serum albumin (BSA) diluted in lysis buffer were used as a standard curve. Samples 
and standards were diluted in 20% Bio-Rad assay in MilliQ water. 200 pi of standard or 
sample were transferred to a 96 well plate. The plate was read at 595 nm on a Dynatech 
MR5000 platereader. The protein concentrations were then calculated by linear 
regression from the standard curve. Equal concentrations of protein could then be 
loaded onto polyacrylamide gels for western analysis.
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3.3.4 Separation of Cellular Proteins by Electrophoresis
Proteins were analysed by one dimensional gel electrophoresis, which under reducing 
conditions separates proteins based on molecular size. Sodium Dodecyl Suphate -  
Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out essentially as 
described by Laemmli (Laemmli, 1970). Proteins were separated by SDS-PAGE using 
the Bio-Rad Mini Protean II.
Minigels of the appropriate percentage were prepared as described in the appendix. The 
resolving gel was poured into the gel equipment and overlaid with MilliQ water. After 
the resolving gel had set, the water was removed and the stacking gel poured on top and 
set with a 10 or 15 well comb inserted. When the stacking gel was set the comb was 
removed. ~ 25 pg of protein was loaded per lane alongside a molecular weight marker. 
Gels were run in running buffer at room temperature at 100V, until the bromophenol 
blue tracking dye entered the resolving gel. The voltage was then increased to 200V. 
Gels were run until the blue band reached the bottom of the running gel. Gels were then 
placed in transfer buffer.
3.3.5 Wet Transfer of Proteins to Nitrocellulose
Each gel was placed on top of a nylon pad and 2 pieces of 3MM filter paper and 
overlaid with nitrocellulose membrane all of which had been dampened with transblot 
buffer (Boehringer Mannheim). Another two pieces of dampened filter paper and a 
nylon pad were placed on top of the nitrocellulose membrane and rolled gently to expel 
air. The sandwich was then placed in a transblot cassette and placed in a transfer tank 
(Bio-Rad) filled with ice-cold transblot buffer. An additional ice pack was also added 
to the tank to prevent the apparatus overheating. The transfer was run at 100V for 1 
hour. The membrane was the stained with Ponceau S (Sigma) to check for successful 
transfer, equal loading and determination of the position of the molecular weight 
markers. The stain was removed by washing the membrane first with distilled water, 
followed by a 10 min was with Tris buffered saline (TBS).
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3.3.6 Immunoblotting of Nitrocellulose bound protein
Non-specific protein binding was blocked by incubation of the membrane for 1 h at 
room temperature in 5% non-fat dried milk protein reconstituted in TBS. Membranes 
were then incubated for 2  h - overnight on a rocking platform at room temperature, with 
an appropriate primary antibody diluted in TBS. Subsequent to incubation membranes 
were washed for two 5 min periods in TBS/Tween and three ten min. periods in TBS 
prior to a 1 h incubation with the appropriate secondary antibody, followed by washing 
as described above. Membranes were drained of excess TBS and 1ml of Enhanced 
Chemiluminescent (ECL) reagent added to their surface for 1 minute before being 
exposed to X-ray film that was developed using an RGII-Fuji X-ray film developer.
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3.4 Prostaglandin E2 ELISA
3.4.1 Overview
This assay to measure PGE2 concentration uses a kit from R&D Systems (Abingdon, 
UK). It is based on the competitive binding technique in which PGE2 present in the 
supernatant competes with a fixed amount of alkaline phosphatase-labelled PGE2 for 
sites on a mouse monoclonal antibody. During an incubation period, the mouse 
monoclonal antibody becomes bound to the goat anti-mouse antibody that coats the 
microplate. Following a wash to remove excess conjugate and unbound sample, a 
substrate solution is added to the wells to determine the bound enzyme activity. The 
intensity of the colour generated is inversely proportional to the concentration of PGE2 
in the sample (Figure 8 ).
3.4.2 Assay procedure
Known concentrations of a PGE2 standard were diluted into cell culture medium and 
used for a standard curve (7.8 pg/ml - 1000 pg/ml). 100 pi of standard or sample were 
loaded into a microplate coated with goat anti-mouse antibody. To each was added 50 
pi of PGE2 conjugate (conjugated to alkaline phosphatase) and 50 pi of PGE2 antibody 
solution (mouse monoclonal). The plates were covered and incubated for 18 -  24 h at 
4°C. After this incubation the wells were aspirated and washed three times with 200 pi 
of wash buffer using multi-channel pipette. After the last wash the plate was inverted 
and blotted against clean paper towelling to ensure removal of all liquid remaining in 
the wells. pNPP substrate (200 pi) was then added to all wells and incubated for 1 h at 
37°C. The optical density at 405 nm was then determined using a Dynatech MR5000 
plate reader. The PGE2 concentrations were calculated by comparison to the sigmoid 
standard curve using BioLinx software.
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3.5 Prostaglandin D2 ELISA
3.5.1 Overview
This assay measures PGD2 in cell supernatants and uses a kit from Cayman Chemicals 
(Ann Arbor, MI, USA). It converts unstable PGD2 to stable PGD2-methoxime (PGD2- 
MOX) by methoximation. This assay is then based upon the competitive binding 
technique in which the now present PGD2-MOX competes with a fixed amount of 
acetylcholinesterase-labelled PGD2-MOX for sites on a specific rabbit antibody. 
During an incubation period, the rabbit anti- PGD2-MOX antibody becomes bound to a 
mouse anti-rabbit monoclonal antibody that coats the microplate. Following a wash to 
remove excess conjugate and unbound sample, a substrate solution (Ellman’s reagent) is 
added to the wells to determine the bound enzyme activity. The intensity of the colour 
generated is inversely proportional to the concentration of PGD2 present in the sample 
(Figure 8 ).
3.5.2 Assay Procedure
A methyl oximating reagent was prepared by diluting supplied methyloxamine HC1 in 
10 ml of 10% (v/v) solution of ethanol in water. To this was added the supplied sodium 
acetate to give the final reagent. The PGD2 standard was diluted in 900 pi of MilliQ 
water and then 1:1 solution was prepared with the methyl oximating reagent. This was 
heated to 60°C for 30 min resulting in a methoximated standard solution with a 
concentration of 20 ng/ml. This was used to generate a standard curve by dilution in 
EIA buffer (7.8 -  1000 pg/ml). Next the cell culture supernatant samples were thawed 
and 100 pi was added to the same volume of methyl oximating reagent. This solution 
was heated to 60°C for 30 mins, then centrifuged at 12000g for 5 mins and the 
supernatant diluted to 1:5 in EIA buffer. The microplate was washed in wash buffer 
prior to use. 50 pi of standard or sample was added to the microplate coated with 
mouse anti-rabbit monoclonal antibody. To each was added 50 pi of PGD2 anti-rabbit 
antibody solution and 50 pi of PGD2 conjugate. The plated were covered and incubated 
overnight at room temperature. After incubation the wells were aspirated and washed 
five times with 2 0 0  pi wash buffer using a multi-channel pipette, the plate was then 
inverted and blotted on clean paper towelling to remove all liquid from the wells. 2 0 0  
pi of Ellman’s reagent was added to all wells and incubated for 1 h in the dark at room 
temperature. The optical density 405 nm was determined using a Dynatech MR5000
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platereader. The PGD2 concentrations were calculated by comparison to the standard 
curve (linear when plotted on log/lin scale) using BioLinx software.
Figure 8  Schematic representation of prostaglandin ELISAs. Competitive binding 
technique used in PGE2 and PGD2 ELISAs
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3.6 IL-8 ELISA
3.6.1 Overview
This assay to measure IL- 8  concentration is based on the competitive binding technique 
in which IL- 8  present in the supernatant competes with a fixed amount of labelled IL- 8  
for sites on a mouse monoclonal antibody. During an incubation period, the mouse 
monoclonal antibody becomes bound to the goat anti-mouse antibody that coats the 
microplate. Following a wash to remove excess conjugate and unbound sample, a 
substrate solution is added to the wells to determine the bound enzyme activity. The 
intensity of the colour generated is inversely proportional to the concentration of IL- 8  in 
the sample.
3.6.2 Assay procedure
An appropriate number of 96 well microplates (Nunc) were coated with 50 pi per well 
of monoclonal anti-human IL- 8  antibody (2pg/ml, R&D Systems) in PBS pH 7.4. 
Plates were covered, incubated overnight at room temperature and then washed three 
times in wash buffer using a multi-channel pipette. Following washing plates were 
inverted on clean paper towelling to extract any liquid present. The plates were blocked 
by the addition of 1 0 0  pi per well of blocking buffer and left for 1 h at room 
temperature. Three more washes followed. A range of IL- 8  standards were prepared 
(0.025-2ng/ml) in MEM medium. Standards and samples (50 pi per well) were added 
in duplicate to the plates and incubated for 2 hours at room temperature. Plates were 
washed 3 times and blotted and 100 pi per well of biotinylated anti-human IL- 8  
detecting antibody (20 ng/ml, R&D Systems) in dilution buffer was added to the plates 
for 1 hour at 37°C. Three more washes and blotting followed and 50 pi per well of 
streptavidin peroxidase (0.5 pg/ml, R&D Systems) in dilution buffer was added to all 
wells for 30 min and incubated at 37°C. Plates were washed three times. One 10 mg 
tablet of 1,2 phenylene dihydrochloride (Sigma) and 20 pi of 30% hydrogen peroxide 
were added to 50 ml of warmed substrate buffer. This solution was added to the plates 
(100 pi per well), which were incubated for 30 minutes at room temperature in the dark. 
The reaction was terminated with 150 pi per well 1 M H2 SO4 . The optical density 490 
nm was determined using a Dynatech MR5000 plate reader. IL- 8  concentrations were
Methods 68
calculated by comparison to the standard curve (linear when plotted on log/lin scale) 
using BioLinx software.
3.7 Glutathione assay
3.7.1 Reduced glutathione (GSH) assay
Cells were washed twice and and resuspended in PBS at lxlO6 ml"1. 500pl aliquots of 
cell samples were sonicated (3 five second pulses, 8  -  10Hz) to disrupt the cell 
membranes. 500pl of assay cocktail (40 pM monochlorobimane, 0.1 u/ml' 1 GSH-S- 
transferase) was immediately added to both sonicated samples and GSH standards (0, 
2, 4, 8 , 16, 32, and 64 pM), and the samples left to develop fluorescent adduct for ten 
minutes at room temperature, protected from light. Samples were then measured on a 
fluorimeter, with a 1cm light path, and excitation wavelength 395nM, emission 
wavelength 470nM. A standard curve was constructed, and GSH levels in cell samples 
determined (per 1 x 1 0 6 cells).
3.8 MTT assay
Cells were grown to 80% confluency, in 3 cm plates, and incubated at 37°C in serum 
free medium. Cells were then either stimulated with either vehicle or ligands as each 
experiment required. After treatment, monolayers were washed twice with PBS and 
500pl of 0.5mg/ml MTT reagent in serum free medium was added to each plate. Plates 
were incubated for 2 hours at 37°C. After incubation the MTT/serum free medium was 
aspirated from the plates and 1ml of DMSO added. Plates were swirled for 2 -  3 
minutes on a shaker and 100 pi was pipetted off each plate into a 96 well plate, this was 
performed in triplicate. The 96 well plate was read at 570nm using DMSO as a blank 
control.
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3.9 Transfection of cell lines with GFP-linked PKB constructs
Cells were grown, until 40 -  60% confluent, on coverslips, in six-well tissue culture 
plates at 37°C in a CO2 humidified incubator. Subsequently, 1 pg of DNA and 6 pl of 
PLUS reagent were diluted into 100 pi serum free medium in a sterile tube. In separate 
tubes lipofectAMINE PLUS reagent diluted in 100 pi serum free medium. These 
tubes were then combined, mixed gently and incubated at room temperature for 15 
minutes. Cells were washed once with serum free medium and replaced with 800 pi of 
fresh serum free medium. For each transfection the DNA/PLUS reagent and 
LipofectAMINE PLUS reagent was added to the 800 pi of serum free medium over­
laying the cells. Cells were then incubated in the presence of the transfection reagents 
for three hours at 37°C in a CO2 humidified incubator. After incubation, the DNA- 
containing medium was replaced with MEM supplemented with 10% foetal calf serum 
and incubate at 37°C in a CO2 humidified incubator for a further 24 h. Cell extracts 
were examined for GFP expression using a confocal microscope 24 h post transfection.
3.10 Statistical analysis
Duplicate determinations were performed in each experiment. The number (n) of 
independent experiments is given in the figure legend. Data were analysed by analysis 
of variance (ANOVA) to determine if any statistical significance existed within data 
groups. ANOVA was followed by Dunnett’s test for the comparison of multiple groups 
to controls. Data were expressed as means ± SEM of n independent experiments. A 
probability value of p<0.05 was taken as the criterion for significant difference.
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Chapter 4: IL-8 and prostaglandin production in human tracheal 
epithelial cell lines. 
4.1 Introduction
Increased levels of PGs have been reported in the sputum of CF patients when 
compared to healthy individuals (Zakrezewski et al, 1987; Strandvik et al, 1996). The 
aim of this work was to examine the production of PGE2 in CF and non-CF human 
tracheal epithelial cells, using the 9HTEo' and £CFTE29o' cell lines as models of the 
human airway epithelium. The 9HTEo" and XCFTE29o' cell lines are both human 
tracheal epithelial cells exhibiting non-CF and a CF phenotype respectively. In order to 
determine that these cell lines express functional receptors for pro-inflammatory 
cytokines and that cytokine signalling pathways are intact, IL- 8  levels were measured in 
each cell line both under basal and stimulated conditions.
4.2 Results
4.2.1 IL-8 production by human tracheal epithelial cell lines 9HTEo~ and 
ICFTE29o' cells
Initial investigations were conducted in order to determine that the cell lines used were 
responsive to pro-inflammatory cytokines. IL- 8  production was investigated using an 
IL- 8  enzyme-linked immunosorbant assay (ELISA), as described in the materials and 
methods section, under both basal and stimulated conditions. IL- 8  levels were 
determined in cell culture supernatants collected from confluent monolayers of 9HTEo‘ 
and ECFTE29o' cells grown at 37°C and serum starved for 6  hours prior to stimulation 
with vehicle or increasing concentrations of TNFa (0.01 -  10 ng/ml), IL-ip (0.01 -  10 
ng/ml), and IFNy (0.01 -  10 units/ml) either alone or in combination for a period of 24 
hours.
Both 9HTEo' and ECFTE29o* cells produced a small amount of IL- 8  in the absence of 
cytokine stimulation (1.96 ± 0.40 ng /106 cells in the 9HTEo' cell line and 2.24 ± 0.62 
ng/106 cells) in the ECFTE29o" cell line (figure 9). The difference between these levels
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was not found to be significant (n = 4, p=0.15). Incubation of the cell lines with either 
TNFa (figure 9) or IL-lp (figure 10) resulted in a concentration dependent increase in 
IL- 8  levels in both the 9HTEo' and £CFTE29o' cell lines. Incubation with TNFa 0.01 
and 0.1 ng/ml had no significant effect upon basal IL- 8  production in either 9HTEo' 
cells or £CFTE29o" cells. In comparison, stimulation of the cells with TNFa (1 and 10 
ng/ml) resulted in a significant increase in IL- 8  generation in both cell lines when 
compared to basal (n = 4, p<0.01). It is worth noting that upon incubation with 
TNFa (10 ng/ml) £CFTE29o" cells produce significantly more IL- 8  than 9HTEo' cells 
(p<0.05). Incubation of 9HTEo" cells with IL-lp (0.01 ng/ml) induced a significant 
increase in IL- 8  production from basal levels of (n = 4, p<0.05). Incubation with IL-ip 
(0.1, 1, and 10 ng/ml) further increased IL- 8  production in the 9HTEo' cell (n = 4, 
p<0.01). In the XCFTE29o' cell line IL- 8  production in response to IL-ip (0.01- 
lOng/ml) exhibited bell-shaped characteristics, IL-lp (0.1 and 1 ng/ml) inducing a 
significant increase in IL- 8  production (n= 4, p<0.01). Additionally, 9HTEo‘ cells 
stimulated with higher concentrations of IL-lp (1 and 10 ng/ml) produced significantly 
more IL- 8  than the £CFTE29o" cell line. Increasing concentrations of pro- 
inflammatory cytokine IFNy had no effect on basal IL- 8  levels in either cell line (figure
11).
Stimulation of the 9HTEo' and £CFTE29o' cells with a combination of IFN-y(l 
unit/ml) with IL-lp (0.01 ng/ml) or TNFa (0.1 ng/ml) did not significantly induce IL- 8  
production in either cell line (figure 12). In combination TNFa (0.1 ng/ml) and IL- 
lp (0.01 ng/ml) significantly increased IL- 8  production in both the 9HTEo' and 
ECFTE29o' cell lines (n = 4, p<0.05). However, the combination of TNFa (0.1 ng/ml) 
and IL-ip (0.01 ng/ml) did not cause a significant increase in IL- 8  generation when 
compared to that induced by either TNFa (O.lng/ml) or IL-ip (O.Olng/ml) individually. 
Additionally, when these cell lines were stimulated with a combination of IFN-y (1 
unit/ml), IL-ip (0.01 ng/ml), and TNFa (0.1 ng/ml) IL- 8  production by both cell lines 
was significantly increased above basal, and above the level generated in response to 
TNFa (O.lng/ml) or IL-ip (O.Olng/ml) individually in =4, p<0.01).
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Incubation of the cell lines with AA had no significant effect on basal IL- 8  production 
by either the 9HTEo' or ZCFTE29o‘ cell lines (figure 13). At the concentrations used 
in this study, 10 and 100 pg/ml, PGE2 also failed to have a significant effect upon IL- 8  
generation by the tracheal epithelial cell lines used in this study (figure 14).
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Figure 9 Effect of TNFa on IL- 8  production by 9HTEo' and ZCFTE29o‘ cells
24 h treatment with increasing concentrations of TNFa (0.01 -  10 ng/ml). Cells were 
serum starved overnight prior to treatment. Basal is the amount of IL-8 produced in 
response to vehicle alone. Each point is the mean ± SEM of four experiments, samples 
are run in duplicate in each assay. (**p<0.01 compared with basal).
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Figure 10 Effect of IL-ip on IL- 8  production by 9HTEo' and SCFTE29o' cells
24 h treatment with increasing concentrations of IL-ip (0.01 -  10 ng/ml). Cells were 
serum starved overnight prior to treatment. Basal is the amount of IL-8 produced in 
response to vehicle alone. Each point is the mean ± SEM of four experiments, each 
sample is measured in duplicate within each assay. (*p< 0.05 compared with basal; 
**p<0.01 compared with basal).
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Figure 11 Effect of IFNy on IL-8 production by 9HTEo' and ZCFTE29o' cells
24 h treatment with increasing concentrations of IFNy (0 .01 -  10 ng/ml). Cells were 
serum starved overnight prior to treatment. Basal is the amount of IL-8 produced in 
response to vehicle alone. Each point is the mean ± SEM of four experiments, each 
sample is measured in duplicate.
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Figure 12 Effect of cytomix on IL- 8  production by 9HTEo‘ and ZCFTE29o' cells
24 h treatment with IFN-y (1 unit/ml), IL-lp (0.01 ng/ml) or TNFa (0.1 ng/ml) either 
alone or in combination. Cells were serum starved overnight prior to treatment. Basal 
is the amount of IL-8 produced in response to vehicle alone. Each point is the mean ± 
SEM of four experiments each carried out in duplicate. (* p<0.05 when compared to 
basal; ** p<0.01 when compared to basal).
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Figure 13 Effect of AA on IL- 8  production by 9HTEo' and £CFTE29o‘ cells
Effect of 24 h treatment with AA (0 -1 0  pM). Cells were serum starved overnight 
prior to treatment. Basal is the amount o f IL-8 produced in response to vehicle alone. 
Each point is the mean of two experiments each carried out in duplicate.
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Figure 14 Effect of PGE2 on IL- 8  production by 9HTEo' and LCFTE29o~ cells
Effect of 24 h treatment with PGE2 10 and 100 pg/ml. Cells were serum starved 
overnight prior to treatment. Basal is the amount of IL-8 produced in response to 
vehicle alone. Each point is the mean of two experiments each carried out in duplicate.
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4.2.2 Cyclooxygenase expression in the human tracheal epithelial cell lines 9HTEo~ 
and ECFTE29o'
Monolayers of 9HTEo" and ZCFTE29o’ cells were grown, at 37°C, until approximately 
90% confluent and subsequently serum starved for 4 hours prior to either harvest or 
stimulation with pro-inflammatory cytokines. COX-1 and COX-2 protein expression 
was determined by immunoblot analysis as described in the materials and methods 
section. Both 9HTEo' and XCFTE29o‘ cell lines constitutively express COX-1 protein 
(figures 15A and 15B), however COX-1 expression in the 9HTEo' cell line is higher 
than that of the XCFTE29o’ cell line. As expected, COX-1 protein expression was not 
induced by TNFa (0.1 - 10 ng/ml), IL-ip, (0.1 -  10 ng/ml), (figures 15A and 15B) 
IFNy (0.1 -  10 units/ml) or a combination of all three of these pro-inflammatory 
cytokines (figures 16A and 16 B).
COX-2 protein expression was observed in untreated 9HTEo' and ECFTE29o" cells 
with no obvious difference in expression between these two cell lines (figure 17). 
COX-2 protein expression has been reported to be up-regulated in response to pro- 
inflammatory cytokines in a number of airway cell lines (Mitchell et al, 1994; Watkins 
et al, 1999; Rodgers et al, 2002). To investigate the time course of COX-2 protein 
induction in response to pro-inflammatory cytokines cells were incubated at 37°C with 
a combination of TNFa (10 ng/ml), IL-l-p (1 ng/ml) and IFNy (10 u/ml) and 
subsequently harvested 2, 6 , 14, and 24 hours post stimulation, concomitantly 
untreated control samples were collected for each time point. No up-regulation of 
COX-2 expression was observed in response to the cytomix compared to control 
samples at any of the time points (figures 18 A and 18B). Additionally, COX-2 protein 
expression was not significantly affected by any of these cytokines administered 
individually at these time points. After 48 hours or when incubated with higher 
concentrations of cytokines the viability of the cells decreased. Microscopic 
examination revealed a decrease in cell number, and an increase in cell debris with cell 
viability typically reducing to >50% in the 9HTEo' cell line. In view of this, time 
courses were routinely constructed over a 24 hour period. In order to determine any 
dose -  dependent effect of pro-inflammatory cytokines on COX-2 protein 9HTEo" and 
XCFTE29o' cells were incubated at 37°C with TNFa (0.1 - 10 ng/ml), IL-ip (0.1 -  10
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ng/ml), IFNy (0.1 - 10 units/ml) either alone or in combination for 24 hours. Once 
again no significant increase in COX-2 expression was detectable in either cell line in 
response to any of the cytokines used in this study (figures 19 A, B, C and D). 
Additionally, cells were serum starved for 6  hours prior to 24 hour stimulation, at 37°C, 
with increasing concentrations of IL-13 (0 .1 -1 0  ng/ml). The cytokine IL-13 has been 
demonstrated to negatively regulate COX-2 protein expression in lung fibroblasts (Saito 
et al, 2003), thus the effect of IL-13 on COX-2 expression was investigated in 
XCFTE29o" and 9HTEo' cells. No detectable change in COX-2 protein expression was 
observed in either 9HTEo' or ECFTE29o" cells in response to any of the concentrations 
of IL-13 used in this study (figure 20).
PGs are products of COX enzymes, however, it has also been demonstrated that they 
are able to modulate the expression of COX-2 (Mitchell et al., 1994; Belvisi et al, 
1997; Pang et al, 1998; Bonazzi et al, 2000). In order to determine whether PGE2 
concentration affects the expression of COX-2 in 9HTEo' and SCFTE29o‘ cells, 
monolayers of these cells were grown, at 37°C, until approximately 90% confluent and 
subsequently serum starved for 4 hours prior to stimulation with vehicle or increasing 
concentrations of PGE2 for 24 h. COX-2 protein expression was detected using 
immunoblot analysis as described in the materials and methods section. No change in 
COX-2 protein expression could be detected in either the 9HTEo* or ECFTE29o' cell 
line in response to any of the concentrations of PGE2 used in this study (figures 2 1 A 
and 2IB). Both cell lines were also incubated, for 6  hours, with either vehicle or PGE2 
to ensure that no earlier change in COX-2 protein expression had been missed. Once 
again no detectable change in COX-2 protein was evident (figure 22).
NSAIDs exert their activity by inhibiting the ability of COX enzymes to convert A A 
into PGG2 and PGH2 . However, NSAIDs have also been observed to modulate COX-2 
expression in a cell type specific manner (Pang et a l , 2003). In order to determine 
whether NSAIDs have a significant effect upon COX-2 protein expression in 9HTEo' 
and £CFTE29o' cells, monolayers of confluent cells were starved for 4 hours and 
subsequently incubated with either the non-specific COX inhibitor indomethacin (10 
pM), COX-2 specific inhibitor NS398 (10 pM), or acetaminophen (10 pM), a reducing 
agent of both COX-1 and COX-2 (Oullet and Percival, 2001), for 24 hours in the
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presence or absence of TNFa 10 (ng/ml). Cells were pre-incubated with the NSAIDs 
30 min prior to the addition of TNFa. Samples were collected and COX-2 protein 
expression determined by immunoblot analysis.
No increase in COX-2 protein expression could be detected in either the 9HTEo‘ or 
ZCFTE29o' cell line in response to the NSAIDs used either individually or in 
combination with TNFa nor could any increase in COX-2 protein expression be 
observed in response to TNFa alone this correlating with earlier observations (figures 
23 A, B, and C).
Attempts were made to transfect monolayers of 9HTEo' and £CFTE29o‘ cells with a 
COX-2 promoter construct in order to assess mechanisms involved in the 
transcriptional regulation of COX-2 in human tracheal epithelial cell lines. Preliminary 
experiments were carried out to optimise lipofectAMINE plus transfection of these cell 
lines using a green fluorescent protein (GFP) -linked PKB construct, as described in the 
materials and methods section. This construct was used as it enabled visualisation of 
the transfection process (figure 24). Unfortunately, these initial experiments revealed 
that the 9HTEo' cell line was unable to survive incubation with lipofectAMINE plus. 
Furthermore, effective transfection of the ZCFTE29o' cell line was not achieved within 
the timescale of this study.
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Figure 15 Effect of cytokines on expression of cyclooxygenase-1 (COX-1) in 
ZCFTE29o and 9HTEo cells
Effect of exogenous application of TNFa (0.1 -  10 ng/ml) over 24 hours. B) Effect of 
exogenous application of IL-lp (0.1 -  10 ng/ml) over 24 hours. Western blot analysis 
of whole cell lysates. Cells were serum starved for 4 hours prior to treatment. The top 
panel is the immunoblot probed with a specific antibody against COX-1. This 
immunoblot is representative of at least 2 other experiments. The middle panel is the 
densitometry o f the immunoblot (each bar is the mean ± SEM of 3 experiments). The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading.
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Figure 16 Effect of cytokines on expression of COX-1 in ZCFTE29o* and 9HTEo' 
cell lines
A) Effect of exogenous application of IFNy (0.1 -  10 ng/ml) over 24 hours. B) Effect 
of exogenous application o f a cytomix o f IFNy (0.1 -  10 units/ml), TNFa ( 0 - 1 0  
ng/ml) and IL-lp (0.1 -  10 ng/ml) over 24 hours.Western blot analysis of whole cell 
lysates. Cells were serum starved for 4 hours prior to treatment. The top panel is the 
immunoblot probed with a specific antibody against COX-1. This immunoblot is 
representative of 2 other experiments. The middle panel is the densitometry of the 
immunoblot (each bar is the mean ± SEM of 3 experiments). The lower panel shows 
membranes probed with an antibody against pan ERK to demonstrate equal loading.
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Figure 17 Basal expression of cyclooxygenase-2 (COX-2) in untreated ECFTE29o' 
and 9HTEo' cells.
Western blot analysis of whole cell lysates. The top panel is the immunoblot probed 
with a specific antibody against COX-2. Lanes 1 -  3 are unstimulated £CFTE29o" 
samples from 4 separate experiments. Lanes 4 -  6 are unstimulated 9HTEo' samples 
from 4 separate experiments. This immunoblot is representative of at least 5 other 
experiments. The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading.
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Figure 18 Time course of effect of cytomix on expression of COX-2 in ECFTE29o' 
and 9HTEo' cell lines
A) Effect of exogenous application o f a cytomix of IFNy (10 units/ml), TNFa 
(lOng/ml) and IL-lp over a time course of 2, 6, 14, and 24 hours on the ECFTE29o’ 
cell line B) Effect of exogenous application of a cytomix of IFNy (10 ng/ml), TNFa 
(lOng/ml) and IL-ip over a time course o f 2, 6, 14, and 24 hours on the 9HTEo' cell 
line.Westem blot analysis of whole cell lysates. Cells were serum starved for 6 hours 
prior to treatment. The top panel is the immunoblot probed with a specific antibody 
against COX-2. These immunoblots are representative of at least 1 other experiment. 
The lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading
panERK~*|
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Figure 19 Effect of cytokines on expression of COX-2 in £CFTE29o' and 9HTEo' 
cell lines
A) Effect of exogenous application o f increasing concentrations o f TNFa (0 -  
lOng/ml), over 24 hours. B) Effect of exogenous application of increasing 
concentrations of IL-ip (0 -  lOng/ml), over 24 hours. C) Effect of exogenous 
application of increasing concentrations o f IFNy (0 -  lOunits/ml), over 24 hours. D) 
Effect of exogenous application of a cytomix of IFNy ( 0 - 1 0  units/ml), TNFa (0.1 - 
lOng/ml) and IL-ip (0 -  lOng/ml) over 24 hours. Western blot analysis of whole cell 
lysates. Cells were serum starved for 6 hours prior to treatment. The top panel is the 
immunoblot probed with a specific antibody against COX-2. These immunoblots are 
representative of at least 3 other experiments. The lower panel shows membranes 
probed with an antibody against pan ERK to demonstrate equal loading.
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Figure 20 Effect of IL-13 on expression of COX-2 in ZCFTE29o‘ and 9HTEo' cell 
lines
Effect of exogenous application of increasing concentrations of IL-13 (0 -  lOng/ml), 
over 24 hours. Western blot analysis of whole cell lysates. Cells were serum starved 
for 6 hours prior to treatment. The top panel is the immunoblot probed with a specific 
antibody against COX-2. This immunoblot is representative of at least 2 other 
experiments. The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading.
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Figure 21 Effect of PGE2 on expression of COX-2 in LCFTE29o’ and 9HTEo' cell 
lines
A) Effect of exogenous application of increasing concentrations of PGE2 (lpM  -  lpM), 
over 24 hours, on the XCFTE29o' cell line. B) Effect of exogenous application of 
increasing concentrations of PGE2 (lpM  -  lpM), over 24 hours on the 9HTEo‘ cell 
line. Western blot analysis o f whole cell lysates. Cells were serum starved for 6 hours 
prior to treatment. The top panel is the immunoblot probed with a specific antibody 
against COX-2. These immunoblots are representative of 1 other experiment. The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading.
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Figure 22 Effect of PGE2 on expression of COX-2 in ECFTE29o' and 9HTEo‘ cells
Effect of exogenous application of increasing concentrations of PGE2 (0.01 -  lpM ) 
over 6 hours. Western blot analysis of whole cell lysates. Cells were serum starved for 
6 hours prior to treatment. The top panel is the immunoblot probed with a specific 
antibody against COX-2. The lower panel shows membranes probed with an antibody 
against pan ERK to demonstrate equal loading
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Figure 23 Effect of NSAIDs on expression of COX-2 in ZCFTE29o’ and 9HTEo‘ 
cell lines
A) Effect of exogenous application of TN Fa (lOng/ml) with or without indomethacin 
(lOpM), over 24 hours. B) Effect of exogenous application of TNFa (lOng/ml) with 
or without NS-398 (10pM), over 24 hours. C) Effect o f exogenous application of 
TNFa (lOng/ml) with or without acetaminophen (10pM), over 24 hours. Western blot 
analysis of whole cell lysates. Cells were serum starved for 6 hours prior to treatment. 
The top panel is the immunoblot probed with a specific antibody against COX-2. The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading
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Figure 24 Transfection of the £CFTE29o‘ cell line with a GFP-tagged PKB 
promoter construct.
Monolayers of cells 40 -  60% confluent growth-arrested, and transfected using 1 pg of 
DNA/well and A) 1 pg lipofectAMINE plus B) 3 pg lipofectAMINE plus and C) 6 
pg lipofectAMINE plus. Expression of construct expression was visualised using a 
confocal microscope at 24 hours post-transfection.
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4.2.3 Expression of the prostaglandin E synthases in human tracheal epithelial cell 
lines 9HTEo‘ and ZCFTE29o_
The COX enzymes synthesise PGH2 from AA. PGH2 is subsequently converted into 
PGE2 by the action of PGE synthase enzymes cPGES, believed to be a constitutive 
isoform functionally linked to COX-1, and mPGES, an inducible isoform functionally 
coupled to COX-2. Confluent monolayers of 9HTEo' and ECFTE29o‘ cells were serum 
starved for 4 hours and cPGES protein expression was determined by immunoblot 
analysis. Figure 25 shows the results of a time course study carried out to determine the 
basal expression of cPGES and to investigate whether TNFa (10 ng/ml) has any effect 
on cPGES over a 48 hour period. As expected cPGES protein was found to be 
constitutively expressed in both 9HTEo‘ and ECFTE29o* cell lines with no observable 
change in this isoforms expression in response to TNFa when compared to basal 
(figures 25 A and B).
The type II alveolar carcinoma cell line A549 was used as a positive control to 
demonstrate that mPGES expression and up-regulation are detectable under the 
conditions implemented in this study. Monolayers of A549, 9HTEo' and XCFTE29o' 
cells were grown at 37°C until confluent and serum starved for 4 hours prior to a 24 
hour incubation with vehicle or TNFa (lOng/ml). The A549 cell line constitutively 
expresses mPGES protein, incubation of these cells for 24 hours increases mPGES 
expression from approximately 45% of maximum to 100% (figure 26). No mPGES 
protein was detectable in either the 9HTEo' or LCFTE29o' cell lines in the presence or 
absence of TNFa (figure 26).
To investigate whether PGE2 exerts an effect upon either cPGES or mPGES expression, 
confluent monolayers of A549, 9HTEo* and ICFTE29o" cells were grown at 37°C until 
confluent and serum starved for 4 hours prior to a 24 hour incubation with vehicle or 
PGE2 (0.1 -  10 nM). No significant change in either cPGES (figure 27 A) or mPGES 
(figure 27 B) protein expression, when compared to basal, could be observed in 9HTEo‘ 
or ECFTE29o' cells in response to PGE2 .
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Both cPGES and mPGES are glutathione (GSH) dependent enzymes, requiring GSH 
for optimal activity. Basal glutathione levels in 9HTEo' and ECFTE29o' cells were 
determined using a glutathione assay, as described in the materials and methods section. 
Confluent monolayers of 9HTEo‘ and XCFTE29o" cells were starved for 4 hours prior 
to resuspension in PBS and sonication to disrupt the cell membranes. No significant 
difference was found between basal glutathione levels in the 9HTEo" cell line 2.5 ± 
0.24 nM/106 and the ECFTE29o‘3.10 ± 0.39 pM/106  ( n = 5, p=0.250) (figure 28).
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Figure 25 Effect of TNFa on expression of cPGES protein in ECFTE29o' and 
9HTEo' cell lines
A) Time course of cPGES expression in XCFTE29o' cells after incubation with vehicle 
or TNFa (lOng/ml) over a 48 hour period B) Time course of cPGES expression in 
9HTEo‘ cells after incubation with vehicle or TNFa (lOng/ml) over a 48 hour period. 
Western blot analysis of whole cell lysates. Cells were serum starved for 4 hours prior 
to treatment. The top panel is the immunoblot probed with a specific antibody against 
cPGES. These immunoblots are representative of at least 2 other experiments. The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading.
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Figure 26 Effect of TNFa on expression of mPGES protein in A549, ECFTE29o' 
and 9HTEo' cell lines
Effect of exogenous application of increasing concentrations of TNFa (0.1 - 10 ng/ml), 
over 24 hours. Western blot analysis o f whole cell lysates. Cells were serum starved 
for 4 hours prior to treatment. The top panel is the immunoblot probed with a specific 
antibody against mPGES, this immunoblot is representative of three others. The middle 
panel is the densitometry of the immunoblot (each bar is the mean ± SEM of 4 
experiments). The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading.
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Figure 27 Effect of PGE2 on expression of cPGES and mPGES proteins in 
XCFTE29o and 9HTEo cell lines
A) Effect of exogenous application of increasing concentrations of PGE2 (0.1 - 10 nM), 
over 24 hours, on cPGESprotein expression B) Effect of exogenous application of 
increasing concentrations o f PGE2 (0.1 - 10 nM), over 24 hours on mPGES protein 
expression in A549, LCFTE29o' and 9HTEo' cell lines. Western blot analysis of whole 
cell lysates. Cells were serum starved for 4 hours prior to treatment. The top panel is 
the immunoblot probed with a specific antibody against A) cPGES and B) mPGES, 
these immunoblots are each representative of three others. The middle panel is the 
densitometry of the immunoblot (each bar is the mean ± SEM of 4 experiments). The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading.
panERK
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Figure 28 Basal glutathione levels in £CFTE2'9o‘ and 9HTEo' cells
The cells were serum starved for 4 hours prior to incubation with a cocktail o f 40 pM 
monochlorobimane and 0.1 units/m l1 GSH-S-transferase and subsequent analysis. 
Each bar is the mean ± SEM of 5 experiments earned out in duplicate.
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4.2.4 Prostaglandin production by the human tracheal epithelium
PGE2 is the most common PG produced in the airways and is thought to be 
predominantly a COX-2 product. In order to investigate the production of PGE2 by 
£CFTE29o" and 9HTEo' cells, monolayers o f cells were grown until confluent and 
serum starved for 6  hours prior to incubation, at 37°C, with either vehicle, cytokines, or 
AA. Subsequently, PGE2 levels were determined in cell culture supernatants using a 
PGE2 ELISA as described in the materials and methods section.
Initial studies were carried out in 9HTEo'(l) and LCFTE29o*(l) cells, PGE2 was 
produced under basal conditions by both cell lines. However, basal levels o f PGE2 
observed in the £CFTE29o"(l) cell line were approximately ten-fold higher than those 
o f the 9HTEo' cell line (figure 29). Stimulation o f ECFTE29o*(l) cells with pro- 
inflammatory cytokines IL -ip , TN Fa and IFNy individually failed to induce PGE2 
production, however a cytomix o f all three cytokines induced a significant increase in 
PGE2 generation by this cell line (figure 29). In contrast, PGE2 production by the 
9HTEo*(l) could not be induced by any o f these cytokines either alone or in 
combination (figure 29). Problems with the growth o f these cells resulted in a new 
batch o f 9HTEo"(l) and LCFTE29o‘( l)  cells being ordered from the original source. 
These new cells, the 9HTEo’ and £CFTE29o‘ cell lines were used for the rest o f this 
study. Furthermore, the data already shown in this report was obtained from the new 
batch o f cells. The data obtained from these new cells differs in some aspects from 
those seen with the original 9HTEo*(l) and XCFTE29o'(l) cell lines. As the new batch 
have been handled by the same person from arrival and their growth and data obtained 
consistent, the data from the 9HTEo' and ECFTE29o' cells are taken to be accurate. 
Therefore, the 9HTEo'(l) and LCFTE29o"(l) cell lines were put aside and the 9HTEo" 
and ZCFTE29o' cells used throughout this study.
Both 9HTEo' and SCFTE29o’ cells produced PGE2 in the absence o f stimulation. 
However, basal levels o f PGE2 observed in the XCFTE29o" cell line were 
approximately seven-fold higher than those o f the 9HTEo' cell line (n = 5, p<0.01) 
(figure 30). The release o f PGE2 by the 9HTEo' cell line was elevated over basal levels 
when incubated for 24 hours with TNFa (10 ng/ml) ( n = 3, p<0.05) and TN Fa in
Prostaglandins in tracheal epithelial cell lines 99
combination with IL -lp  (both lOng/ml) ( w = 3, p<0.05). IL -lp (10 ng/ml) and 
IFNy (10 units/ml) had no significant effect on PGE2 production, by the 9HTEo' cell 
line, either alone or in combination. The greatest increase in PGE2 generation observed 
at the 24 hour time point, in this cell line, occurred after stimulation with a combination 
o f IL -ip  (10 ng/ml), TN Fa (10 ng/ml), and IFNy (10 units/ml) in = 3, p<0.01). In the 
SCFTE29o* cell line only the cytomix o f IL-1 p (10 ng/ml), TN Fa (10 ng/ml), and 
IFNy (10 units/ml) induced a significant increase, from basal levels, o f PGE2 generation 
at the 24 hour time point (n = 3, p<0.01) (figure 31). These data are similar to that 
gathered from the 9HTEo'(l) and ECFTE29o"(l) cell lines (figure 29), however 
differences are seen in the inducibility o f PGE2 production by pro-inflammatory 
cytokines.
Time course studies were carried out in order to investigate if  stimulation o f the airway 
epithelial cells with TN Fa 10 ng/ml or the cytomix o f IL -lp  (10 ng/ml), TN Fa (10 
ng/ml), and IFNy (10 units/ml) resulted in induction o f PGE2 at time points other than 
24 hours.. These studies revealed that incubation o f 9HTEo' cells with TNFa resulted 
in a significant increase in PGE2 generation at the 2 hour time point (n = 3 p<0.05). 
These levels had fallen by the 6 and 24 hour time points and were no longer 
significantly increased when compared to control levels. In the ZCFTE29o‘ cell line 
TN Fa (lOng/ml) induced elevated levels o f PGE2 by the 6 hour time point (n =3 
p<0.05), as with the 9HTEo‘ cell line, these levels had fallen by the 24 hour time point 
and were no longer significantly different to their time matched controls (figure 32). 
Incubation of 9HTEo' cells with the cytokine mixture induced a significant increase in 
PGE2 production at the 2, 6 and 24 hour time points (n = 3 p<0.01). Similarly, PGE2  
generation by SCFTE29o‘ cells was also increased at 2, 6, and 24 hour time point in 
response to the mixture o f cytokines (n =3 p<0.01) (figure 33).
AA is converted into PGE2 by the sequential actions o f the COX and PGES enzymes. 
In order to investigate the effect o f increasing concentrations o f AA on basal PGE2  
generation by the 9HTEo' and £CFTE29o" cell lines, serum starved monolayers o f cells 
were incubated for 24 hours, at 37°C, with increasing concentrations o f AA ( 0 - 1 0  
pM). Both cell lines showed a concentration dependent increase in PGE2 production in 
response to AA (figure 34).
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NS398 is a COX-2 specific inhibitor. In order to determine the contribution of COX-2 
to basal PGE2 production 9HTEo‘ and ECFTE29o‘ cells were incubated over 2, 6 , and 
24 hours at 37°C with 10 pM NS398 and PGE2 production by both cell lines 
determined (figure 35). Indomethacin inhibits both COX-1 and COX-2. Cells were 
incubated with lOpM indomethacin or vehicle for 6  and 24 hours at 37°C and its effect 
upon PGE2 generation by both cell lines determined (figure 36). Surprisingly both 
NS398 and indomethacin failed to have an effect upon basal PGE2 generation in either 
the 9HTEo' and XCFTE29o* cell lines. This may be because the concentrations of these 
COX inhibitors used in this study were below that required for COX inhibition.
Attempts were made to investigate the production of PGD2 by 9HTEo' and SCFTE29o* 
cells, but this PG was either absent or levels produced were too low to be detected by 
the assay used (< 5pg/ml), induction of this PGs production could not be observed at 
the 2, 6 , 18 or 24 hour time points either basally or in response to TNFa (lOng/ml) 
(figure 37) or a cytomix of IL-ip (10 ng/ml), TNFa (10 ng/ml), and IFNy (10 units/ml) 
(figure 38).
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Figure 29 PGE2 production by original batch ZCFTE29o'(l) and original batch 
9HTEo‘(l) cells
Effect of 24 hour treatment with cytokines TNFa (10 ng/ml), IL-lp (10 ng/ml), and 
IFNy (10 units/ml) either alone or in various combinations. The cells were serum 
starved for 6 hours prior to treatment. Control is the amount of PGE2 produced in the 
presence of vehicle alone. Each bar is the mean ± SEM for 3 experiments each carried 
out in duplicate. (** p<0.01 when compared to basal)
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Figure 30 Basal PGE2 production by ECFTE29o' and 9HTEo' cells.
The cells were serum starved for 6 hours prior to analysis. Each point in the mean ± 
SEM of five experiments each carried out in duplicate. (** p<0.01)
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Figure 31 Effect of cytokines on PGE2 production by LCFTE29o' and 9HTEo' cells
Effect o f 24 hour treatment with cytokines TNFa (10 ng/ml), IL-lp (10 ng/ml), and 
IFNy (10 units/ml) either alone or in various combinations. The cells were serum 
starved for 6 hours prior to treatment. Basal is the amount of PGE2 produced in the 
presence of vehicle alone. Each bar is the mean ± SEM for 3 experiments each carried 
out in duplicate. (* p<0.05 when compared to basal; ** p<0.01 when compared to 
basal)
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Figure 32 Effect of TNFa on PGE2 production by ZCFTE29o' and 9HTEo' cells
Time course of incubation with vehicle or with TNFa (10 ng/ml). The cells were 
serum starved for 6 hours prior to treatment. Basal is the amount of PGE2 produced in 
the presence of vehicle alone. Each point is the mean ± SEM for 3 experiments each 
carried out in duplicate. (* p<0.05 when compared to basal)
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Figure 33 Effect of cytomix on PGE2 production by ZCFTE29o' and 9HTEo' cells
Time course of incubation with vehicle or a cytomix of TNFa (10 ng/ml), IL-ip (10 
ng/ml), and IFNy (10 units/ml). The cells were serum starved for 6 hours prior to 
treatment. Basal is the amount of PGE2 produced in the presence o f vehicle alone. 
Each point is the mean ± SEM for 3 experiments, each carried out in duplicate. 
(** p<0.01 when compared to basal)
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Figure 34 Effect of AA on PGE2 production by ECFTE29o' and 9HTEo' cells
Effect o f 24 hour treatment with increasing concentrations of AA ( 0 - 1 0  pM). The 
cells were serum starved for 6 hours prior to treatment. 0 is the amount of PGE2 
produced in the presence of vehicle alone. Data are from duplicate measurements in a 
single assay.
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Figure 35 Effect of NS398 on PGE2 production by ZCFTE29o' and 9HTEo‘ cells
Time course of incubation with vehicle or NS398 (lOpM). The cells were serum 
starved for 6 hours prior to treatment. Unstimulated is the amount of PGE2 produced in 
the presence of vehicle alone. Each point is the mean of duplicate wells from one 
experiment.
Prostaglandins in tracheal epithelial cell lines 108
250
200 H
~  150
E
i
Q.
«N
LU
0
100 -
50
■  CFTE Unstimulated
■  CFTE Stimulated
■ FITE Unstimulated
■ FITE Stimulated
24
Time (h)
Figure 36 Effect of indomethacin on PGE2 production by ZCFTE29o' and 9HTEo' 
cells
Effect of incubation with vehicle or indomethacin (lOpM) at 6 and 24 h time points. 
The cells were serum starved for 6 hours prior to treatment. Unstimulated is the
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amount of PGE2 produced in the presence of vehicle alone. Each point is the mean of 
duplicate wells from one experiment.
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Figure 37 Effect of TNFa on PGD2 production by ZCFTE29o' and 9HTEo* cells
Time course of incubation with vehicle or with TNFa (10 ng/ml). The cells were 
serum starved for 6 hours prior to treatment. Unstimulated is the amount of PGD2 
produced in the presence of vehicle alone. Each point is the mean of duplicate wells 
from one experiment.
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Figure 38 Effect of cytomix on PGD2 production by ZCFTE29o' and 9HTEo' cells
Effect of incubation with vehicle or a cytomix of TNFa (10 ng/ml), IL-lp (10 ng/ml), 
and IFNy (10 units/ml) over 24 hours. The cells were serum starved for 6 hours prior to 
treatment. Control is the amount of PGD2 produced in the presence of vehicle alone. 
Each point is the mean of duplicate wells from one experiment.
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4.2.5 15-hydroxyprostaglandin dehydrogenase expression by 9HTEo' and 
ZCFTE29o' cells
15-hydroxyprostaglandin dehydrogenase (PGDH) is considered the primary enzyme 
for prostanoid metabolism in most tissues, particularly for metabolism of PGE2 (Jerde et 
al., 2004). Ivanov and Romanovsky (2004) report that PGE2 is a principal downstream 
mediator of fever and that in systemic inflammation levels of PGDH expression in the 
lungs are markedly down-regulated. This may suggest that during an inflammatory 
response increases in PGE2 may be, in part, resultant to down regulation of its catabolic 
pathway. In order to investigate whether levels of PGDH may account for the 
differences observed in PGE2 production by the cell lines used in this study, or whether 
the increases in PGE2 production, observed in response to pro-inflammatory cytokines, 
may be linked to changes in PGDH protein expression, confluent monolayers of 
9HTEo' and ECFTE29o" cells, grown at 37°C, were serum starved for overnight prior to 
a 6  hour incubation with either vehicle or TNFa (0 .1 -10  ng/ml) and PGDH expression 
determined by immunoblot analysis as described in the materials and methods section. 
Additionally, in order to investigate whether increasing PGE2 concentration is able up- 
regulate PGDH protein expression, confluent monolayers of 9HTEo‘ and ECFTE29o' 
cells, grown at 37°C, were serum starved for overnight prior to a 6  hour incubation with 
either vehicle or PGE2 (0 . 1  -  10 pM) and, once again, PGDH expression was 
determined by immunoblot analysis.
PGDH is constitutively expressed at similar levels in both 9HTEo' and ECFTE29o' 
cells (figure 39). No change in PGDH expression was detectable in either cell line, 
when compared to basal, in response to stimulation over 6  hours with increasing 
concentrations of pro-inflammatory cytokine TNFa (0.1 -  lOng/ml) (figure 40). 
Similarly, no change in PGDH expression was detectable, in comparison to basal, in 
either 9HTEo' or £CFTE29o' cells in response to incubation with increasing 
concentrations of PGE2 (0.1 -  lOnM) (figure 41).
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Figure 39 Basal expression of PGDH protein in ZCFTE29o' and 9HTEo' cells
Western blot analysis of whole cell lysates. Cells were serum starved for 6 hours prior 
to harvest. The top panel is the immunoblot probed with a specific antibody against 
PGDH, lanes 1 -  3 are unstimulated ZCFTE29o' samples from 3 separate experiments; 
Lanes 4 -  6 are unstimulated 9HTEo' samples from 3 separate experiments.. This 
immunoblot is representative o f three others. The lower panel shows membranes 
probed with an antibody against pan ERK to demonstrate equal loading.
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Figure 40 Effect of TNFa on expression of PGDH protein in ZCFTE29o' and 
9HTEo cells
Effect of exogenous application o f increasing concentrations of TNFa (0.1 - 10 ng/ml), 
over 6 hours. Western blot analysis o f whole cell lysates. Cells were serum starved 
overnight prior to treatment. The top panel is the immunoblot probed with a specific 
antibody against PGDH, this immunoblot is representative of two others. The lower 
panel shows membranes probed with an antibody against pan ERK to demonstrate 
equal loading.
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Figure 41 Effect of PGE2 on expression of PGDH protein in £CFTE29o' and 
9HTEo' cells
Effect o f exogenous application of increasing concentrations of PGE2 (0.1 - 10 nM), 
over 6 hours. Western blot analysis of whole cell lysates. Cells were serum starved 
overnight prior to treatment. The top panel is the immunoblot probed with a specific 
antibody against PGDH, this immunoblot is representative of two others. The lower 
panel shows membranes probed with an antibody against pan ERK to demonstrate 
equal loading.
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4.2.6 Metabolic activity of human tracheal epithelial cell lines 9HTEo' and 
ICFTE29o‘
In order to determine that differences observed in protein expression and PGE2  
production between the 9HTEo' and ECFTE29o‘ cell lines are not a result of differences 
in the basic metabolic rate of the cell lines, monolayers of cells, approximately 90% 
confluent, were serum starved for 24 hours and MTT assays performed as detailed in 
the materials and methods section. Additionally, MTT assays were conducted on cells 
stimulated with cytomix and increasing concentrations of TNFa, at 6  and 24 hour time 
points, in order to ascertain that the decrease in PGE2 production observed at the 24 
hour time point in both the 9HTEo‘ and £CFTE29o' cell lines was not a result of a 
reduction in the cellular viability as a result of serum starvation and / or cytokine 
stimulation.
No difference in metabolic rate could be detected between 9HTEo' cells (87.8 ± 10.7 % 
max absorbance (550nm)) and ECFTE29o* cells (100 ± 8.1 % max absorbance 
(550nm)) after 6  hours of serum starvation (figure 42). The cells were serum starved 
for 6  hours prior to stimulation with increasing concentrations of TNFa (0.01 - 10 
ng/ml) for 6  hours (figure 43) and 24 hours (figure 44). No significant change in the 
cells activity could be detected in either cell line at either time point or in response to 
any of the different concentrations of TNFa used in this study. Additionally, no change 
in metabolic activity was apparent in response to the cytokine mixture of TNFa 
(lOng/ml), IL-lp, (10 ng/ml) and IFNy (10 units/ml) in either the 9HTEo' or the 
ECFTE29o’ cell line (figure 45).
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Figure 42 Relative basal metabolic activity of 9HTEo' and £CFTE29o' cells after 
24 hours in serum free medium, as measured by MTT assay.
The cells were serum starved for 6 hours prior to analysis. Basal is the absorbance 
measured at a wavelength of 550 nm for unstimulated cells. Each bar is the mean ± 
SEM expressed as a percentage of the maximum absorbance for 5 experiments carried 
out in triplicate.
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Figure 43 Relative basal metabolic activity of 9HTEo‘ and ZCFTE29o' - Effect of 
TNFa
Effect o f increasing concentrations of TNFa (0.01 -  10 ng/ml) over 6 hours, as 
measured by MTT assay. The cells were serum starved for 6 hours prior to analysis. 
Basal is the absorbance measured at a wavelength of 550 nm for cells stimulated with 
vehicle alone. Each bar is the mean ± SEM expressed as a percentage of the maximum 
absorbance for 3 experiments each performed in triplicate.
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Figure 44 Relative basal metabolic activity of 9HTEo* and ECFTE29o‘ in response 
to increasing concentrations of TNFa (0 -10  ng/ml) over 24 hours, as measured by 
MTT assay
The cells were serum starved for 6 hours prior to analysis. Basal is the absorbance 
measured at a wavelength of 550 nm for cells stimulated with vehicle alone. Each bar 
is the mean ± SEM expressed as a percentage of the maximum absorbance for 3 
experiments each carried out in triplicate.
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Figure 45 Relative basal metabolic activity of 9HTEo' and ZCFTE29o‘ - Effect of 
cytomix
Effect of increasing concentrations of a cytomix of TNFa (10 ng/ml), IL-lp (10 ng/ml), 
and IFNy (10 units/ml) over a period of 24 hours on basal metabolic actvity. As 
measured by MTT assay. The cells were serum starved for 6 hours prior to analysis. 
Basal is the absorbance measured at a wavelength of 550 nm for cells stimulated with 
vehicle alone. Each bar is the mean ± SEM for 3 experiments each carried out in 
triplicate
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4.3 Discussion
Prostaglandins (PGs) are generated under both physiological and pathophysiological 
conditions and regulate many aspects of airway physiology. Airway epithelial cells 
respond to inflammatory insults by increasing production of cytokines such as TNFa, 
IL-lp, and IFNy which, in turn, regulate the production of pro-inflammatory mediators, 
such as PGs, by inducing the expression of their synthesising enzymes (Mitchell et al, 
1994). One of the hallmarks of CF airway disease is a persistent and exaggerated 
inflammatory response that leads to destruction of the host tissue and ultimately 
pulmonary failure. Escotte et al, 2002 report that this exaggerated inflammatory 
response is associated with an abnormal increase in the production of pro-inflammatory 
cytokines. Furthermore, a number of studies report that PG levels in the sputum of CF 
patients are elevated when compared to healthy controls and may participate in the 
pathophysiology of the disease (Zakrzewski et al, 1987; Strandvik et al, 1996). It is 
postulated that the induction and regulation of COX-2 may be a crucial element in 
inflammatory disorders of the airways such as cystic fibrosis where a chronic 
inflammatory response leads to destruction of host tissue. PGE2 stimulates mucus 
secretion and oedema, characteristics commonly found in the CF lung, and is reported 
to synergise with IL- 8  to enhance neutrophil migration (Smith et al, 2002). The 
constitutive expression of COX-2 by airway epithelial cells and the ability of PGs to act 
as both positive and negative regulators of inflammation may suggest a homeostatic 
role for COX-2 products in the airways. Therefore, elucidation of the role and 
regulation of PG production by airway epithelial cells may provide insight into more 
effective therapeutic approaches to regulate inflammatory disorders of the airways such 
as CF. The work in this study investigates the regulation of PGE2 production in human 
tracheal epithelial cell lines 9HTEo" and ECFTE29o', cells of a non-CF and CF 
phenotype respectively. Attempts were also made to investigate PG production in 
genetically matched CF and non-CF phenotype cell lines, however the data obtained 
from these cell lines were unreproducible and were not included in this study.
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Both COX-1 and COX-2 proteins are reported to be constitutively expressed in airway 
epithelial cells (Mitchell et al, 1994; Asano et al, 1996; Watkins et al, 1999; Rodgers 
et al, 2002). Consistent with these findings this study reports that both COX-1 and 
COX-2 proteins are expressed in human tracheal epithelial cell lines 9HTEo* and 
£CFTE29o' in the absence of cytokine stimulation. While no difference between COX- 
2 protein expression could be detected between these cell lines, 9HTEo' cells expressed 
more COX-1 protein than XCFTE29o" cells. A number of studies report that IFNy, 
TNFa, and IL-lp induce COX-2 protein expression in airway cells (Mitchell et al, 
1994; Belvisi et al, 1997; Pang et al, 1998; Bonazzi et al, 2000) while IL-13 inhibits 
COX-2 expression (Berg et al, 2000). In the study reported here, stimulation of the 
9HTEo‘ and £CFTE29o' cell lines over 24 hours with pro-inflammatory cytokines 
IFNy, TNFa, and IL-ip either alone or in combination had no effect upon COX-1 or 
COX-2 protein expression. Additionally, IL-13 had no effect on COX-2 protein 
expression in either cell line. At the 48 hour time point microscopic examination of the 
cells revealed a decrease in cell number and an increase in cell debris, particularly 
affecting the 9HTEo' cell line. At all other time points cell viability was much higher 
(approximately 85%). In light of this, stimulation of these cells was routinely carried 
out over a 24 hour time course. As COX-1 is a housekeeping enzyme the inability of 
pro-inflammatory cytokines to induce its expression was to be expected. However, the 
inability of these cytokines, either alone or in combination, to induce COX-2 protein 
expression was of more interest.
In order to be certain that the lack of COX-2 induction by cytokines was not a result of 
the cytokines being non-viable, IL- 8  ELISAs were conducted on supernatants from 
cells stimulated with increasing concentrations IFNy, TNFa, and IL-ip either alone or 
in combination. IL- 8  is a potent neutrophil chemoattractant that has been implicated in 
a number of inflammatory airway diseases such as cystic fibrosis. IL- 8  has been 
reported to be up-regulated in response to pro-inflammatory cytokines in a number of 
airway epithelial cell lines (Schweibert et a l , 1999). In this study, both the 9HTEo‘ and 
ICFTE29o' cell lines produced a small amount of IL- 8  in the absence of cytokine 
stimulation; this finding is consistent with other reports (Aldallal et al, 2002; Becker et 
a., 2004). IL- 8  generation was seen to increase in response to TNFa and IL-ip either
Prostaglandins in tracheal epithelial cell lines 122
alone or in combination. Maximal induction of IL- 8  was observed in response to a 
combination of TNFa, IL-lp, and IFNy. However, IFNy alone had no effect on basal 
IL- 8  production. The lack of IL- 8  induction by IFNy alone, and the apparent synergy 
between TNFa, IL-ip and IFNy has previously been observed in the 9HTEo" and 
£CFTE29o' cell lines (Lavelle, 2002 unpublished data). However, from the data in this 
study it is not possible to speculate on the mechanisms behind the cooperative effect of 
these cytokines. The induction of IL- 8  production by both cell lines used in this study 
confirmed the viability of the cytokines and their signal transduction pathways.
PGE2 is the most common PG in the airways and is believed to be predominantly a 
COX-2 product. The major finding of this study was that the CF-phenotype cell line 
XCFTE29o' produced significantly higher levels of PGE2 under basal conditions than 
the non-CF phenotype cell line 9HTEo~ (p<0.01). Despite these cell lines not being a 
genetically matched pair, the difference in PGE2 levels observed between the CF and 
non-CF phenotype cell lines is supported by the findings of Zakrzewski et al., 1987 and 
Strandvik et al, 1996 who report that PG levels are elevated in the sputum of CF 
patients when compared to healthy controls. Additionally, Freedman et al, 1999 and 
2 0 0 2  report the presence of a membrane lipid defect in the lung, pancreas and ileum 
from cftr''mice that is characterised by an increase in phospholipid-bound AA and an 
increase in levels of PGE2 in the BAL fluid from cftrA mice when compared to wild- 
type controls. Attempts were made to investigate the production of PGD2 by 9HTEo' 
and XCFTE29o" cells, but this PG was either absent or levels produced were too low to 
be detected by the assay used. PGD2 levels are reported to be elevated in the rat 
carrgeenin-induced pleurisy model of inflammation at a 48 hour time point (Gilroy et 
al, 1999). However, as cells were not determined to be viable at the 48 hour time 
point PGD2 levels at this time point could not be investigated in this study.
Interestingly, PGE2 has been demonstrated to promote the inherent activity of the 
p65/RelA subunit of NF-kB, strongly synergising with TNFa promoting NF-kB 
dependent gene transcription (Poligone and Baldwin, 2001). However, despite basal 
levels of PGE2 produced by the ECFTE29o' cell line being approximately seven times
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those of the 9HTEo' cell line no difference in the level of IL- 8  produced under basal 
conditions by these cell lines could be detected. XCFTE29o' cells produced more IL- 8  
in response to high concentrations of TNFa (p<0.05) than 9HTEo' cells, however, the 
CF-phenotype cells produced significantly less IL- 8  than the non-CF cell line in 
response to high levels of IL-lp. It is possible that these differences are a result of 
differences between the cell lines’ pattern of receptor expression, but from the data 
gathered in this study it is difficult to speculate on the mechanisms behind these 
differences. Additionally, PGE2 and AA are reported to induce IL- 8  in airway 
epithelial cells (Rodgers et al, 2002). However, in this study no change in IL- 8  
production could be observed in response to either PGE2 or AA.
Despite the inability of cytokines to induce COX-2 protein expression, stimulation of 
the cell lines with TNFa resulted in an increase in PGE2 generation at the 2 hour time 
point in 9HTEo' cells (p<0.05) and at the 6  hour time point in £CFTE29o' cells 
(p<0.05). Levels in both cell lines were not determined to be different from basal by 
the 24 hour time point. A similar pattern of induction was observed in response to a 
combination of IFNy, TNFa, and IL-lp, however the increase observed in PGE2 
generation was significant at 2, 6 , and 24 hours in both cell lines (p<0.01) and was 
significantly higher than levels generated in response to TNFa alone (p<0.01). The 
rapid increase in PGE2 generation in response to pro-inflammatory stimuli is reported to 
occur in the rat carrgeenin-induced pleurisy model of inflammation and is associated 
with maximal COX-2 protein expression at the 2 hour time point, COX-1 protein 
expression remaining constant. Furthermore, this study reports that COX-2 protein 
expression increases again at the 48 hour time point and is associated with and increase 
in PGD2 production thought to be involved in the resolution of the inflammatory 
response (Gilroy et al, 1999). The role of PGs in the airways is complex. PGE2 is 
reported to have both pro-inflammatory and anti-inflammatory effects dependent upon 
the receptor sub-type it activates, the time point of its production and the tissue that it is 
acting upon. The induction of PGE2 production by the cell lines used in this study, in 
response to pro-inflammatory cytokines, at the 2  and 6  hour time points suggests that 
PGE2 plays a role in the initial phase of the inflammatory response. High basal 
expression of PGE2 by the £CFTE29o' cell line compared to the 9HTEo‘ cell line is
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also consistent with the pro-inflammatory phenotype of CF cells and highlights the 
airway epithelium as a contributor to the inflammatory response and as a therapeutic 
target in airway diseases, such as CF, where inflammation plays a key role. The 
inability of cytokines to induce COX-2 at any time point observed in this study suggests 
that the increase in levels of PGE2 generated in response to pro-inflammatory cytokines 
may be resultant of either an increase in the activity of the COX enzymes or a change in 
expression and / or activity of PGE synthase enzymes.
The conversion of PGH2 to PGE2 is catalysed by PGE synthase. Three major isoforms 
of PGES have been identified to date. cPGES a constitutively expressed isoform 
reported to act in concert with COX-1 (Murakami et al, 2000), mPGES acts in concert 
with COX-2 and is inducible by cytokines (Murakami et al, 2000), and mPGES-2 a 
constitutively expressed isoform that promotes PGE2 production via both COX-1 and 
COX-2 (Murakami et al, 2003). At the time this study was conducted antibodies were 
only available for cPGES and mPGES and so expression of mPGES-2 was not 
investigated. cPGES was constitutively expressed by both 9HTEo' and 2CFTE29o' 
cells, as expected for a housekeeping enzyme its expression was not up-regulated by 
pro-inflammatory cytokines. Interestingly, mPGES protein was not detectable in either 
tracheal epithelial cell line. A549 cells were used as a positive control to demonstrate 
that mPGES protein was detectable under the conditions used in this study and that 
mPGES protein expression can be elevated in response to TNFa. A lack of mPGES 
expression paired with high basal expression of both cPGES and COX-2 has also been 
observed in cultured KAT-50 thyrocytes (Han and Smith, 2002). The authors of this 
report postulate that low PGE2 production by this cell line, despite high levels of COX- 
2 protein being expressed, may be a result of inefficient coupling between cPGES and 
COX-2 in the absence of mPGES. In this study PGE2 only appears to be low in the 
9HTEo‘ cell line, despite this cell line expressing more COX-1 protein than the 
ECFTE29o' cell line. This may be a result of more efficient coupling of cPGES and 
mPGES by the ECFTE29o‘ cells or it may be a consequence of differences in 
expression of mPGES-2 between these cells. However, from the data gathered in this 
study it is not possible to reach a definite conclusion.
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As the PGES enzymes are glutathione (GSH) dependent requiring glutathione for 
optimal activity (Murakami et al., 2000), basal GSH levels were investigated in 
ECFTE29o‘ and 9HTEo* cells in order to determine whether differences in levels of 
glutathione could be affecting PGE2 production. Additionally, GSH production in CF 
airways is reported to be deficient compared to production by non-CF airways (Roum 
et al, 1999). It is therefore of interest to investigate whether these differences are 
observable in CF and non-CF cell lines. Under the conditions used in this study, no 
difference could be detected in basal GSH levels between the CF and non-CF cell lines. 
Consequently differing GSH levels could be ruled out as a factor contributing to the 
differences in PGE2 production observed.
As no difference in the expression of PGE2 synthesising enzymes could be detected to 
explain the difference in PGE2 production by the 9HTEo' and XCFTE29o’ cell lines, the 
expression of PGE2 metabolising enzyme PGDH was investigated. PGDH is 
considered the primary source of PG metabolism in most tissues, particularly 
metabolism of PGE2 but mechanisms regulating its expression are poorly understood 
(Jerde et al., 2004). If the 9HTEo’ cell line constitutively expressed higher levels of 
this protein than the ECFTE29o" cell line, it may have explained why PGE2 levels were 
so different. However, PGDH was found to be constitutively expressed in both airway 
epithelial cell lines at similar levels, therefore differences in the expression of this 
enzyme can not be held accountable for the differences in PGE2 observed in this study. 
Furthermore, PGDH protein expression could not be induced by stimulation of these 
cell lines with cytokines, this may be a result of maximal expression of PGDH being 
present under basal conditions as a consequence of constitutive production of PGE2 by 
the 9HTEo' and ECFTE29o' cell lines. Whether PGDH has a higher level of activity 
in the 9HTEo' cell line was not investigated in this study.
As no differences in the expression of enzymes involved in the production or 
metabolism of PGE2 were detected, MTT assays were conducted to determine the basal 
metabolic rates of these cells. If the £CFTE29o' cells proved to be basally more active
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than the 9HTEo' cells this may to some extent have provided explanation for the higher 
levels of PGE2 produced by the CF cell line. However, basal metabolic activity was not 
significantly different between the two cell lines. Incubation of the cells with pro- 
inflammatory cytokines did not affect the basal metabolic activity of either cell line, 
even at concentrations and time points that induced increases in PGE2 and IL- 8  
generation. It is possible that these cells are constantly in a high state of metabolic 
activity producing factors such as IL- 8  and PGE2 under basal conditions as a primary 
defence mechanism against external insults. The tracheal epithelium is constantly in 
contact with inhaled air and pathogens, it may be that expression of enzymes involved 
in the generation of an inflammatory response are constitutively expressed at maximal 
concentrations as a consequence of continuous exposure to low-level environmental 
stimuli.
As previously stated, PGE2 is a product of the actions of COX and cPGES enzymes. 
Furthermore, it is reported that PGE2 participates in the regulation of COX-2 protein 
expression and subsequently modulates further PG production (Faour et al, 2001; 
Poligone and Baldwin, 2001). However, little is known about the feedback effects of 
PGE2 on COX, PGES and PGDH enzymes in the tracheal epithelium. In this study, 
exogenously applied PGE2 had no effect upon COX-2, cPGES, mPGES or PGDH 
protein expression in either 9HTEo' or XCFTE29o' cell lines. This may indicate that 
PGE2 does not exert an effect upon its metabolic pathway in this cell line. Alternatively 
the constitutive expression of PGDH by these cell lines may result in inactivation of 
PGE2 before it can exert an effect upon this pathway. Furthermore, Pang et al, 2003 
reports that COX inhibitors indomethacin and NS-398 are able to modulate COX-2 
protein expression in a cell specific manner. In this study, these NSAIDs had no effect 
upon COX-2 protein expression in the presence or absence of TNFa.
In conclusion, the data presented here demonstrate that COX-2 is constitutively 
expressed in human tracheal epithelial cell lines 9HTEo' and ECFTE29o\ Consistent 
with reports that PG production by CF airways is elevated when compared to that of 
non-CF airways (Zakrzewski et al, 1987; Strandvik et al, 1996), this study reports that
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CF-phenotype £CFTE29o" cells produce significantly more PGE2 than non-CF 
phenotype 9HTEo" cells. No elevation in enzymes from the biosynthetic pathway could 
be observed in ECFTE29o‘ cells compared to 9HTEo* cells nor could any difference in 
PGDH expression be observed suggesting that differences in PGE2 production by the 
cell lines may be a result of differences in the activity of the enzymes present or 
differences in substrate levels. The latter hypothesis would be consistent with the 
findings of Freedman et al, 1999, who report the presence of a membrane lipid 
imbalance in the lungs of cftr1' mice characterised by elevated levels of phospholipid- 
bound AA. The high basal expression of the enzymes of the PGE2 synthetic pathway 
by tracheal epithelial cell lines, and the rapid induction of PGE2 production by pro- 
inflammatory cytokines suggests that PGE2 expression by the tracheal epithelium may 
be part of a natural defence mechanism as well as a contributor to airway inflammation.
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4.3 Summary of Results
• The 9HTEo' and LCFTE29o‘ cell lines produce low basal levels of IL- 8  which can 
be elevated by incubation with pro-inflammatory cytokines demonstrating that these 
cell lines express functional receptors for cytokines
• Both the 9HTEo* and SCFTE29o' cell line constitutively express COX-1 protein 
with 9HTEo' cells producing more COX-1 than 2CFTE29o‘ cells
• Stimulation of the 9HTEo" and XCFTE29o" cell lines with pro-inflammatory
cytokines did not result in elevation of COX-1 protein expression
• COX-2 protein is constitutively expressed by both 9HTEo' and ECFTE29o' cells,
there is no detectable difference between the levels of COX-2 expressed in these
cells lines
• Basal COX-2 protein expression is not affected by incubation with pro-
inflammatory cytokines in either the 9HTEo' or XCFTE29o' cell lines at any time 
point from 2 -4 8  hours
• NSAIDs do not effect COX-2 protein expression in 9HTEo' or ECFTE29o' cells 
and at the concentrations used in this study failed to inhibit PGE2 production by 
either cell line
• Exogenously applied PGE2 did not have any effect on COX-2 protein expression
• cPGES is constitutively expressed at a similar level in both the 9HTEo' and
ECFTE29o" cell lines and is not up-regulated by pro-inflammatory cytokines or 
exogenously applied PGE2
• mPGES protein is constitutively expressed in the A549 cell line and its expression 
is elevated by TNFa
• mPGES protein is not detectable in either the 9HTEo' or ECFTE29o‘ cell lines 
under basal conditions or upon stimulation with TNFa
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The 9HTEo' and ECFTE29o" cell lines produce PGE2 under basal conditions with 
the ECFTE29o‘ cells producing approximately seven times more PGE2 than the 
9HTEo‘ cells
PGE2 generation can be induced by incubation of the cells with pro-inflammatory 
cytokines. Maximal induction of PGE2 in response to cytokines occurs at the 2  hour 
time point in 9HTEo' cells and 6  hour time point in ECFTE29o' cells 
Exogenous application of AA induces a concentration dependent increase in PGE2 
generation by both cell lines
PGDH is expressed in 9HTEo' and XCFTE29o' cells in the absence of cytokine 
stimulation.
Incubation of the cell lines with cytokines or PGE2 did not effect basal PGDH 
expression
No difference in the basal metabolic rate of 9HTEo' and ECFTE29o" cell lines could 
be detected
Cytokines do not appear to have a significant effect upon the metabolic activity of 
either cell line
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Chapter 5: The role of Peroxisome proliferator-activated receptors and 
ligands in the regulation of prostaglandin production in human 
tracheal epithelial cell lines 
5.1 Introduction
Airway epithelial cells are reported to express constitutively high levels of PPARy and it 
is postulated that one of its roles in the airways may be that of a negative regulator of 
inflammation (Wang et al, 2001). The aim of this work was to study the expression of 
PPARy in non-CF and CF phenotype cell lines 9HTEo' and ECFTE29o" and to 
investigate the role of PPARy ligands in the regulation of the PGE2 metabolic pathway.
5.2 Results
5.2.1 Expression of PPARy in 9HTEo' and ZCFTE29o’ cells
In order to determine basal expression of PPARy in the 9HTEo‘ and £CFTE29o" cell 
lines, confluent monolayers of cells were serum starved for 6  hours at 37°C and PPARy 
protein was determined using immunoblot analysis, as described in the materials and 
methods section. £CFTE29o' cells express high levels of PPARy. 9HTEo' cells also 
express PPARy but at a lower level than observed in the XCFTE29o" cell line (9HTEo's 
express approximately 10% of the maximal expression seen in the XCFTE29o" cells 
under basal conditions) (figure 46). To assess whether endogenous ligands for PPARy 
affect the pattern of expression of this receptor, confluent monolayers of 9HTEo' and 
XCFTE29o' cells were serum starved for 6  hours and subsequently stimulated with 
increasing concentrations of 15-dPGJ2 (0 .1 -10  pM), at 37°C, for 24 hours. No change 
in expression of PPARy could be detected in response to stimulation with high 
concentrations of 15-dPGJ2 (figure 47).
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Figure 46 Expression of PPARy in ZCFTE29o‘ and 9HTEo' cells
Western blot analysis o f whole cell lysates. Cells were serum starved for 4 hours prior 
to harvest. The top panel is the immunoblot probed with a specific antibody against 
PPARy. Lanes 1 -  4 are unstimulated XCFTE29o' samples from 4 separate 
experiments. Lanes 5 -  8 are unstimulated 9HTEo' samples from 4 separate 
experiments. This immunoblot is representative of at least 3 other experiments. The 
middle panel is the densitometry of the immunoblot (each bar is the mean ± SEM of 3 
experiments). The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading.
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Figure 47 Effect of 15d-PGJ2 on expression of PPARy ECFTE29o' and 9HTEo' 
cells
Effect of increasing concentrations o f 15d-PGJ2 (0.1 -  10 pM) on expression of PPARy 
ICFTE29o' and 9HTEo' cells over 24 hours. Western blot analysis of whole cell 
lysates. Cells were serum starved for 4 hours prior to harvest. The top panel is the 
immunoblot probed with a specific antibody against PPARy. This immunoblot is 
representative of 1 other experiment. The lower panel shows the membrane probed 
with an antibody against pan ERK to demonstrate equal loading.
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5.2.2 The effect of PPARy ligands on COX-2 protein expression and PGE2 
productoion in 9HTEo' (1) and ZCFTE29o‘ (1) cells
Confluent monolayers of 9HTEo‘(l) and XCFTE29o'(l) cells were serum starved for 6 
hours and subsequently stimulated with vehicle or increasing concentrations of 
endogenous PPAR ligand, 15d-PGJ2 (3nM - 3 pM), and synthetic PPARy ligands 
troglitazone (3 nM - 3 pM) and GW2531 (3 nM - 3 pM) at 37°C for 24 hours. COX-2 
protein expression was determined by immunoblot analysis, as described in the 
materials and methods section.
Initial investigation revealed that stimulation of ECFTE29o'(l) cells with 15d-PGJ2 
(3nM - 3 pM) (figure 48A) and PPARy ligand GW2531 (3 nM - 3 pM) (figure 48B) 
resulted in complete inhibition of COX-2 protein expression. Additionally, troglitazone 
(3 nM - 3 pM) reduced COX-2 expression in this cell line (figure 48C). These ligands 
appeared to have no effect upon COX-2 protein expression in 9HTEo'(l) cells (figures 
48 A,B, and C). PGE2 ELISAs were performed, as detailed in the materials and 
methods section, on supernatants collected from 9HTEo'(l) and £CFTE29o'(l) cells 
incubated at 37°C overnight in the presence of vehicle, 15-dPGJ2 (10 pM), or 
Troglitazone (10 pM). These Elisas revealed that while Troglitazone had little effect 
upon PGE2 production by ICFTE29o'(l) cells, 15-dPGJ2 reduces PGE2 generation by 
approximately 60% (figure 49). Once again, these ligands appeared to have no effect on 
9HTEo'(l) cells (figure 49).
As previously mentioned, because of problems with the growth of these cells a new 
batch of tracheal epithelial cells were ordered from the original source. These new 
cells, the 9HTEo' and ECFTE29o' cell lines were used for the rest of this study. The 
data obtained from this new batch of cells differs from those seen with the original 
9HTEo'(l) and ECFTE29o'(l) cell lines. As the new batch have been handled by the 
same person from arrival and their growth and data obtained consistent, this data from 
the 9HTEo' and ZCFTE29o" cells are taken to be accurate. Therefore the 9HTEo*(l) 
and £CFTE29o'(l) cell lines were put aside and the 9HTEo' and £CFTE29o" cells used 
throughout the rest of this study.
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Figure 48. Expression of COX-2 in original batch ECFTE29o' (1) and original batch 
9HTEo‘ (1) cell lines, effect of PPARy ligands
A) Effect of exogenous application of increasing concentrations of 15d-PGJ2 (3nM -  
3pM), over 24 hours, on the ECFTE29o(l) and 9HTEo'(l) cell lines. B) Effect of 
exogenous application of increasing concentrations of Troglitazone (3nM -  3pM)), over 
24 hours on the XCFTE29o'(l) and 9HTEo' cell lines. C) Effect of exogenous 
application of increasing concentrations of GW2351e (3nM -  3pM)), over 24 hours on 
the ICFTE29o'(l) and 9HTEo' cell lines. Western blot analysis of whole cell lysates. 
Cells were serum starved for 6 hours prior to treatment. These immunoblots are 
representative of 2 other experiments.
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Figure 49 PGE2 production by original batch ZCFTE29o' (1) and original batch 
9HTEo' (1) cell lines, effect of PPARy ligands
The cells were serum starved for 6 hours prior to incubation with vehicle, 15-dPGJ2 (10 
pM) or Troglitazone (10 pM). Basal is the amount of PGE2 produced in the presence of 
vehicle alone. Each point is the mean for 2 experiments carried out in duplicate.
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5.2.3 The effect of PPARy ligands on COX-2 protein expression in 9HTEo‘ and 
ECFTE29o' cells
Confluent monolayers of 9HTEo" and XCFTE29o' cells were serum starved for 6  hours 
and subsequently stimulated with vehicle or increasing concentrations of endogenous 
PPAR ligand, 15d-PGJ2 (lpM - 10 pM), synthetic PPARy ligand troglitazone (lpM - 10 
pM), and PPARy antagonist BADGE (lOpM - 10 pM) at 37°C for 24 hours. COX-2 
protein expression was determined by immunoblot analysis, as described in the 
materials and methods section.
Increasing concentrations of 15-dPGJ2 had no effect upon basal COX-2 expression in 
either cell line (figure 50 A and B). Similarly troglitazone did not appear to have any 
effect upon COX-2 protein expression in either 9HTEo* or XCFTE29o' cells, at any of 
the concentrations used in this study (figure 51 A and B). Additionally, 
PPARy antagonist BADGE failed to induce a change in the expression of COX-2 by the 
airway epithelial cell lines (figure 52 A and B). To be certain that a change in COX-2 
protein expression, induced by stimulation with PPARy ligands, hadn’t occurred at an 
earlier time point, confluent monolayers of 9HTEo' and ECFTE29o' cells were serum 
starved for 6  hours and subsequently incubated for 2 and 6  hours, at 37°C, with either 
vehicle or 10 pM PGJ2 . No change, in COX-2 expression, from basal could be 
observed in either cell line at either 2 or 6  hours in response to 10 pM 15d-PGJ2 (figure 
53).
5.2.4 The effect of PPARy ligands on PGES protein expression in the 9HTEo" and 
ICFTE29o'cell lines
In order to investigate whether PPARy ligands exert any effect on cPGES or mPGES 
protein expression either the 9HTEo' or ECFTE29o‘ cell line, confluent monolayers of 
cells were serum starved for 6  hours and subsequently stimulated with vehicle or 
increasing concentrations of endogenous PPAR ligand, 15d-PGJ2 (lOpM -10 pM), 
synthetic PPARy ligand troglitazone (lOpM -10 pM), and PPARy antagonist BADGE
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(lOpM - 10 pM) at 37°C for 24 hours and CPGES and mPGES protein expression 
determined by immunoblot analysis as described in the materials and methods section. 
A549 cells were used as a positive control for mPGES expression.
15d-PGJ2 (lOpM -  10 pM) had no discemable effect on either cPGES expression (figure 
54 A) or mPGES expression (figure 44 B) in either the 9HTEo' or XCFTE29o" cell 
lines. Similarly, stimulation of the cells with troglitazone (lOpM -  10 pM) did not alter 
basal cPGES (figure 55 A) or mPGES (figure 55 B) expression at the 24 hour time 
point. Incubation of the cell with PPARy antagonist BADGE also failed to elicit any 
change in basal cPGES expression by either airway epithelial cell line (figure 56).
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Figure 50 Effect of 15d-PGJ2 on expression of COX-2 in ECFTE29o' and 9HTEo' 
cell lines
A) Effect of exogenous application of increasing concentrations of 15d-PGJ2 (lpM  -  
1 OpM), over 24 hours, on the ECFTE29o‘ cell line. B) Effect of exogenous application 
of increasing concentrations of 15d-PGJ2 (lpM  -  10pM)), over 24 hours on the 9HTEo' 
cell line. Western blot analysis of whole cell lysates. Cells were serum starved for 6 
hours prior to treatment. The top panel is the immunoblot probed with a specific 
antibody against COX-2. These immunoblots are representative of 4 other experiments. 
The lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading.
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Figure 51 Effect of troglitazone on expression of COX-2 in ECFTE29o' and 
9HTEo* cell lines
A) Effect of exogenous application of increasing concentrations of troglitazone (lpM  -  
10pM), over 24 hours, on the £CFTE29o" cell line. B) Effect of exogenous 
application of increasing concentrations of troglitazone (lpM  -  10pM)), over 24 hours 
on the 9HTEo" cell line. Western blot analysis o f whole cell lysates. Cells were serum 
starved for 6 hours prior to treatment. The top panel is the immunoblot probed with a 
specific antibody against COX-2. These immunoblots are representative of 3 other 
experiments. The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading.
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Figure 52 Effect of BADGE on expression of COX-2 in ECFTE29o" and 9HTEo" 
cell lines
A) Effect of exogenous application of increasing concentrations of BADGE (lOpM -  
lOpM), over 24 hours, on the ECFTE29o' cell line. B) Effect of exogenous 
application of increasing concentrations o f BADGE (1 OpM -  1 OpM)), over 24 hours on 
the 9HTEo’ cell line. Western blot analysis of whole cell lysates. Cells were serum 
starved for 6 hours prior to treatment. The top panel is the immunoblot probed with a 
specific antibody against COX-2. These immunoblots are representative of 4 other 
experiments. The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading
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Figure 53 Effect of 15d-PGJ2 on expression of COX-2 in ECFTE29o' and 9HTEo' 
cell lines
Two and six hour time points post stimulation with either vehicle (Unstim.) or 15d-PGJ2 
(lOpM) (Stim.). Western blot analysis o f whole cell lysates. Cells were serum starved 
for 6 hours prior to treatment. The top panel is the immunoblot probed with a specific 
antibody against COX-2. The lower panel shows membranes probed with an antibody 
against pan ERK to demonstrate equal loading
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Figure 54 Expression of cPGES or mPGES protein in ZCFTE29o' and 9HTEo' cell 
lines
A) Effect of exogenous application of increasing concentrations o f 15d-PGJ2 (lOpM - 
10 nM), over 24 hours on cPGES expression B) Expression of mPGES protein in 
A549, XCFTE29o' and 9HTEo' cell lines -  Effect of exogenous application of 
increasing concentrations of 15-dPGJ2 (lOpM - 10 nM), over 24 hours. Western blot 
analysis of whole cell lysates. Cells were serum starved for 6 hours prior to treatment. 
The top panel is the immunoblot probed with a specific antibody against A) cPGES and
B) mPGES, these immunoblots are each representative of one other. The middle panel 
is the densitometry of the immunoblot (each bar is the mean of 2 experiments). The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading
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Figure 55 Expression of cPGES or mPGES protein in SCFTE29o‘ and 9HTEo" 
cell lines
A) Effect of exogenous application of increasing concentrations of 15d-PGJ2 (lOpM - 
10 nM), over 24 hours, on cPGES expression B) Expression of mPGES protein in 
A549, £CFTE29o‘ and 9HTEo' cell lines -  Effect of exogenous application of 
increasing concentrations of 15-dPGJ2 ( 1 - 1 0  nM), over 24 hours. Western blot 
analysis of whole cell lysates. Cells were serum starved for 6 hours prior to treatment. 
The top panel is the immunoblot probed with a specific antibody against A) cPGES and
B) mPGES, these immunoblots are each representative of one other. The middle panel 
is the densitometry of the immunoblot (each bar is the mean of 2 experiments). The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading
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Figure 56 Effect of BADGE on expression of cPGES protein in ZCFTE29o' and 
9HTEo' cell lines
Effect of exogenous application of increasing concentrations of BADGE (lOpM - 10 
nM), over 24 hours. Western blot analysis of whole cell lysates. Cells were serum 
starved for 6 hours prior to treatment. The top panel is the immunoblot probed with a 
specific antibody against cPGES. This immunoblot is representative of one other. The 
lower panel shows membranes probed with an antibody against pan ERK to 
demonstrate equal loading
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5.2.5 The effect of PPARy ligands on PGE2 production by ZCFTE29o' and 
9HTEo' cells
In order to determine the effect o f PPARy ligands on PGE2 production by the 
ECFTE29o' and 9HTEo' cell lines, monolayers o f cells were grown until confluent and 
serum starved for 6 hours prior to incubation, at 37°C, with either vehicle or 15-dPGJ2 
(10 pM) for 2, 6, and 24 hours. Additionally, the effect o f PPARy ligands on TN Fa (10 
ng/ml) induced PGE2 generation, was investigated by pre-incubating the cells with 15- 
dPGJ2 (10 pM) or troglitazone (10 pM) for 30 minutes prior to 24 hour stimulation with 
TNFa. Supernatants were collected and PGE2 determined by PGE2  ELISA as described 
in the materials and methods section.
In the ECFTE29o' cell line, 15-dPGJ2 (10 pM) appeared to induce PGE2 production at 
the 2, 6 and 24 hour time points (n =2). 15-dPGJ2 (10 pM) also induced an increase in 
PGE2 generation by the 9HTEo' cell line at the 2, 6, and 24 hour time points (n = 2) 
(figure 57). Troglitazone (10 pM) appeared to inhibit PGE2 production by the both cell 
lines. Additionally, troglitazone inhibited TN Fa (10 ng/ml) induced PGE2 generation by 
ZCFTE29o‘ cells (n =2) (figure 58). Pre-incubation o f £CFTE29o‘ and 9HTEo' cells 
with 15-dPGJ2 (10 pM) appeared to reduce TN Fa induced PGE2 production (figure 58), 
whether this reduction is significant or not requires further investigation. In an attempt 
to determine whether the effect of 15-dPGJ2 on TN Fa induced PGE2 generation could 
be an effect o f 15-dPGJ2S actions on NFkB, IL-8 ELIS As were carried out on 
supernatants from the same cell cultures as used for the PGE2 ELISA. 15d-PGJ2 did not 
appear to have any effect upon basal IL-8 production or TN Fa stimulated IL-8 
generation by ECFTE29o' and 9HTEo' cells (figure 59).
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Figure 57 Time course of PGE2 production by ZCFTE29o' and 9HTEo' cells after 
incubation with vehicle or 15-dPGJ2 (10 pM)
The cells were serum starved for 6 hours prior to treatment. Basal is the amount of 
PGE2 produced in the presence of vehicle alone. Each point is the mean for 2 
experiments carried out in duplicate.
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Figure 58 Effect of TNFa, 15d-PGJ2 and troglitazone on PGE2 production at the 
24 hour time point byECFTE29o‘ and 9HTEo' cells
The cells were serum starved for 6 hours prior to incubation with vehicle, TNFa 
(lOng/ml), or 15-dPGJ2 (10 pM) either individually or in combination or Troglitazone 
(T) (10 pM) either alone or in combination with TNFa (lOng/ml). Basal is the amount 
of PGE2 produced in the presence of vehicle alone. Each point is the mean for 2 
experiments carried out in duplicate.
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Figure 59 Effect of TNFa and 15d-PGJ2 on IL- 8  production at the 24 hour time 
point byZCFTE29o' and 9HTEo' cells
The cells were serum starved for 6 hours prior to treatment with vehicle, TNFa 
(lOng/ml), or 15-dPGJ2 (10 pM) either individually or in combination. Basal is the 
amount of IL-8 produced in the presence o f vehicle alone. Each point is the mean for 2 
experiments carried out in duplicate.
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5.2.6 The effect of PPARy ligands on the expression of PGDH in £CFTE29o' 
and 9HTEo" cells
Confluent monolayers of 9HTEo' and ICFTE29o" cells were serum starved for 6  hours 
and subsequently stimulated with vehicle or increasing concentrations of endogenous 
PPAR ligand, 15d-PGJ2 (1-10  pM), synthetic PPARy ligand troglitazone (1-10  pM), 
and PPARy antagonist BADGE ( 1 - 1 0  pM) at 37°C for 24 hours. PGDH protein 
expression was determined by immunoblot analysis as described in the materials and 
methods section.
PGDH protein expression was not affected by incubation with 15d-PGJ2 (1-10 pM) at 
the 24hour time point in either the 9HTEo' or ECFTE29o' cell line (figure 60 A). 
Troglitazone ( 1 - 1 0  pM) did not induce any detectable change in the expression of 
PGDH in either cell line (figure 60 B). Furthermore, PPARy antagonist BADGE (1-10 
pM) failed to induce an effect on PGDH protein expression in either 9HTEo" or 
ECFTE29o' cells (figure 60 C).
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Figure 60 Expression of PGDH protein ZCFTE29o‘ and 9HTEo' cells
Effect of exogenous application of A) 15d-PGJ2 (0,1, and 10 nM) B) Troglitazone (0.1, 
and 10 nM) and C) BADGE (0,1, and 10 nM), over 24 hours. Western blot analysis of 
whole cell lysates. Cells were serum starved for 6 hours prior to treatment. The three 
panels are immunoblots probed with a specific antibody against PGDH.
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5.3 Discussion
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription 
factors belonging to the nuclear receptor superfamily. The PPARy subtype is reported 
to be expressed in high levels in the airway epithelium (Michael et al, 1997; Wang et 
al, 2001). A number of studies have demonstrated that both natural and synthetic 
ligands of PPARy possess anti-inflammatory properties, attenuating the release of 
macrophage-derived cytokines such as IL-1 and TNFa (Jiang et al, 1998; Ricote et 
al, 1998; Welch et al., 2003) and regulating expression of COX-2 and inducible nitric 
oxide synthase (Colville-Nash et al, 1998). Wang et al, 2001 report that activation of 
PPARy in airway epithelial cell lines dramatically inhibits cytokine-induced expression 
of inflammatory mediators by these cells and suggest that PPARy may act as a negative 
immunomodulator in the airways. This is supported by the findings of Patel et al, 2003 
who report that PPARy ligands suppress cell growth, inhibit apoptosis, and inhibit GM- 
CSF release from HASM cells. The apparent ability of PPARy ligands to down-regulate 
inflammatory pathways makes this receptor isoform a potential target for therapies 
aimed at disorder in which the inflammatory response is elevated or dysregulated. 
Studies into the effect of PPARy ligands have revealed that the effect of this receptor 
and its ligands on COX-2 expression are tissue specific. Elucidation of the tissue 
specific effects of PPARy in inflammation is necessary in the development of new 
approaches to therapy for chronic inflammatory diseases based upon the effects of 
PPARy ligands. Additionally, a number of studies report that the anti-inflammatory 
actions of PPARy ligands are not only attributable to activation of PPARy, but to 
modulation of transcription factors including NF-kB (Castrillo et al, 2000; Straus et 
a l,2000). In diseases such as CF where activation of NF-kB is thought to be 
exaggerated resulting in increased inflammatory mediator production, PPARy ligands 
may prove effective in reducing inflammation and airway damage. In light of these 
findings, this study investigated the expression of PPARy and the effect of PPARy 
ligands on PGE2 production in 9HTEo' and ZCFTE29o' cells, human tracheal epithelial 
cell lines with a non-CF and CF phenotype respectively.
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Both the 9HTEo‘ and ECFTE29o" cell lines constitutively expressed PPARy, however, 
expression of this receptor by £CFTE29o' cells was markedly higher than expression in 
9HTEo' cells. As these cell lines are not a genetically matched pair, it is difficult to 
ascertain whether or not the differences observed in receptor expression between the CF 
and non-CF cells have any relevance. Attempts were made to assess relative PPARy 
expression in a genetically matched pair of cell lines expressing a CF and non-CF 
phenotype, however, lack of reproducibility of data from these cells resulted in the data 
being disregarded. Incubation of the cell lines with high concentrations (pM range) of 
endogenous PPARy ligand 15d-PGJ2 did not produce any significant effect upon 
expression of PPARy in either cell line.
Inoue et al, 2000 report that COX-2 protein expression is regulated by a negative 
feedback loop mediated through PPARy making possible a dynamic production of PG in 
the macrophage-like cell line U937. PGD2 degradation product 15d-PGJ2 is an 
endogenous high affinity ligand for PPARy (Forman et al, 1995; Kliewer et al, 1995) 
in vivo levels of which are reportedly in the low pM range (Shibata et al, 2002; Bell- 
Parikh et al., 2003). 9HTEo' and XCFTE29o‘ cell lines were incubated with 
concentrations of 15d-PGJ2 ranging from lpM to lOpM for 24 hours. No change in 
COX-2 protein expression was be observed in either cell line in response to stimulation 
with this PG. Additionally, incubation of these cells with synthetic PPARy ligand 
troglitazone or endogenous PPARy antagonist BADGE at concentrations ranging from 
from lpM to lOpM had no effect upon COX-2 expression. Furthermore, no significant 
change in cPGES or mPGES enzymes could be induced by the PPARy ligands used in 
this study. These data suggest that modulation of COX-2 and PGES enzyme 
expression in the tracheal epithelium is not a valid target for PPARy based therapeutic 
approaches.
Despite the inability of PPARy ligands to affect COX-2, cPGES or mPGES protein 
expression in 9HTEo' and ICFTE29o' cell lines, PGE2 ELISAs revealed that in 
response to stimulation with 10 pM 15d-PGJ2, PGE2 is increased in both cell lines at the
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2, 6 , and 24 hour time points. These data suggest that 15d-PGJ2 is able to modulate the 
activity rather than the expression of PGE2 synthesising enzymes. Additionally, the 
effects of 15d-PGJ2 on TNFa induced PGE2 production was assessed, in contrast with 
the finding that 15d-PGJ2 alone enhances PGE2 generation 15d-PGJ2 appears to inhibit 
TNFa induced PGE2 production. However, further investigation is required to 
determine the significance of these results. These data pose interesting questions about 
the mechanisms behind the actions of 15d-PGJ2 on basal PGE2 generation versus its 
action upon PGE2 generation stimulated by pro-inflammatory mediators. 
Unfortunately, this study does not provide evidence to explain the mechanism by which 
15d-PGJ2 exerts its effect upon PGE2 synthesis. Interestingly, troglitazone appeared to 
inhibit basal PGE2 production by both the 9HTEo' and £CFTE29o" cell lines and to 
inhibit TNFa induced PGE2 generation by ZCFTE29o* cells. It is not possible to 
conclude that the effect of troglitazone on PGE2 production is solely a product of 
PPARy activation as, while Castrillo et al (2000) suggest that 15d-PGJ2 but not 
troglitzone is able to ligate to and modulate the NFkB signalling pathway, a number of 
studies have reported that thiazolidinediones troglitazone and rosiglitazone are able to 
inhibit NFkB activity (Ghanim et al, 2001; Mohanty et al, 2004). The mechanisms 
behind the conflicting effects of PPARy ligands on PGE2 production provide an 
interesting avenue for future research.
As previously mentioned, a number of studies report that the anti-inflammatory actions 
of PPARy ligands are not only attributable to activation of PPARy, but to modulation of 
transcription factors including NF-kB (Castrillo et al, 2000; Straus et a l,2000). 
Concentrations of 15d-PGJ2 required to ligate proteins in the NF-kB pathway in vitro 
range from 2.5 -  100 pM (Castrillo et al, 2000; Narumiya and Fitzgerald, 2001). The 
concentration of 15d-PGJ2 producing an effect upon PGE2 production in this study was 
10 pM and therefore within the concentration range capable of affecting the NF-kB 
pathway. In order to determine whether the effects of 15d-PGJ2 on PGE2 production 
could be a result of 15d-PGJ2S actions upon NF-kB, IL- 8  ELISAs were performed on 
the supernatants from cells stimulated with TNFa and 15d-PGJ2 alone and from cells 
pre-incubated with 15d-PGJ2 prior to TNFa stimulation. As IL- 8  production is 
governed by the activity NF-kB (Reviewed in Hoffmann et al, 2002), it is reasonable to
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assume that if 15d-PGJ2 is exerting a significant effect upon this transcription factor it 
should be reflected in IL- 8  generation. No difference in basal IL- 8  concentration or 
TNFa could be detected in response to 15d-PGJ2. These data suggest that at the 
concentration and time point observed in this study, 15d-PGJ2 does not significantly 
affect the activity of the transcription factor NF-kB in either the 9HTEo' or ECFTE29o' 
cell lines.
The increase in PGE2 production by 15d-PGJ2 could not be explained by changes in the 
expression of PGE2 biosynthetic enzymes, thus the effect of PPARy ligands on PGE2  
metabolising enzyme PGDH were investigated. Once again, no change in enzyme 
expression was observed in response to incubation with pM concentrations of 15d-PGJ2, 
troglitazone, or BADGE.
PPARy ligands have been demonstrated to negatively regulate inflammatory pathways 
in A549 cells (Wang et al, 2000; Trifilieff et al, 2003), HASM cells (Patel et al, 
2003), and bronchial epithelial cells (Hetzel et al, 2003). Thus the inability of PPARy 
ligands to significantly either positively or negatively regulate the expression of 
enzymes involved in the biosynthesis or catabolism of PGE2 or IL- 8  in either 9HTEo' or 
ECFTE29o" tracheal epithelial cell lines was surprising. However, the conflicting 
effects of PPARy ligands on different tissues point to the effects of these ligands being 
highly tissue specific. The ability of 15d-PGJ2 to up-regulate PGE2 supports the 
findings of Inoue et al, 2000 in that 15d-PGJ2 is able to modulate PG expression, 
however, in this study the modulation of PG production can not be attributed to changes 
in COX expression.
In summary, this study demonstrates that PPARy is constitutively expressed in human 
tracheal epithelial cell lines 9HTEo' and ECFTE29o\ Despite stimulation with a wide 
concentration range, PPARy ligands do not affect protein expression of enzymes 
involved in the biosynthesis or catabolism of PGE2 . The mechanisms behind the ability 
of 15d-PGJ2 to induce PGE2 expression by the human tracheal epithelial cell lines
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9HTEo' and XCFTE29o" could not be explained by the data gathered in this study, but 
the complex pro- and anti-inflammatory effects of PGE2 raises the possibility that 
pharmacological use of 15d-PGJ2 on the tracheal epithelium, could in some 
circumstances be detrimental to health.
The data gathered from the 9HTEo (l) and ECFTE29o (l) cell lines, differs markedly 
from the data obtained from the 9HTEo' and ECFTE29o' cell lines. The ability of 
PPARy ligands to abrogate COX-2 in ECFTE29o'(l) cells but not ECFTE29o* cells 
indicates that changes may occur in this cell line over time. The difference in data and 
problems with the growth of the older 9HTEo'(l) and £CFTE29o(l) cell lines suggest 
that caution should be employed when using these cell lines to investigate the effect of 
PPARs on PG generation as age related changes to the cell lines appear to affect these 
pathways.
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Summary of Results
PPARy is constitutively expressed in both the 9HTEo' and ECFTE29o" cell lines
£CFTE29o' cells express higher levels of PPARy than 9HTEo' cells
PPARy ligands 15d-PGJ2, troglitazone, and BADGE do not affect basal COX-2
expression in either the 9HTEo' or 2CFTE29o" cell lines
15d-PGJ2 appears to increase PGE2 production by both cell lines, but does not
have an effect upon TNFa induced PGE2 generation
Troglitazone appears to inhibit basal PGE2 production in both airway epithelial 
cell lines. Additionally, troglitazone did appear to reduce TNFa induced PGE2  
generation by XCFTE29o' cells
IL- 8  production was not affected by 15d-PGJ2 in either 9HTEo" £CFTE29o~ 
cells
PGDH protein expression is not affected by PPARy ligands 15d-PGJ2, 
troglitazone, and BADGE
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Chapter 6: The role of prostaglandins in cytoprotection
6.1 Introduction
It has been reported that 15d-PGJ2 can induce expression of HO-1, an enzyme with anti­
oxidant activity in a number of cell lines (Colville-Nash et al, 1998; Koppal et al, 
2000; Wayman et al, 2002; Lee et al, 2003). HO-1 is predominantly thought to be an 
inducible enzyme, expression of which is induced by pro-inflammatory cytokines, 
oxidative stress, and UV light. The aim of this study was to investigate the expression 
of HO-1 in human tracheal epithelial cell lines 9HTEo' and £CFTE29o" and to 
investigate the effect of PGs PGE2 and 15d-PGJ2 upon its expression.
6.2 Results
6.2.1 The Expression of HO-1 by 9HTEo" and ECFTE29o" cells
HO-1 protein expression by 9HTEo" and LCFTE29o' cells was investigated by 
immunoblot analysis as described in the materials and methods section. Confluent 
monolayers of 9HTEo' and £CFTE29o' cells were serum starved for 6  hours prior to 
incubation, at 37°C, with either vehicle or increasing concentrations of TNFa (0 -  
lOng/ml), PGE2 ( 0 - 1 0  pM), or 15d-PGJ2 (0 -10  pM).
HO-1 was expressed by both the 9HTEo‘ and SCFTE29o‘ cell lines in the absence of 
cytokine stimulation. No difference in HO-1 expression could be detected between these 
cell lines. Stimulation of the cells with increasing concentrations of TNFa did not 
appear to effect basal expression of HO-1 in either airway epithelial cell line (figure 61). 
Incubation of 9HTEo" and ZCFTE29o" cells with increasing concentrations of PGE2 (0 -  
10 pM) did not induce any detectable change in basal HO-1 expression by either cell line 
(figure 62). Stimulation of 9HTEo" with increasing concentrations of 15d-PGJ2 ( 0 - 1 0  
pM) did not have any effect upon HO-1 expression at the 24 hour time point (figure 63). 
However, incubation of SCFTE29o' cells with lOpM 15d-PGJ2 induced a significant 
increase in HO-1 expression at the 24 hour time point, a small increase could be
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observed in response to stimulation with lpM 15d-PGJ2, but no change in HO-1 
expression was induced by 15d-PGJ2 (0.1 pM) (figure 63).
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Figure 61 Expression of HO-1 by 9HTEo' and ECFTE29o' cells -  Effect of 
incubation with TNFa over 24 hours.
Western blot analysis of whole cell lysates. Cells were serum starved for 6 hours prior 
to stimulation with TNFa (0.1 -  10 ng/ml) at 37°C. The top panel is the immunoblot 
probed with a specific antibody against HO-1. This immunoblot is representative of 2 
other experiments. The lower panel shows membranes probed with an antibody against 
pan ERK to demonstrate equal loading.
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Figure 62 Expression of HO-1 by 9HTEo' and LCFTE29o' cells -  Effect of 
incubation with PGE2 over 24 hours.
Western blot analysis o f whole cell lysates. Cells were serum starved for 6 hours prior 
to stimulation with PGE2 (0.1 -  10 pM) at 37°C. The top panel is the immunoblot 
probed with a specific antibody against HO-1. This immunoblot is representative of 1 
experiment. The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading.
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Figure 63 Expression of HO-1 by 9HTEo' and ECFTE29o' cells -  Effect of 
incubation with increasing concentrations of 15d-PGJ2 (0 -10  pM) over 24 hours.
Western blot analysis of whole cell lysates. Cells were serum starved for 6 hours prior 
to stimulation at 37°C. The top panel is the immunoblot probed with a specific antibody 
against HO-1. This immunoblot is representative of 2 other experiments. The middle 
panel is the densitometry of the immunoblot (each bar is the mean ± SEM of 3 
experiments). The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading.
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In order to determine whether 15d-PGJ2 had an effect upon HO-1 expression at time 
points other that 24 hours, monolayers of 9HTEo' and £CFTE29o" cells were serum 
starved for 6  hours and subsequently stimulated with lOpM 15d-PGJ2 for 2, 6 , 14 and 24 
hours at 37°C.
In the XCFTE29o' cell line lOpM 15d-PGJ2 did not appear to significantly affect HO-1 
protein expression at either the 2 or 6  hour time points. However, by the 14 hour time 
point HO-1 expression had increased to approximately 25% of maximal expression. 
Maximal HO-1 expression was induced after 24 hour stimulation with lOpM 15d-PGJ2 
(figure 64 A). In 9HTEo' cells basal expression of HO-1 was unaffected by stimulation 
with lOpM 15d-PGJ2 at the 2 hour time point. However, maximal expression of HO-1, 
for this cell line, was induced at the 6  hour time point in response to lOpM 15d-PGJ2. 
HO-1 expression had returned to basal levels by the 14 hour time point and remained 
low at the 24 hour time point (figure 64 B). To investigate whether the increase in HO-1 
expression, observed in both the 9HTEo' and XCFTE29o‘ cell lines, in response to 15d- 
PGJ2 was a result of activation of PPARy monolayers of 9HTEo‘ and £CFTE29o" cells 
were serum starved for 6  hours and subsequently stimulated with lOpM troglitazone for 
2, 6 , 14 and 24 hours at 37°C. No change in basal expression of HO-1 was detected in 
response to troglitazone in either ECFTE29o‘ cells (figure 65 A) or 9HTEo‘ cells (figure 
65 B).
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Figure 64 Expression of HO-1 -Time course of effect of 15d-PGJ2 (10 pM) in A) 
ZCFTE29o cells and B) 9HTEo cells.
Western blot analysis of whole cell lysates. Cells were serum starved for 6 hours prior 
to stimulation at 37°C. The top panel is the immunoblot probed with a specific antibody 
against HO-1. This immunoblot is representative of 2 other experiments. The middle 
panel is the densitometry of the immunoblot (each bar is the mean ± SEM of 3 
experiments). The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading
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Figure 65 Expression of HO-1 -Time course of effect of troglitazone (10 pM) in A) 
LCFTE29o cells and B) 9HTEo cells.
Western blot analysis of whole cell lysates. Cells were serum starved for 6 hours prior 
to stimulation at 37°C. The top panel is the immunoblot probed with a specific antibody 
against HO-1. The lower panel shows membranes probed with an antibody against pan 
ERK to demonstrate equal loading
Prostaglandins in cytoprotection 165
6.2.2 Effect of PGs and PPARy ligands on the metabolic activity of 9HTEo' and 
ECFTE29o" cell lines
Monolayers o f cells were serum starved for 6  hours prior to stimulation with either 
vehicle, 15d-PGJ2 (lOpM), PGE2 (lOpM), or troglitazone (lOpM) for 2, 6 , 14, and 24 
hours. MTT assays were subsequently conducted in order to investigate whether these 
ligands have an effect upon cellular metabolic activity in either the 9HTEo' or 
2CFTE29o' cell line.
Incubation o f SCFTE29o" cells with PGE2 (lOpM) did not significantly affect the basal 
metabolic activity o f these cells at the 2, 6 , 14, or 24 hour time points (figure 56). 
Similarly, 15d- PGJ2 (lOpM) did not alter the basal metabolic activity o f £CFTE29o' 
cells at any o f the time points observed in this study (figure 6 6 ). Furthermore, PPARy 
ligand troglitazone (10 pM) did not appear to induce a change in the activity o f this cell 
line (figure 6 6 ). Incubation o f 9HTEo' cells with PGE2 (lOpM) over 2, 6 , 14, and 24 
hours, did not appear to have an effect on the basal metabolic activity o f this cell line 
(figure 67). However, incubation o f the 9HTEo* cell line with 15d- PGJ2 (lOpM) caused 
a significant decrease in the cells metabolic activity when compared to basal (from 8 8  ± 
19% o f max. absorbance (550nm) for basal to 41 ± 3 % o f max absorbance (550 nm) for 
15d- PGJ2 stimulated cells n = 3 p<0.05). The metabolic activity o f the 9HTEo' cell line 
had returned to levels comparable to basal by the 14 and 24 hour time points and 15d- 
PGJ2 (lOpM) was not determined to significantly change the basal metabolic activity of 
this cell line at these time point (figure 67). In contrast, troglitazone (lOpM) had no 
effect on the basal metabolic activity of the 9HTEo' cell line at any o f the time points 
observed in this study.
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Figure 6 6  Metabolic activity of ECFTE29o‘ cells -  Effect of incubation with 
vehicle, 15d-PGJ2 (10 iiM), PGE2 (10 pM), or troglitazone (10 pM) over 2 , 6,14 and 
24 hours.
The cells were serum starved for 6 hours prior to analysis. Basal is the absorbance 
measured at a wavelength of 550 nm for cells stimulated with vehicle alone. Each bar is 
the mean ± SEM expressed as a percentage o f the maximum absorbance for 3 
experiments
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Figure 67 Metabolic activity of 9HTEo' cells -  Effect of incubation with vehicle, 
15d-PGJ2 (10 jiM), PGE2 (10 fiM), or troglitazone (10 pM) over 2, 6 , 14 and 24 
hours.
The cells were serum starved for 6 hours prior to analysis. Basal is the absorbance 
measured at a wavelength of 550 nm for cells stimulated with vehicle alone. Each bar is 
the mean ± SEM expressed as a percentage of the maximum absorbance for 3 
experiments (* P<0.05 compared to basal)
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6.2 Discussion
Heme-oxygenase-1 (HO-1) is an inducible anti-oxidant enzyme that conveys protecion 
to oxidative cellular injury by the catabolism of pro-inflammatory heme to biliverdin 
and bilirubin, potent antioxidants; and carbon monoxide (CO), a neurotransmitter that 
has anti-inflammatory properties. Several studies report that HO-1 has anti­
inflammatory properties. Li Volti et al, 2003 report that HO-1 and its enzymatic 
products down-regulate the inflammatory response by repressing the induction of 
cytokines and chemokines. Additionally, Poss et al, 1997 demonstrate that HO-1 
deficient mice develop a chronic inflammatory state that increases with age. 
Furthermore, overexpression of HO-1 by gene transfer into rat lungs provided protection 
from hyperoxic injury (Otterbain et al, 1999). Paredi et al, 1999 report an increase in 
exhaled CO levels, that may be of pathophysiological significance, in patients with 
cystic fibrosis. The authors of this study postulate that the source of this CO is HO-1. 
Donnelly and Barnes, 2001 report that HO-1 expression is inducible in airway epithelial 
cell lines and put forward the hypothesis that the airway epithelium may be the source of 
increased CO in airway diseases. It therefore seemed reasonable to investigate the 
expression of HO-1 in human tracheal epithelial cell lines 9HTEo‘ and XCFTE29o", 
cells of a CF and non-CF phenotype respectively. Additionally, prostaglandin 15d-PGJ2 
is considered to be an anti-inflammatory molecule with therapeutic properties 
production of which has been demonstrated to present in inflammatory exudates and is 
increased during the resolution phase of inflammation (Gilroy et al, 1999). Several 
studies indicate that 15d-PGJ2 exerts its anti-inflammatory activity by inhibiting the 
expression of pro-inflammatory mediators (Ricote et al, 1998; Jiang et al, 1998; 
Cuzzocrea et al, 2002). Recent studies have illustrated that 15d-PGJ2 induces HO-1 
expression in a variety of cells including activated microglial cells (Koppal et al, 2000), 
murine macrophages (Colville-Nash et al, 1998; Lee et al, 2003), cardiac myocytes 
(Wayman et al, 2002), and human lymphocytes (Alvarez-Maqueda et al, 2004). To 
date, the induction of HO-1 expression by 15d-PGJ2 has not been reported in the human 
airway epithelium. In this study HO-1 protein expression has been investigated in 
9HTEo‘ and SCFTE29o' cells and its induction by cytokines, PGE2 , 15d-PGJ2 and 
troglitazone assessed.
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Donnelly and Barnes, 2001 report that primary human airway epithelial cells express a 
low baseline of HO-1 mRNA under basal conditions; culture of these cells with a 
cytomix of TNFa, IL-lp, and IFNy induces a fivefold increase in HO-1 expression at 
the 4 hour time point that decreases by the 12 hour time point. In this study low basal 
expression of HO-1 protein could be observed in both 9HTEo' and SCFTE29o' cells 
under basal conditions. Basal expression of HO-1 by the human tracheal epithelium 
may be induced by a continuous low level production of pro-inflammatory cytokines by 
these cells in response to a constant low-grade inflammatory response elicited by 
constant exposure to external stimuli. In this study expression of HO-1 could not be 
induced by pro-inflammatory cytokines at any time point between 2 and 24 hours. 
Furthermore, no difference in HO-1 expression could be observed between 9HTEo' and 
ECFTE29o' cells.
As previously stated, 15d-PGJ2 has been reported to increase HO-1 expression in a 
number of tissues. As PGE2 is the most abundant PG produced by the airway 
epithelium, and in this study expression of PGE2 has been demonstrated to be elevated 
in £CFTE29o‘ cells compared to 9HTEo' cells, the effect of PGE2 on HO-1 expression 
was investigated. However, no change in the expression of HO-1 could be detected in 
response to 24 hour stimulation with micro-molar concentrations of PGE2 . It is not 
possible to rule out the prospect of PGE2 producing an effect upon HO-1 expression 
from these data, more physiologically relevant concentrations of PGE2 could be used 
and earlier time points studied.
This study demonstrated that high concentrations of 15d-PGJ2 (1 and 10 pM) induce 
HO-1 protein expression in the ICFTE29o' cells but not 9HTEo' cells. In order to elicit 
its an effect on HO-1 expression, concentrations of 15d-PGJ2 substantially higher than 
those endogenously present at the sites of inflammation (pM - nM levels) ((Gilroy et al., 
1999) had to be used; this the effects of this PG on HO-1 expression in the airway 
epithelium could be of pharmacological rather than physiological relevance. 
Experiments constructed to investigate the time course of HO-1 induction by 15d-PGJ2 
revealed that HO-1 protein expression can be up-regulated in both cell lines. In the 
9HTEo' cell line expression of this enzyme can be observed to be increased at the 6  hour
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time point and to have reduced back to basal levels by the 14 hour time point. Induction 
of HO-1 expression is also observed to be induced by 15d-PGJ2 at the 6  hour time point 
in £CFTE29o' cells, however, expression does not fall back to basal but continues to 
increase at the 14 and 24 hour time points. As 15d-PGJ2 can act on cells through either 
PPARy -dependent or -independent mechanisms, the same time course was constructed 
to determine whether synthetic PPARy ligand troglitazone could also induce HO-1 
protein expression. The inability of troglitazone to affect HO-1 expression suggests that 
the induction of this enzymes expression by 15-dPGJ2 may be PPARy - independent.
The induction of HO-1 by 15d-PGJ2 suggests that 15d-PGJ2 may be inducing 
intracellular oxidative stress. In support of this, Chen et al, 2002 report that, in a 
thyroid papillary cancer cell line 15d-PGJ2 caused cytotoxicity and increased the 
amount of intracellular reactive oxygen species (ROS) inducing apoptosis and/or 
inhibiting cell proliferation. Furthermore, Alvarez-Maqueda et al, 2004 report that 
HO-1 induction in human lymphocytes is dependent on ROS produced via the 
xanthine/xanthine oxidase system and/or through Fenton reactions. Using MTT assays 
this study demonstrates that PGE2 , troglitazone and 15d-PGJ2 have no effect on the basal 
metabolic activity of the ZCFTE29o' cell line. This is despite 15d-PGJ2 inducing 
significant levels of HO-1 protein. These data suggest that 15d-PGJ2 is not cytotoxic to 
these cells. Similarly, PGE2 and troglitzone did not significantly effect the basal 
metabolic activity of the 9HTEo’ cell line. However, these experiments demonstrate 
that at the 6  hour time point 10 pM significantly reduces the metabolic activity of 
9HTEo‘ cells; this occurs concomitantly with an increase in HO-1 expression. By the 14 
hour time point both HO-1 expression and the basal metabolic activity of the 9HTEo* 
cell line have returned to levels not significantly different from time matched controls. 
These data indicate that 15d-PGJ2 induces oxidative stress in the 9HTEo* cell line and 
that as a result HO-1 protein expression is induced. However, while the non-CF 
phenotype cell line can be observed to recover from the effects of stimulation with 15d- 
PGJ2 , the ECFTE29o' cell line continues to express increasing levels of HO-1. 
Prolonged expression of HO-1 in response to transient oxidative stress may provide 
some explanation for elevated CO observed in CF compared to normal controls 
(Horvarth et al, 1998).
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In summary, this study demonstrates that the anti-oxidant enzyme HO-1 is expressed by 
human tracheal epithelial cell lines ECFTE29o' and 9HTEo' under basal conditions and 
cannot be up-regulated by pro-inflammatory cytokines. While 15d-PGJ2 can be 
observed to induce an increase in HO-1 expression, the high concentrations of this PG 
needed to elicit a response are unlikely to be of physiological relevance. Interestingly 
while differences in the basal expression of HO-1 expressed by XCFTE29o" and 9HTEo' 
cells cannot offer any explanation as to the source of increased CO levels observed in 
the exhaled breath of CF patients compared to non-CF individuals (Horvarth et al., 
1998), a prolonged pattern of expression of HO-1 by the CF airway epithelium 
compared to the non-CF airway epithelium may provide a mechanism behind this 
phenomenon.
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Summary of Results
HO-1 is protein is constitutively expressed, at similar levels, in both the 9HTEo" 
and LCFTE29o' cell lines
Pro-inflammatory cytokine TNFa does not appear to induce HO-1 protein in 
9HTEo' or XCFTE29o* cells over 24 hours
PGE2 , in micro-molar concentrations, does not affect HO-1 protein expression at 
a 24 hour time point in either cell line
At a 24 hour time point 1 and 10 pM 15d-PGJ2 induce HO-1 protein expression 
by the ZCFTE29o* cell line. No increase in HO-1 expression is observed at this 
time point in response to 15d-PGJ2 in 9HTEo‘ cells
HO-1 protein expression is induced , compared to basal, by stimulation with 
lOpM 15d-PGJ2 in 9HTEo" cells at a 6  hour time point but not at 2,14, and 24 
hour time points
In £CFTE29o‘ cells HO-1 protein expression is elevated, compared to basal, in 
cells stimulated for 14 and 24 hours with 10 pM 15d-PGJ2 
Troglitazone (10 pM) has no significant effect on HO-1 expression in either cell 
a 2, 6,14 or 24 hour time points
PGE2 (10 pM) does not significantly affect the basal metabolic activity of either 
the HTEo' or £CFTE29o" cell lines
Troglitazone (10 pM) does not significantly affect the basal metabolic activity of 
either the 9HTEo' or ICFTE29o' cell lines
15d-PGJ2 (10 pM) significantly reduces the basal metabolic activity of the 
9HTEo' cell line at the 6  hour time point
15d-PGJ2 (10 pM) does not significantly affect the basal metabolic activity of 
ECFTE29o' cells at any of the time points observed in this study
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7. General Discussion
In CF, defective function of the CFTR in airway epithelial cells and submucosal glands 
results in chronic disease of the airways leading to deterioration of lung function and 
ultimately death (Van Heeckeren, 1997). An imbalance in the ionic and/or osmotic 
balance of the ASL results in clogging of the airways with thick, sticky mucus, and 
facilitates colonisation by bacteria such as Burkholderia cepacia, Staphylococcus 
aureus, and Psudomonas aeruginosa. The CF airway mounts a vigorous inflammatory 
response to the bacteria, which in early life is often successful in preventing chronic 
colonisation (Dakin et al., 2002). However, eventually the CF lung becomes unable to 
clear infection and bacterial colonisation of the airway becomes chronic. Konstan et al. 
(1994) report that older children and adults with CF have large numbers of bacteria in 
their lower airways accompanied by neutrophil influx and uninhibited elastase activity. 
Furthermore, a number of studies report that a modest inflammatory response can be 
observed in the airways of CF infants in the absence of a bacterial infection (Reviewed 
by Chmiel and Davies, 2003), this suggests that inflammation may be intrinsic in CF 
airways or that the inflammatory response mounted by the CF airway in response to 
bacterial infection is not down-regulated once the pathogen has been eliminated. A 
persistent and exaggerated inflammatory response, associated with elevated levels of 
cytokines, is one of the major factors leading to damage of the host tissue in CF 
(Escotte, 2002). DiMango et al. (1995) report that CF cell lines produce higher levels 
of IL-8 , in response to Pseudomonas stimulation, than non-CF cells. Additionally, 
Thomas et al. (2000) demonstrate that CF mice show increased production of TNFa, in 
response to challenge with bacterial LPS, than their non-CF littermates. Furthermore, a 
number of studies have reported elevated levels of PGs in the sputum of CF patients 
when compared to healthy controls (Zakrzewski et al., 1987; Strandvik et al, 1996). 
Ultimately, the chronic and excessive inflammatory response seen in CF airways leads 
to destruction of host tissue and pulmonary failure. Consequently, the host 
inflammatory response is viewed as a therapeutic target with potential to delay the 
deterioration in lung function seen in CF.
Elevated levels of PGs observed in the sputum of CF patients compared to healthy 
controls suggest a role for PGs in the excessive inflammatory response, therefore
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elucidation of the role and regulation of PG production by airway epithelial cells may 
provide insight into more effective anti-inflammatory therapies for diseases of the 
airways such as CF. In light of these findings, this study set out to investigate the role 
of tracheal epithelial cell lines in the production of PGs, the expression and regulation 
of enzymes involved in PG production, and to define which agents might affect their 
expression.
PGE2 is the most common PG in the airways and is believed to be predominantly a 
COX-2 product. The airway epithelial cell lines 9HTEo' and XCFTE29o" produced 
PGE2 constitutively. Interestingly, the XiCFTE29o" produced significantly higher levels 
of PGE2 than the non-CF phenotype 9HTEo' cell line. This data suggests that the 
airway epithelium could be the souce of elevated PG levels seen in CF and supports the 
clinical findings of Zakrzewski et al (1987) and Strandvik et a l (1996) who report 
elevated levels of PGs in the sputum of CF patients compared to healthy controls, and 
the work of Freedman et al. (1999 and 2002) who report an elevated level of phospho­
lipid bound AA and an increase in levels of PGE2 in the BAL fluid from cftr^'micQ 
when compared to wild-type controls. This was not the case, however, for IL-8 . No 
significant difference in basal IL- 8  production could be observed between the 9HTEo' 
and XCFTE29o‘ cell lines. While some differences could be observed between IL- 8  
production in these cell lines in response to stimulation with pro-inflammatory 
cytokines, the disparity was not highly significant nor did one cell line demonstrate 
consistently higher levels than the other, suggesting that differences in IL- 8  production 
observed in response to cytokines may be a result of differences in cytokine receptor 
expression rather than IL- 8  being more inducible in one cell line over the other. The 
ability of pro-inflammatory cytokines to significantly up-regulate IL- 8  production by 
the 9HTEo' and XCFTE29o' cell lines confirms that the airway epithelium can be a 
source of IL- 8  in the setting of airway inflammation and that the cytokine signalling and 
NFkB activation pathways must be intact in these cells. These data are in line with the 
findings of Becker et al (2003) who report that primary human airway epithelial cell 
lines with a CF- and non-CF phenotype generally display similar patterns of IL- 8  
production and NFkB activation at baseline or in response to a diverse set of relevant 
stimuli. The study by Becker et al does, however, report that IL- 8  production by the
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CF cell line is exaggerated and sustained in response to P. aeruginosa in the presence 
but not in the absence of serum. These data suggest that baseline differences in 
inflammation due to mutant CFTR are not a primary cause for the hyperinflammatory 
status of the CF lung. But support the hypothesis that severe inflammation occurs in 
response to bacteria, their products and that CF cells are less capable of downregulating 
proinflammatory responses.
In line with the findings of Mitchell et al, 1994; Asano et al, 1996; Watkins et al, 
1999; and Rodgers et al, 2002, this study found that the airway epithelial cells observed 
constitutively expressed both COX-1 and COX-2. Interestingly, while no difference in 
COX-2 expression was observed between the CF and non-CF phenotype cell lines, 
9HTEo' cells constitutively expressed higher levels of COX-1 protein than SCFTE29o‘ 
cells, despite XCFTE29o" cells producing approximately eight times more PGE2 than 
9HTEo' cells. In contrast to the findings of the aforementioned studies, COX-2 protein 
expression could not be up-regulated by stimulation of the cell lines with pro- 
inflammatory cytokines. The constitutive expression of COX-2 and rapid up-regulation 
of PGE2 by human tracheal epithelial cells suggests that PGE2 expression by the 
tracheal epithelium may be part of a natural defense mechanism as well as a contributor 
to airway inflammation, as implied by elevated levels of this PG detected in the CF 
Phenotype cell line when compared to the non-CF cell line. The potential for COX-2 to 
be playing a homeostatic role in the airways suggests that, under certain circumstances, 
its inhibition may be deleterious. Reuter et al 1996 report that in animal models of pre­
existing gastrointestinal injury and inflammation daily treatment with a selective 
inhibitor of COX-2 (L745337) at doses that did not inhibit COX-1 resulted in 
significant inhibition of mucosal prostaglandin synthesis and a marked increase in the 
severity of colonic damage. These findings may also of relevance to the CF airway 
where a persistent inflammatory response, featuring elevated levels of PGs, leads to 
tissue damage but COX-2 expression is constitutive and may play a homeostatic role. 
It would, therefore, be of interest to assess the affect of COX-2 inhibition in subjects 
with chronic inflammation of the airways.
The role of PGs in the airway is complex and their effects may be pro- or anti­
inflammatory dependent upon the time point during inflammation, the receptor sub­
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types activated and the model being observed. The up-regulation of PGE2 , by the 
9HTEo' and £CFTE29o* cell lines, at the 2 hour and 6 hour time points after stimulation 
with pro-inflammatory cytokines suggests a pro-inflammatory role for this PG in the 
human tracheal epithelium. This finding raises the possibility that the specific PGE 
synthases may be a valid therapeutic target in airway inflammation. As previously 
mentioned, three major isoforms o f PGES have been identified to date cPGES a 
reportedly constitutive isoform functionally coupled to COX-1 (Murakami et al ,  2000), 
an inducible isoform, mPGES, coupled to COX-2 (Murkami et al ,  2000), and mPGES- 
2 a constitutive isoform that promotes PGE2 production via both COX-1 and -  2 
(Murakami et al ,  2003). The apparent absence o f mPGES in human tracheal epithelial 
cell lines 9HTEo‘ and XCFTE29o", indicates that COX-2 may be coupling with cPGES 
or mPGES-2 to produce PGE2 . The ability o f cPGES to functionally pair with COX-2 
is supported by the findings o f Han and Smith (2002) who report the absence o f 
mPGES in KAT-50 thyrocytes and postulate that in its absence, cPGES and COX-2 
form an inefficient couple resulting in low PGE2 production despite high expression o f 
COX-2. It was not possible to determine the expression o f mPGES-2 protein at the 
time this study was conducted, as the relevant anti-body was not available.
In line with the finding that PGE2 is constitutively expressed by both the 9HTEo* and 
ECFTE29o‘ cell lines was the observation that the PGE2 metabolising enzyme PGDH is 
constitutively expressed by these cells. No difference in the expression or regulation o f 
PGDH could be detected between the tracheal epithelial cell lines used in this study. 
This indicates that the higher levels o f PGE2 produced by the XCFTE29o' cell line when 
compared to the 9HTEo' cell line are not a consequence o f elevated PGDH expression 
in 9HTEo' cells. This study did not investigate the activity o f PGDH and it is possible 
that differences in the activity o f PGDH between the cell lines may, in part, contribute 
to the disparity in PGE2 production observed. However, the ability of pro-inflammatory 
cytokines TN Fa and IL -lp to up-regulate PGE2 production by both 9HTEo‘ and 
ECFTE29o" cells despite having no effect upon the expression o f COX, PGES, or 
PGDH protein expression suggests that they are modulating the release o f substrate 
from the cell membrane rather than affecting enzymes downstream o f AA. These 
findings are summarised in figure 68. Pro-inflammatory cytokines IFNy, TNFa, and 
IL -lp  are reported to up-regulate/activate PLAs in airway epithelial cells (Wu et al ,
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1997; Yao et al, 1998). It is therefore possible that the increases in PGE2 production, 
induced by pro-inflammatory cytokines, in the 9HTEo‘ and £CFTE29o' cell lines is a 
result of elevated PLA expression and/or activity. However, the pattern of induction of 
PGE2 and the fold-increase from basal of PGE2 production, in response to pro- 
inflammatory cytokines, is similar for both cell lines. These data suggest that the 
difference in PGE2 production is likely to be a consequence of increased AA 
availability in the CF Phenotype £CFTE29o" cell line compared to the non-CF 
phenotype 9HTEo' cell line. This hypothesis is supported by the findings of Freedman 
et al, (1999; 2002) who, as previously stated, report an elevated level of phospho-lipid 
bound AA and an increase in levels of PGE2 in the BAL fluid from cftr Amice when 
compared to wild-type controls. In their 2002 study Freedman et al report that oral 
administration of DHA resulted in a selective decrease in eicosanoid formation in cftrA 
mice that was not observed in WT mice suggesting that the membrane lipid imbalance 
observed in lungs from cftr1' mice may play an important role in the pathogenesis of the 
enhanced pulmonary inflammation observed in CF. The findings in this study add to the 
body of evidence that PGE2 levels are elevated and contribute to the inflammatory 
phenotype seen in CF. Furthermore, these data provide evidence to suggest that the 
disparity observed in PG levels between cells of a CF and non-CF phenotype are a 
result of factors upstream of the COX enzymes in the PG biosynthetic pathway.
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Figure 68 A model of PGE2 formation by human tracheal epithelial cell lines.
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Konstan et al (1995) report that in patients with cystic fibrosis and mild lung disease, 
high-dose ibuprofen, taken consistently for four years, significantly slows the 
progression of the lung disease. However, despite the ability of high dose ibuprofen to 
retard progression of lung disease, adverse events, such as renal toxicity (Scott et al, 
2 0 0 1 ) and potentiation of intestinal damage caused by pancreatic enzyme treatment 
(Kimura et al, 1999), mar its therapeutic utility. Therefore, the development of 
alternative anti-inflammatory agents is necessary. PPARs are ligand activated 
transcription factors belonging to the nuclear receptor superfamily. A growing body of 
evidence suggests that ligands of PPARy may be suitable anti-inflammatory agents and 
provide an alternative to the currently used therapies for inflammation control. A 
number of studies have reported that both natural and synthetic ligands for PPARy 
possess anti-inflammatory properties, attenuating the release of cytokines, NOS and 
COX-2 in a number of cell types (Jiang et al, 1998; Ricote et al, 1998; Welch et al; 
2003; Colville-Nash et al, 1998; Patel et al, 2003). Wang et a l (2001) report that 
activation of PPARy in airway epithelial cells dramatically inhibits cytokine-induced 
expression of inflammatory mediators by these cells and suggest that PPARy may act as 
a negative immunomodulator in the airways. Patel and co-workers (2003) demonstrate 
that PPARy ligands suppress cell growth, induce apoptosis and inhibit GM-CSF release 
from HASM cells, supporting the hypothesis that PPARy may be a potential target for 
therapies aimed at inflammatory disorders of the airways. However, the fact that 
PPARy ligands are also able to up-regulate COX-2 expression on colonic epithelial cell 
and mammary epithelial cells (Meade et al, 1999) suggests that the effects of PPARy in 
inflammation are tissue specific and require elucidation.
In line with the finding that airway epithelial cells express PPARy (Michael et al, 1997; 
Wang et al, 2001) this study found that PPARy was expressed by both 9HTEo" and 
XCFTE29o' cells. Interestingly, the CF Phenotype cell line expressed significantly 
higher levels of this receptor than the non-CF phenotype tracheal epithelial cell line. As 
the cell lines used in this study are not a genetically matched pair, it is difficult to draw 
any conclusions as to the relevance of the high expression in the CF Phenotype cell line. 
15d-PGJ2, a degradation product of PGD2 , is an endogenous high affinity ligand for 
PPARy (Forman et al, 1995; Kliewer et al, 1995). The low levels of PGD2 observed 
to be produced by the cell lines used in this study suggest that very little 15d-PGJ2
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would be present in the cells’ milieu and therefore in these cell lines, it would not be an 
endogenous activator of PPARy. In this study, exogenously applied 15d-PGJ2, 
troglitazone, and PPARy antagonist BADGE, at concentrations ranging from pM to pM, 
could not be observed to have any effect on expression of the enzymes in the PGE2  
biosynthetic pathway at protein level. However, 15d-PGJ2 (lOpM) induced an increase 
in basal PGE2 production by both the 9HTEo' and ECFTE29o" cell lines. Conversely, 
troglitazone appeared to inhibit PGE2 generation by both cell lines. This may indicate 
that the effect of 15d-PGJ2 on PGE2 generation is PPARy-independent. Castrillo et 
a/. (2000) and Chawla et al (2001) demonstrate that 15d-PGJ2 is able to elicit responses 
in cells that do not express PPARy and state that its role in inflammation is attributable 
not only to its binding and activating PPARy but to its ability to modulate the activity of 
the transcription factors including NFkB. This group also state that in vitro 
concentrations of 15d-PGJ2 of 2.5pM and above are required to ligate the proteins in the 
NFkB signalling pathway. Therefore, it is possible that the concentration of 15d-PGJ2 
used in this study could be inducing PGE2 by modulating the NFkB pathway. 
However, IL- 8  transcription is regulated by NFkB, and at a concentration of lOpM, 
15d-PGJ2 had no effect on basal IL- 8  generation by either cell line used in this study 
suggesting that the basal activity of NFkB is not being affected by this ligand at the 
concentrations used in this study. These findings are summarised in figure 69.
The ability of 15d-PGJ2 to induce basal PGE2 production but to inhibit TNFa induced 
PGE2 generation is of interest as it suggests that this ligand may regulate PGE2 
generation via a negative feedback-loop. The control of COX-2 expression by a 
negative-feedback loop mediated through PPARy has been demonstrated by Inoue et al 
(2000) in the macrophage-like cell line U937. As previously stated, in the cell lines 
used in this study, 15d-PGJ2 was not observed to have any effect upon COX-2 protein 
expression. However, this study did not look at the expression of the PLA enzymes. 
Alaoui-El-Azher et a l (2002) report that 15d-PGJ2 mediates inhibition of LPS- 
stimulated sPLA(2)-IIA expression via a PPAR-gamma-dependent pathway. It is 
therefore possible that 15d-PGJ2 is affecting PGE2 generation by modulating expression 
of PLA enzymes.
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The ability of 15d-PGJ2 to both up- and down-regulate PGE2 production by human 
tracheal epithelial cell lines requires further investigation. As the CF airways have been 
demonstrated to produce elevated levels of PGs (Zakrzewski et al., 1987; Strandvik et 
al., 1996) and these PGs may be contributing to the excessive inflammatory response. 
The use of pharmacological use of PPARy ligands as anti-inflammatory therapy in the 
CF airway, could in some circumstances be detrimental to health. Elucidation of the 
mechanisms by which PPARy ligands regulate PGE2 production in these cell lines may 
clarify the suitability of these ligands to be used in the inflammatory setting of CF.
The data gathered from the 9HTEo'(l) and £CFTE29o"(2) cell lines, with respect to the 
effect of PPARy ligands on COX-2 expression, differs markedly from the data obtained 
from the 9HTEo' and ZCFTE29o* cell lines. After problems with the growth of the 
9HTEo'(l) and XCFTE29o'(2) cells a new batch of each cell line, 9HTEo' and 
ICFTE29o', was procured from the original source (generously supplied by D.C. 
Gruenert, University of San Francisco, CA). The growth pattern and data obtained from 
the new cells was consistent. Additionally, the ability of pro-inflammatory cytokines to 
up-regulate PGE2 production, absent in 9HTEo'(l) cells, suggests that the PG 
biosynthetic pathway is intact in these cells. Therefore, the data obtained from the old 
batch of cells was disregarded. The difference in data and problems with the growth 
suggest that caution should be employed when using these cell lines to investigate the 
effect of PPARs on PG generation as age related changes to the cell lines appear to 
affect these pathways.
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Figure 69 Model of effect of PPARy ligands on the PGE2 biosynthetic pathway in 
9HTEo' and ECFTE29o' cells
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HO-1 is an inducible anti-oxidant enzyme with anti-inflammatory properties mediated 
by the ability of its enzymatic products to down-regulate the inflammatory response 
(Poss et al, 1997; Li Volti et al, 2003). A study by Horvarth et a l (1998) reports 
elevated levels of exhaled CO in the breath of CF patients which may be of 
pathophysiological significance in patients with this disease. Horvarth et a l postulate 
that HO-1 is the source of this CO. Furthermore, Donnelly and Barnes (2001) put 
forward the hypothesis that the airway epithelium may be the source of increased CO in 
airway diseases. The aforementioned report finds that primary human airway epithelial 
cell lines express low levels of HO-1 constitutively and that the expression of this 
enzyme can be increased upon incubation of the cells with a mixture of pro- 
inflammatory cytokines. The increase in HO-1 protein expression was observed at the 4 
hour time point and had decreased by the 12 hour time point. In line with this report, 
this study finds that airway epithelial cell lines 9HTEo' and ECFTE29o" express similar 
levels of HO-1 under basal conditions. However, in contrast to the findings of Donnelly 
and Barnes, the expression of this enzyme could not be induce by incubation of the cells 
with pro-inflammatory cytokines, either alone or in combination. It is possible that the 
constitutive expression of HO-1 by human tracheal epithelial cell lines is a consequence 
of continual low level of cytokine production by these cells.
Zhou et a l (2004) state that that the induction of HO-1 in patients with CF is a 
cytoprotective event and that augmenting its expression may be a potential therapy 
against bacterial injury. A number of studies have illustrated that 15d-PGJ2 induces 
HO-1 expression in a variety of cell systems (Colville-Nash et al, 1998; Koppal et al, 
2000; Wayman et al, 2002; Lee et a l,2003; Alvarez-Maqueda et al, 2004). This study 
demonstrates that micro-molar concentrations of 15d-PGJ2 induce HO-1 expression by 
both 9HTEo' and £CFTE29o' cell lines, it should be noted, however, that concentrations 
of 15d-PGJ2 in the micro-molar range are more likely to be of pharmacological than 
physiological relevance. The finding that HO-1 expression was induced by 15d-PGJ2 
suggests that 15d-PGJ2 may be inducing intracellular oxidative stress. HO- 1  was 
transiently increased in the non-CF phenotype cell line, increasing at the 6  hour time 
point and returning to basal levels by the 14 hour time point. Concomitantly, the basal 
metabolic activity of this cell line dropped at the 6  hour time point but returned to levels 
not significantly different from normal by the 14 hour time point. Interestingly,
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induction of HO-1 in the CF Phenotype cell line occurred at a later time point after 
incubation with 15d-PGJ2 than in the non-CF phenotype cell line. Furthermore, HO-1 
expression by the ZCFTE29o' cell line continued to increase at the 24 hour time point. 
However, the metabolic activity of these cells did not appear to be affected by this 
ligand. These data suggest that 15d-PGJ2 induces oxidative stress resulting in increased 
HO-1 expression in human tracheal epithelial cell lines, but that while this event is 
transient in the non-CF phenotype cell line the effects are sustain in the CF Phenotype 
cells. As stated by Horvarth et al (1998) HO-1 may be a source of increased CO in the 
exhaled breath of CF patients when compared to healthy controls and as such may be 
contributing to the pathophysiology of this disease. This study demonstrates that whilst 
differences in basal expression of HO-1 between the CF Phenotype airway epithelial 
cell line and the non-CF Phenotype airway epithelial cell line do not offer any 
explanation for the increased levels of CO observed in exhalations from CF patients, the 
prolonged induction of HO-1 CF in airway epithelial cells, compared to non-CF airway 
epithelial cells, in response to transient oxidative stress may provide insight into a 
mechanism behind this phenomenon. These data also support the hypothesis of 
Donnelly and Barnes (2001) who postulate that the airway epithelium is the source of 
elevated CO in CF airways.
Once again, these findings raise questions about the relevance of PPARy ligands as anti­
inflammatory agents in the CF lung. In the non-CF cell line, 9HTEo", these ligands 
appear to have anti-inflammatory activity, decreasing both basal and pro-inflammatory 
cytokine induced PGE2 generation and transiently up-regulating expression of HO-1, 
which may prove beneficial in an inflammatory setting. However, in the CF Phenotype 
cell line, XCFTE29o", the contradictory effects of PPARy ligands 15d-PGJ2 and 
troglitazone on basal PGE2 generation and the sustained induction of HO-1 by 15d-PGJ2 
suggest that these ligands may exacerbate the existing inflammatory condition and 
cause further damage to the host.
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8. Conclusions
This study demonstrates that, in line with the finding that PG levels in the sputum from 
CF patients are elevated when compared to healthy controls, the CF phenotype human 
tracheal epithelial cell line ZCFTE29o' produces significantly more PGE2 under basal 
conditions than the non-CF phenotype cell line 9HTEo\ These findings provide 
evidence that the airway epithelium is potentially a major source o f PGE2 in the airways 
and implicate the airway epithelium as a contributor to the excessive inflammatory 
response observed in the CF lung.
Despite the fact that the £CFTE29o' cell line produces significantly higher levels o f 
PGE2 than the 9HTEo* cell line, no significant difference in the expression o f PGE2  
biosynthetic enzymes could be observed between the cell lines to explain this disparity. 
The airway epithelial cells used in this study were found to constitutively express both 
COX-1 and COX-2 proteins. The PGES cPGES was constitutively expressed by both 
cell lines. Interestingly, the COX-2 coupled mPGES was absent from both cell lines 
and its expression could not be induced by any o f the ligands used in this study. 
Therefore, the production o f PGE2 by the human tracheal epithelial cell lines used in 
this study may be a product o f the action o f COX-2/cPGES coupling or the functional 
coupling o f COX-2 /mPGES-2. At the time this study was conducted, there was not an 
antibody for mPGES-2 available to investigate this further. It would be o f interest to 
investigate the expression and regulation o f this enzyme in these cell lines. As the time 
scale o f PGE2 induction by these cell lines suggest that it is acting as a pro- 
inflammatory mediator, elucidation o f the role and regulation o f the PGES enzymes 
may provide insight into therapeutic targets aimed at reducing pro-inflammatory PG 
production whilst maintaining levels o f homeostatic PGs. Expression o f the PGE2  
metabolising enzyme PGDH was constitutive in both cell lines and also could not be 
induced by pro-inflammatory stimuli. This finding suggests that elevated expression o f 
his enzyme cannot be implicated as a contributory factor to the difference in PGE2  
expression observed between the ECFTE29o‘ and 9HTEo' cell lines.
The finding that enzymes of the PGE2 biosynthetic pathway are expressed at similar 
levels by both cell lines and that, despite differences in the level o f PGE2 production by
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these cell lines, a similar fold increase in PGE2 generation can be observed in response 
to pro-inflammatory cytokines, suggests that the high levels of PGE2 generated by the 
CF phenotype cell line are a result of elevated AA rather than the expression or activity 
of down-stream enzymes.
Human airway epithelial cell lines were found to constitutively express the nuclear 
hormone receptor transcription factor PPARy. The ZCFTE29o* cell line expressed 
higher levels of this receptor than the 9HTEo‘ cell line, whether this finding has any 
significance with regards to CF cannot be concluded from these data as the cell lines 
used for this study are not a genetically match pair. Despite the ability of PPARy 
ligands to inhibit PGE2 generation and transiently increase HO-1 expression by the non- 
CF phenotype cell line, the conflicting effects of PPARy ligands on the production of 
PGE2 and the induction of sustained HO-1 expression in CF phenotype cells, indicate 
that use of these ligands may not be suitable anti-inflammatory agents in the CF lung 
and may exacerbate the exaggerated inflammatory response already present. Further 
investigation is required into the exact mechanisms behind the action of PPARy ligands 
on PG production in airway epithelial cells, particularly in an inflammatory setting.
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9. A ppendices
9.1 Buffers and Solutions
9.1.1 Solutions for tissue culture
Tissue culture reagents were used for all cell cultures and solutions were prepared using 
sterile MilliQ water.
Phosphate Buffered Saline, pH 7.4
140 mM NaCl 
2.7 mM KC1 
1.5 mM KH2H P04 
8.1 mM Na2H P04
CFTE and HTE medium - MEM
Supplemented with penicillin (10 
units/ml), streptomycin (10 units/ml) and 
fungizone (0.5 pg/ml)
Trypsin -  EDTA Solution Freeze medium
0.05% (w/v) Trypsin and 0.02% (w/v) 
EDTA
10% (v/v) DMSO 
40% (v/v) FBS
50% (v/v) CFTE/HTE medium
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9.1.2 Solutions for SDS-PAGE and Western blotting
Lysis Buffer Stock solutions
50 mM Tris-HCl pH 7.5 (stock 1 M) 1 M Tris-HCl pH 8.8
150 mM NaCl (stock 5 M) 1 M Tris-HCl pH 6.8
1% (v/v) Nonidet P40 (stock 10%(v/v)) 10% (w/v) SDS
10% glycerol 10% (w/v) ammonium persulfate
5 mM EDTA (stock 0.5 M, pH 8.0) TEMED
1 mM sodium orthovanadate
1 mM sodium molybdate
10 mM sodium fluoride
40 pg/ml phenylmethylsulfonyl fluoride
(PMSF)
1 pg/ml pepstatin A
10 pg/ml aprotinin
10 pg/ml leupeptin
10 pg/ml soyabean trypsin inhibitor
MilliQ water
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SDS-PAGE running buffer
25 mM Trizma base 
192 mM glycine 
0.1% (w/v) SDS 
MilliQ water
5X SDS-sample buffer
5% SDS
50% glycerol
200 mM Tris-HCl pH 6.8
MilliQ water
5% 2-mercaptoethanol
Bromophenol blue
Store in dark
Wet transfer buffer
39 mM glycine 
48 mM Trizma base 
20% (v/v) methanol
Tris-buffered saline (TBS)
20 mM Tris-HCl pH 7.5 
150 mM NaCl 
MilliQ water pH 7.5
Ponceau S solution
0.1 % (w/v) Ponceau S 
5% (v/v) Acetic acid
Blocking buffer
5% (w/v) non
-fat powdered milk (Marvel) in TBS
7.5% w/v Acrvlamide running gel (10ml)
3.75ml Protogel (30%(w/v) acrylamide, 
0.8% (w/v) bisacrylamide 
1M TRIS-HC1, pH 8.8 
0.1% SDS
0.1 % ammonium persulphate 
5.6ml Milli-Q water
20 pi N,N,N’,N’, tetramethylene-diamine 
(TEMED)
5% w/v Acrvlamide stacking gel (8ml)
1.33ml Protogel (30%(w/v) acrylamide, 
0.8% (w/v) bisacrylamide 
1M TRIS-HC1, pH 6.8 
0.1% SDS
0.1% ammonium persulphate
6.36ml Milli-Q water
20 pi N,N,N’,N \ tetramethylene-diamine
(TEMED)
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9.2 Antibodies used for immunoblotting
Antigen Molecular weight (kDa) 
of antigen
Secondary antibody
C O X -1 6 8 -7 4 Anti-goat HRP
COX- 2 6 8 -7 4 Anti-goat HRP
Pan ERK 1/2 4 2 / 44 Anti-rabbit HRP
PPARy 5 0 - 5 4 Anti-rabbit HRP
cPGES 23 Anti-rabbit HRP
mPGES 16 Anti-rabbit HRP
PGDH 29 Anti-rabbit HRP
HO-1 32 Anti-rabbit HRP
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